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ABSTRACT

The µ opioid receptor (µOR) exerts a powerful excitatory effect in cortical circuits and
cultured neurons by promoting glutamatergic activity after binding endogenous or
exogenous opioids. While most research indicates that the receptor does this by
decreasing activity or output of GABAergic interneurons that inhibit glutamate-releasing
Pyramidal Neurons, other experiments suggest that the µOR directly upregulates
excitatory Pyramidal Neurons instead. Thus, the cellular target of cortical opioid agonists
remains unclear, and the µOR’s net excitatory mechanisms are not fully understood.
Consequently, utilizing electrophysiology to detect µOR responses to the specific agonist
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin (DAMGO) has yielded incomplete
information on its effects. This receptor has been shown to modulate both αDTX
sensitive and insensitive currents in thalamic neurons to exert its effects, but this has not
been investigated in cortical neurons. Here, we utilized a combination of calciumimaging and patch-clamp electrophysiology in cultured rat neocortical neurons to
investigate the network and cellular effects of the µOR to understand its mechanisms and
their consequences. With our experiments testing its effects on spontaneous calcium
oscillations, we found that the µOR exerts its net excitatory effects through inhibition of
GABAergic interneurons. Our separate set of studies using patch-clamp
electrophysiology reveals that the µOR has multiple inhibitory effects on firing frequency
and action potential kinetics, including αDTX-sensitive and insensitive ones. Thus,
opioids suppress GABAergic interneurons to promote net excitation in cortical circuits.
Collectively, these findings promote our understanding of effects of endogenous or
exogenous opioids on cortical networks, as well as provide robust analyses of the
electrophysiological effects of the µOR which could provide insight into further studies
of this receptor on cortical neurons.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

1.1 Opioids and neuropharmacology
Our understanding of neuroscience has been profoundly shaped by the pharmacological
tools we have available. This is particularly true for the development and research in
opioids, which have been used for thousands of years for both recreational and medicinal
purposes (Santella & Triggle, 2007). Opium’s active component, morphine, was
successfully isolated from the plant product by the mid-19th century (Blakemore &
White, 2002). Since then, this chemical has been successfully modified to enhance its
properties; in some instances, to enhance its pain-killing properties, and in other cases for
nefarious purposes by leveraging its addictive and euphoric qualities. Codeine,
papaverine, buprenorphine, fentanyl, methadone, and diamorphine (heroin) are all
opioids – either natural or synthetic that have been developed over the generations
(Brownstein, 1993; Pathan & Williams, 2012). These drugs are all exogenous opioids that
are ingested, injected, or inhaled by the subject and they are not normally found in
humans or other animals.
Chemists eventually discovered drugs (such as naloxone and naltrexone) that can
be co-administered to reverse the effects of morphine. But the mechanisms that all these
opioid-derived drugs used to induce their effects on living beings remained a mystery for
several generations. Some of earliest studies in modern neuropharmacology were
dedicated to determining how these drugs physically interact with our physiology to
produce their characteristic pain relief and euphoria.
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Over 100 years later, in the 1970s, researchers identified the means that opioids
use to exert their chemical effects using radio-labelled ligands; these drugs interacted
with various receptor proteins located on cell membranes and were distributed unevenly
in the brain and body (Goldstein, Lowney, & Pal, 1971; Kuhar, Pert, & Snyder, 1973;
Pert & Snyder, 1973; E. J. Simon, Hiller, & Edelman, 1973; Terenius, 1973). The µ
Opioid Receptor (µOR) is presently known to be the main target of these drugs and is the
principal opioid receptor (OR) that mediates pain analgesia and euphoric effects of opioid
drugs (Valentino & Volkow, 2018).
Since it seemed unlikely that animals produce the µOR specifically for exogenous
opiates, scientists predicted that these receptors were evolved for unidentified natural,
neurotransmitters that may fulfill a pain-killing role in the brain (Brownstein, 1993).
These hypothesized neurotransmitters were called endogenous opioids because they were
believed to occur naturally within animals and bind to the same opioid receptors that the
exogenous opioids were already known to target. Their existence was shown in
experiments in the 1970s; it was discovered naloxone, which can reverse the effects of
morphine, could also reverse the analgesia seen after repeated, painful shocks (Akil,
Mayer, & Liebeskind, 1976). Thus, it appeared that animals secrete endogenous opioids
which can be reversed the same way that an administered opioid drug could also be
reversed.
Several different endogenous opioids, and a few receptors for those endogenous
opioids, were subsequently discovered over the decades. Fascinatingly, consuming opioid
drugs are not the only means that the opioid neurotransmitter system can be disrupted;
2

several neuropsychiatric conditions are shown to feature a disrupted endogenous opioid
system, which can lead then to aberrations in pain-sensitivity, and deficient motivation
and poor mood (Ashok, Myers, Reis Marques, Rabiner, & Howes, 2019; Der-Avakian &
Markou, 2012). The endogenous opioid neurotransmitter system is now a target for
treatment in mood disorders exhibiting these symptoms (Butelman & Kreek, 2015; Lutz
& Kieffer, 2013; Valentino & Volkow, 2018). The endogenous opioid system is also
implicated in binge-eating disorders, which arise from defective reward-valuation
processes by drive satiated animals to consume food (Giuliano & Cottone, 2015). Much
of this research has centered on the neocortex, the center of higher-function and decisionmaking.
Yet despite the long history of medical opioids, the usage of opioids is perilous.
Specifically, the addictiveness and rapid accumulation of tolerance to the drug has
birthed the “opioid epidemic” of abuse. Some opioids, like heroin, originally were
developed for medical applications but rapidly became popular as a drug of abuse
(Hosztafi, 2001). Heroin is one of the most addictive substances in human history. In
addition to the addictiveness and tolerance issues, opiates can induce respiratory
depression through the µOR and, ultimately, to death in high doses (Valentino &
Volkow, 2018).
Around 750,000 Americans have died since 1999 from opioid overdose; about
2/3rds of all drug overdoses are associated with opioids. This problem is also attributed
partly to abuse of prescription opioids, which accounted for about 1/3rd of opioid-related
deaths in 2018 (Services, 2020). Currently, there has been an interest in developing new
3

opioidergic drugs that can treat depression, impulsivity, and paradoxically, to also
prevent addictions (Shippenberg, 2009; Sullivan, 2018). There is a critical need to
understand how the µOR and opioidergic drugs function to exert their effects on brains.
1.2 Overview of the cerebral cortex
The human cortex constitutes almost half of the human brain and is associated with
higher-order functions, such as perception, cognition, and voluntary movements (Molnár
& Pollen, 2014; Rakic, 2009). This region of the brain has expanded immensely over
mammalian evolution leading to greater brain complexity and is crucial for the
intellectual capability and flexibility (Lui, Hansen, & Kriegstein, 2011). However, this
greater complexity has been accompanied by greater vulnerability; this vast brain region
is implicated in schizophrenia (Hashimoto et al., 2008; David A. Lewis, Curley, Glausier,
& Volk, 2012), autism (Amaral, Schumann, & Nordahl, 2008; Carper & Courchesne,
2005; Courchesne & Pierce, 2005; Zilbovicius et al., 1995), major depressive disorder
(Bremner et al., 2002; Drevets, 2007; George et al., 2000; Lemogne, Delaveau, Freton,
Guionnet, & Fossati, 2012), and attention-deficit hyperactivity disorder (Rubia et al.,
2010; Wolf et al., 2009).
The human cerebral cortex encompasses the “wrinkly” superficial surface of the
brain and is heavily gyrated (Lui et al., 2011). This region includes about 50 Brodmann’s
Areas that often have differences in their cytoarchitecture, depending on their function
and connections (Johns, 2014; Rakic, 2009). All cortical areas are constituted of several
layers of neurons, and the various types of neurons can be distributed unevenly through
the layers and region of cortex (Lui et al., 2011).
4

The cerebral cortex can be divided into 3 major components; firstly, the neocortex
(also called isocortex); secondly, the allocortex, constituted of the paleocortex (primary
olfactory cortex) and the archicortex (the hippocampus); and thirdly, the mesocortex
(cingulate cortex and parahippocampal gyrus) (Johns, 2014). The neocortex usually has 6
layers of stratified cortical neurons while the allocortex has 3 layers. The mesocortex,
which is found between the allocortex and neocortex, has between 3-6 layers (Johns,
2014). This dissertation project deals exclusively with the neocortex (specifically the
frontal cortex), but the hippocampus expresses similar cell types, and they are sometimes
used as models for each other. However, some differences between the neurons of the
hippocampus and neocortex will be noted in this text. Whenever possible, I have cited
experiments done in neocortical neurons, but I cite hippocampal studies in lieu of
neocortical studies because of the sometimes-disproportionate volume of relevant
research done on hippocampal neurons.
All branches of science have benefited greatly from animal models. Animal
models for neuroscience is particularly important because only animals possess brains,
and brain research is sometimes a dangerous endeavor for the subject. While modern
brain scans (PET, fMRI) are virtually harmless in moderation, much of neuroscience
research requires “breaking” certain pathways and genes, or by introducing toxic reagents
to understand how neurons work and interact with each other. Otherwise, all of
neuroscience would strictly be correlational. Indeed, most every branch of science
therefore requires models to serve as a stand-in for human participants, so that
researchers can conduct science as ethically as possible. These findings can eventually be
5

translated into human medical science and improve the lives of humans (and nonhuman
animals). However, neuroscience has a unique problem when compared to other branches
of science; the brains of humans are incredibly complex when compared to other animals.
Thus, while the genes of a fruit fly and a human may be sufficiently similar with genetics
research - but the structure of their brains are not similar enough for most brain research.
This problem is especially true for the neocortex of the human brain, which is uniquely
complex and therefore difficult to compare with other animals.
Our fellow primates (for example, chimpanzees) have well-developed
neocortices, but they are difficult to handle and carry serious ethical ramifications.
Rodents are a sensible starting point for studying neocortex because they are a model that
are frequently used, and they can be handled relatively easily. Therefore, when scientists
notice things about the brain that are initially observed in the brain scans of human
subjects, other scientists can follow up on this research with studies done in rodents.
1.3 Cortical neuroanatomy of the endogenous opioid system
Much of the discussion in the literature about the roles of the endogenous opioid system
revolves around several regions in the frontal cortex of humans. This region, fortunately,
has homologs that can be studied in rats, and so I will delineate the relevant components.
This includes the prefrontal cortex (PFC), the orbitofrontal cortex (OFC), and the anterior
cingulate cortex (ACC). In humans, the PFC is the dorsolateral prefrontal cortex (dlPFC),
ventrolateral prefrontal cortex (vlPFC), the medial prefrontal cortex (mPFC) and the
ventral prefrontal cortex (vPFC) (Striedter, 2005).
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But do rats have a region homologous to the human PFC? At first, the consensus
was that rats do not, because their own medial PFC was agranular; it lacked a layer of
small (Pyramidal) neurons that populated the middle cortical layers that was present in
humans. But, with the evolution of techniques that allowed scientists to trace afferent and
efferent fiber pathways in the brain, more attention was devoted to their connections than
their histology. The functions of the human prefrontal cortex are present in rats as the
mPFC in a simplified form. Currently the use of rat mPFC as a model for human PFC is
justified for several reasons, including being targeted by fibers from the mediodorsal
nucleus of the thalamus, which is a thalamic region associated with memory and planning
– thus suggesting that rat mPFC was involved in these “higher functions” (Funahashi,
2013; Rose & Woolsey, 1948). Similarities are also expressed on the neurotransmitter
receptors; both human prefrontal cortex and rat mPFC have reciprocal connections of
cholinergic fibers from basal forebrain nuclei, and as well reciprocal dopaminergic fibers
to/from the ventral tegmental area (the VTA is part of the opioidergic reward system)
(Carr & Sesack, 2000). The mPFC is also well-connected with the periaqueductal gray, a
pain-killing neuroanatomical region that I will be discussing later (An, Bandler, Öngür, &
Price, 1998; Hardy & Leichnetz, 1981; Ong, Stohler, & Herr, 2019; Y.-f. Xie, Huo, &
Tang, 2009). Lesion studies also indicate that the human dlPFC and rat mPFC both
mediate executive functions, such as decision-making, directing attention, and working
memory (Hoover & Vertes, 2007). Therefore, the complex “human” brain functions that
are distributed throughout a relatively large area, but can be found in a small, simplified
form in the rat mPFC where it fulfills a similar function to humans.
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Whether rats have a PFC has been a contentious topic, but the mPFC in rats is
also intimately related to decision-making and the endogenous opioid system. This region
expresses opioid receptors and opioid peptides (C. Jiang et al., 2019). This region is
involved in suppressing impulsivity, binge-eating, mood disorders, reactivity to fear
(Blasio, Steardo, Sabino, & Cottone, 2014; Selleck et al., 2015; Tejeda et al., 2015). In
rats, the ORs in this region can instigate overeating with a preference for carbohydrateenriched foods(Mena, Sadeghian, & Baldo, 2011; Mena, Selleck, & Baldo, 2013).
Like the mPFC, the orbitofrontal cortex (OFC) in rats is also connected with the
mediodorsal nucleus and subcortical structures associated with the endogenous opioid
system in humans and rats, which will be discussed later in this review (Heilbronner,
Rodriguez-Romaguera, Quirk, Groenewegen, & Haber, 2016; Rose & Woolsey, 1948).
This includes afferents from the ventral tegmental area, a region associated with the
reward system (M. J. M. Murphy & Deutch, 2018). The OFC is implicated in addiction,
decision-making, and depression (Bremner et al., 2002; Rolls & Grabenhorst, 2008;
Volkow & Fowler, 2000).
The ACC is located along the medial surface of the brain and consists of a ribbon
of tissue that encloses the anterior portion of the corpus callosum. The OFC and ACC
also play an important role in decision-making, attention, and behavior. They show
prominent expression of opioid receptors and endogenous opioids in both humans and
rodents (Lau, Ambrose, Thomas, Qiao, & Borgland, 2020; Mitchell et al., 2012). Rat
neurons cultured from the ACC also express these receptors in vitro (E. Tanaka & North,
1994). The ACC is implicated in behavior, affective disorders, schizophrenia and effort8

related decisions (Benes, McSparren, Bird, SanGiovanni, & Vincent, 1991; Devinsky,
Morrell, & Vogt, 1995; Elston, Croy, & Bilkey, 2019; Schweimer, Saft, & Hauber,
2005). This region also interacts with the reward and antinociceptive systems(Narita et
al., 2010; Navratilova et al., 2015).
Although the hippocampal formation is not a neocortical region, this literature
review will frequently reference their µORs. Some hippocampal neurons express µORs
and endogenous opioids that bind to the receptor (Drake & Milner, 2006; H. K. Lee,
Dunwiddie, & Hoffer, 1980; Madison & Nicoll, 1988; Przewlocki et al., 1999; Stumm,
Zhou, Schulz, & Höllt, 2004; M. Whittington, Traub, Faulkner, Jefferys, & Chettiar,
1998). Interfering with the endogenous opioid system there, by direct infusion of µOR
antagonists into the CA3, interferes with both the encoding and the retrieval of spatial
memory (Meilandt, Barea-Rodriguez, Harvey, & Martinez, 2004). These receptors may
also interfere with memory retrieval during stress (Shi et al., 2020). Chronic
administration of opioids is believed to reduce neurogenesis in this region, which may
then contribute to some of the long-lasting cognitive effects of opioid addiction (Eisch,
Barrot, Schad, Self, & Nestler, 2000; Persson et al., 2003). Therefore, the µORs and the
endogenous opioids of the hippocampal formation are an important feature of memory
encoding and retrieval.
The endogenous opioid system of the neocortex collectively modulates
antinociception, reward valuation and reward-seeking behaviors. Disruption of this
neurotransmitter system is believed to contribute to pathological and compulsive
behaviors, such as behaviors eating disorders, pathological gambling, and drug-seeking
9

(B. Bencherif et al., 2005; Badreddine Bencherif et al., 2005; Joutsa et al., 2018; Mick et
al., 2016; Mitchell et al., 2012; Qu, Huo, Huang, & Tang, 2015; Zubieta et al., 1996).
Some neuropsychiatric disorders, such as schizophrenia are associated with abnormalities
in the cortical opioid system, which may produce some of the cognitive symptoms
(impairments in executive control) featured in that disorder (Volk, Radchenkova, Walker,
Sengupta, & Lewis, 2012). People with schizophrenia also have reduced affective
responses to pain (Ashok et al., 2019; de la Fuente-Sandoval, Favila, Gómez-Martín,
León-Ortiz, & Graff-Guerrero, 2012; Linnman, Coombs, Goff, & Holt, 2013; Stubbs et
al., 2015), which can also be found in animal models for the disease (Kekesi et al., 2011;
Szűcs, Büki, Kékesi, Horváth, & Benyhe, 2016). In a broader context, poor inhibitory
control and motivational drive is featured in many psychiatric conditions, such as
depression, attention deficit hyperactivity disorder, and drug addiction (American
Psychiatric Association; Jentsch & Pennington, 2014; Kaye et al., 2013; Merriam, Thase,
Haas, Keshavan, & Sweeney, 1999; Puumala & Sirviö, 1998; Smith, Mattick, Jamadar, &
Iredale, 2014; Wise, Murray, & Gerfen, 1996). Although the pain-modulation component
appears related to cortical connections to the PAG, these latter functions are likely
mediated through cortical projections to the hypothalamus and nucleus accumbens
(Baldo, 2016).
Taken together, the anterior cingulate, orbitofrontal and mPFC of rodents express
ORs, opioid neurotransmitters, and are interconnected with other neuroanatomical
regions that mediate the notable functions of opioids. These cortical regions interact with
a vast network of subcortical regions to compose the endogenous opioid system.
10

1.4 Subcortical neuroanatomy of the endogenous opioid system
Although the primary focus of these experiments is the ORs of the neocortex, both the
cortical and subcortical opioidergic systems interact to exert their effects on animals. This
is particularly true because opioids that are taken orally or injected intravenously can
often bind to ORs in both areas. In addition, neuropsychiatric conditions that afflict the
endogenous opioid neurotransmitter system may also include both cortical and
subcortical regions, and extensive research on subcortical µORs has been performed for
many years. These experiments can be used to make predictions about their mechanisms
in the neocortex. I will therefore describe these subcortical components to explain how
they collaborate with cortical regions.
The periaqueductal gray (PAG) of the midbrain (in the brainstem) is perhaps the
best-known pain-modulating center of the brain (Devinsky et al., 1995; Hardy &
Leichnetz, 1981; Royce, 1983). The PAG manages descending pain inhibition mostly
through its input on the rostroventral medulla (RVM). The RVM sends serotonergic
fibers (interacting regions may send noradrenergic fibers) down the spinal cord and
activate neurons in the dorsal horn of the spinal cord (Ossipov, Morimura, & Porreca,
2014). The effect of serotonin on their spinal targets is predicted by the particular
receptor subtype, but opioids administered to directly to the PAG results in recruitment of
RVM neurons, which then leads to descending inhibition of pain (for review, see
(Ossipov et al., 2014)). Many parts of the brain modulate activity of the PAG because, by
extension, this allows many parts of the brain to modulate pain transmission.
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The ventral tegmental area (VTA) is a part of the brainstem that has strong control
over motivated/rewarding behaviors (Fields & Margolis, 2015). The VTA is rich the
dopamine-secreting efferent fibers (fibers from principal cells of the VTA) which project
to several parts of the brain, including the prefrontal cortex. Application of opioids into
the VTA increases firing rates of the principal neurons there, and leads to greater
dopamine secretion (Carr & Sesack, 2000). It serves as a critical link between opioids and
reward/addictive behaviors; ORs in the VTA can modulate the secretion of dopamine to
the nucleus accumbens to reinforce drug-seeking, while also projecting to cortical regions
to influence decisions being made there (Langlois & Nugent, 2017). For instance, the
VTA’s bidirectional connections with the anterior cingulate cortex facilitates the
consideration of cost/benefit decisions in animals (rats, in this experiment) (Elston et al.,
2019). The prefrontal cortex also provides excitatory input back to the VTA and is
therefore able to influence activity there as well by synapsing on the neurons of the VTA
(Carr & Sesack, 2000).
The amygdala is involved in fear and anxiety responses of animals, but it also
plays a role in decision-making which will be discussed in greater detail later. But its
function extends beyond its typical role of the “fear sensor” of the brain, and this region
likewise contributes to reward-valuation in animals (Wassum, Ostlund, Maidment, &
Balleine, 2009). Sensory cortices and the sensory portion of the thalamus project here to
provide this region with their input (Janak & Tye, 2015). The central nucleus of the
amygdala (CeA) projects to the PAG to modulate pain sensation. Meanwhile, the
basolateral amygdala (BLA) projects to the prefrontal cortex to contribute to decision12

making with rewards or aversive consequences (Barbas, 2000; Bechara, Damasio, Tranel,
& Damasio, 1997; Morrison & Salzman, 2010). Opioids in this region can modulate
excitability in the central nucleus and basal lateral amygdala (Winters et al., 2017).
The data I have cited here mostly come from data about focal or application of
opioids to a confined neuroanatomical region through microinfusions. This procedure
allows researchers to determine the exact contribution of µORs in a given region of
interest, but systemically-administered opioids tend to cause many effects (e.g., euphoria
and pain-relief) to come hand-in-hand because they act on virtually all the components of
the opioidergic system. For instance, by causing pain relief and euphoria to coincide by
acting on opioid receptors in the cortex, PAG, amygdala, and VTA all simultaneously.
Therefore, while the µORs in precise regions may fulfill narrow roles, all these effects
tend to happen simultaneously when someone takes an opioidergic drug.
1.5 Opioids: decisions and rewards
One of the most well-known features of the opioid system is its relationship with reward
valuation, addiction, and drug abuse. The relationship between opioids and rewards is
partially due to the high levels of opioid receptors expressed in the VTA – a region rich
in dopamine-expressing principal neurons which, in turn, then lead to
rewarding/pleasurable feelings and could encourage certain behaviors in the future (for
review, see (Fields & Margolis, 2015)). Decisions and reward-seeking behaviors is a
closely related feature based on valuations, which is a function of the VTA and cortical
areas. Binge-eating, for instance, is an aberration in the valuation process that leads an
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animal to overconsume food even when they are presently satiated (Giuliano & Cottone,
2015; Mena et al., 2011; Mena et al., 2013; Selleck et al., 2015).
To explore the link between brain regions and the activity of endogenous opioids,
researchers use radio-labeled µOR-agonists and brain scans to monitor the activity of
those receptors when a subject is participating in a designated task. Drug use is correlated
with the release of endogenous opioids in the human orbitofrontal and ACC (Colasanti et
al., 2012; Mick et al., 2014; Mitchell et al., 2012). These scans also allowed researchers
to explore the relationship between expected outcomes and activity in the neocortex as
well; placebo effects enhance dopamine and opioid release in the cortex and VTA, while
nocebo effects correlate with reduced dopaminergic and opioidergic activity there (Scott
et al., 2008).
Beyond the brain scans and correlative data, a great deal of information about the
cortical contribution to reward-valuation and decision-making is also derived from
microinfusions of opioids into discrete regions of the brain. Infusion of the opioid
agonists (specifically, the µOR agonist DAMGO) into rat mPFC drives feeding,
carbohydrate intake, and locomotive behaviors in satiated rats and is accompanied by
enhanced activity in the hypothalamus and nucleus accumbens shell (Mena et al., 2011;
Mena et al., 2013; Selleck et al., 2015). Blockade of the µOR from endogenous opioid
neurotransmitter with naltrexone in the mPFC inhibits binge-eating in rats, which
suggests a causal link between engaging in compulsive actions and release of endogenous
opioids in the mPFC (Bartus et al., 2003; Blasio et al., 2014). Opioid antagonists (namely
naltrexone) are also FDA-approved for treating poor impulse-control, presumably due to
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their ability to unlink opioidergic and dopaminergic activity in the brain (Pettinati et al.,
2006; Soyka & Rosner, 2008).
The VTA’s efferent connections to other parts of the brain allow it to stimulate
reward-seeking behaviors where effort is invested (Narita et al., 2010; Ramsey, Gerrits,
& Van Ree, 1999; Schweimer et al., 2005). In the VTA, like other areas of the brain,
opioid receptors suppress local inhibitory neurons, which then produces an acute increase
in activity of efferent principal neurons (Billy Chieng, Azriel, Mohammadi, & Christie,
2011; Johnson & North, 1992; Margolis, Toy, Himmels, Morales, & Fields, 2012). These
dopaminergic connections then project to several locations, including the nucleus
accumbens and hypothalamus (Narita et al., 2010; Pierce & Kumaresan, 2006; Zheng,
Patterson, & Berthoud, 2007). The nucleus accumbens is important to reinforce
addictions/rewards, while the hypothalamus can drive feeding behavior (Carr & Sesack,
2000). Additionally, the VTA also projects to cortical regions, such as the mPFC, OFC,
ACC to facilitate the decision-making processes (Narita et al., 2010; Pierce &
Kumaresan, 2006; Zheng et al., 2007)
Both the mPFC and OFC play important roles in decision-making, but they do not
have exactly the same roles. The OFC’s contribution to the reward system is encoding the
hedonic value of the reward. For example, this region is associated with the devaluation
of the reward during satiety or illness (Rudebeck & Rich, 2018). Consistent with this,
infusion of opioid agonists in this region enhances the valuation of rewards (Castro &
Berridge, 2017). Meanwhile the mPFC mediates the execution and monitoring of the
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selected action once the decision has been made (Phillips, MacPherson, & Della Sala,
2002).
1.6 Opioids: analgesia and pain-perception
Pain perception is sometimes (and erroneously) seen as a simple and reflexive process
from the painful stimulus to the perception of it. But pain perception is profoundly
shaped by emotional and affective processes happening in the frontal cortex (for review
of the PFC and pain, see (Devinsky et al., 1995; Hardy & Leichnetz, 1981; Lasagna,
1964; Ong et al., 2019; Petrovic, Kalso, Petersson, & Ingvar, 2002; Royce, 1983;
Westlund & Willis, 2015). Expectations, moods, and dispositions all affect the way we
perceive and express pain. For instance, the analgesic effects of placebos are mediated by
the ACC, PFC, insula (Choi et al., 2016; Qiu, Wu, Xu, & Sackett, 2009; Zubieta et al.,
2001), which shows that pain perception is shaped by complex processes in the
neocortex.
Much of pain modulation is carried out by the PAG, which has control over
descending fibers that can interfere with the transmission of pain in the spinal cord.
Exogenous/endogenous opioids, drugs, and other neurotransmitters can enhance PAG
activity, which then modulates the RVM. The RVM projects serotonergic efferent fibers
down the spinal cord, along with noradrenergic fibers from associated regions. Thus,
opioids can have a tremendous effect on descending pain modulation and reducing the
pain signal that enters the brain. But opioids can reduce the affective expression of pain
but leave the actual pain perception component intact (Amir & Amit, 1978; Oertel et al.,
2008). Therefore, animals may feel the pain, but simply just care less about it. Several
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regions of the brain can modify the activity of the RVM and PAG to influence pain
perception, including the PFC (Bingel et al., 2011).
The PAG receives most of its afferent input from the mPFC, with smaller input
from the somatosensory, insular, and cingulate cortices (Hardy & Leichnetz, 1981; Ong
et al., 2019; Y.-f. Xie et al., 2009). This pathway appears to be specifically activated
when treatments are expected to lead to pain relief (including placebos) (Choi et al.,
2016). Placebo and nocebo effects appear to have opposite polarity in opioid and
dopamine release in cortical areas and the PAG which demonstrates a relationship
between these two regions, evidence for cortical processing of pain perception, and the
relationship between opioids and dopamine (Scott et al., 2008).
To investigate the correlational studies from brain imaging, scientists have done
experiments with microinfusions in animal models. For instance, infusion of opioid
agonists into the ACC of rats blocks pain-induced aversion during conditioned place
preference tasks (Navratilova et al., 2015). Infusions of opioid agonists into the
ventrolateral cortex of rats induces a naloxone-reversible inhibition of their tail-flick
reflex in response to pain (X. Huang, Tang, Yuan, & Jia, 2001). Therefore, it appears that
opioid receptors in neocortical (ACC) regions can modulate our reactions and aversion to
pain.
Reactivity and expression of pain is also a very important feature that neocortical
regions and the endogenous opioid system contribute to. Fear-conditioned analgesia
(where an animal has a weak reactivity to painful stimuli in a place that has been
previously paired with painful stimuli) has been shown to be modulated by endogenous
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opioids through microinfusions into the amygdala (Butler et al., 2011; Tershner &
Helmstetter, 2000). This is most likely related to projections from the amygdala to the
PAG (Helmstetter, Tershner, Poore, & Bellgowan, 1998). However, in addition to
directly projecting to the PAG, the BLA neurons can also project to the mPFC, and PNs
in Layer 5 can then project down to the PAG as well (Cheriyan, Kaushik, Ferreira, &
Sheets, 2016). The amygdala has bilateral connections with the cortex that are believed to
be involved in fear conditioning an anticipation of pain and strengthened in people with
chronic pain (Butler et al., 2011; Cheriyan et al., 2016; Simons et al., 2014). These
nociceptive neurons of the mPFC are likely to be related to affective demonstration of
pain, or the expectation of pain rather than to detect and discriminate pain (Onozawa,
Yagasaki, Izawa, Abe, & Kawakami, 2011). µORs in the mPFC can modulate reactivity
to fear (relayed by input from the basolateral amygdala) (Tejeda et al., 2015).
So then if all of these brain regions collaborate to affect nociception, what then is
the unique role of the PFC in this network? It is believed that the PFC uses the mood or
expectations of the subject to modify the perception of their pain. Many factors could
contribute these moods and expectations - for example, expectations from
pharmacotherapy, memories, psychotherapy, and conscious suppression of pain could all
modify the perception and expression of pain (Ong et al., 2019).
The mPFC, OFC and ACC are therefore involved in pain perception, pain
expression, and decision-making. They also have opioid receptors that can be used to
affect all these features. Having explained the gross neuroanatomy component of the
endogenous opioid system, I will now refocus the attention on the neocortex by
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introducing the neurons in that region. By doing this, we can then begin to understand
how endogenous opioids exert their effects on neocortical networks and individual
neocortical neurons.
1.7 Introduction to neocortical neurons
Neurons of the neocortex are composed of 2 main categories of neurons that interact and
form a network to carry out the functions of the neocortex: the excitatory neurons and
inhibitory neurons. These excitatory and inhibitory neocortical neurons form synapses on
other neurons, which allows them to influence the firing on the neuron that they synapse
onto. Any given neocortical neuron may receive input from both inhibitory and excitatory
neurons, as well as afferent fibers from distant brain regions that I have previously
discussed here. Since these neurons receive both excitatory and inhibitory input, their
own firing tendency (excitability) depends on which of the two types of input are stronger
in any given moment.
The most common type of neocortical neuron (about 80%) are the excitatory
(glutamatergic) neurons that can synapse on nearby neurons, as well as neurons that are
far away (DeFelipe & Fariñas, 1992; Noback, Strominger, Demarest, & Ruggiero, 2005).
The other 20% are inhibitory (GABAergic) which synapse only on nearby neurons.
The inhibitory neurons will suppress the nearby excitatory neurons by secreting
GABA (γ-aminobutyric acid). Meanwhile the excitatory neurons synapse onto both near
and far neurons and secrete the excitatory neurotransmitter glutamate. Both neuronal
types may also produce other neurotransmitters, including endogenous opioids, which
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may also produce other effects on their targets. These two neuron types interact heavily
to regulate each other’s excitability (tendency to fire).
1.8 Excitatory cortical neurons
Most cortical excitatory neocortical neurons have a pyramidal shape and therefore are
called Pyramidal Neurons (PNs). A smaller group of excitatory neurons, called granule or
stellate neurons, can be also found, but they are mostly found in sensory cortex (Johns,
2014).
Pyramidal Neurons (PNs) are glutamatergic neurons found in all cortical layers
except Layer I (DeFelipe & Fariñas, 1992); Noback et al., 2005). However, they tend to
stratify in Layers 2/3 and Layer 5. Their projections can be directed locally or directed to
other parts of the cortex and subcortical areas. They form asymmetric synapses at their
targets, which include interneurons and dendritic spines of other PNs. Although these
cells are relatively homogenous when compared to interneurons, PNs can assume a
variety of shapes (DeFelipe & Fariñas, 1992). Generally, though, they have a pyramidalshaped soma between 20-120 µM wide and have elaborate branches directly off their
soma. Their apical dendrites project into Layer I of the neocortex and disperses into
branches. All PNs bear ~10,000 spines along their apical dendrites which represent an
excitatory postsynaptic density – which is where another excitatory neuron has synapses
onto them. They may also have smaller, basal dendrites at the other 2 angles of their
pyramidal soma. Their axon projects from the basal part of the neuron, opposite the
apical dendrite (Johns, 2014).
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Excitatory neurons develop from the dorsal telencephalon (the pallium) and
migrate radially to the cortical plate from the germinal zone during embryonic
development(Campbell, 2005). PNs in the deep layers develop first and then are bypassed
by newer progenitors that create the superficial cortical layers (Campbell, 2005).
Therefore, the Layer 5 PNs usually develop earlier than Layer 2/3 PNs.
Some research in the neocortex using immunocytochemistry (ICC; an antibodybased technique to identify the localization of specific proteins) have specifically looked
for expression of the µOR in PNs. For the most part, PNs in neocortical regions do not
express the µOR. For example, 96.9% of the µOR-expressing (µOR+) neurons in the
neocortex have been found to produce GABA (Taki, Kaneko, & Mizuno, 2000). On the
other hand, some research teams have reported µOR-immunoreactivities on neocortical
PNs during their immunocytochemistry (ICC) experiments – so there is a possibility that
some do express the µOR (Schmidt et al., 2003).
1.9 Inhibitory cortical neurons
Cortical interneurons make up the remaining 20% of neocortical neurons and they can
belong to smaller subcategories of interneurons. All the inhibitory neurons secrete the
neurotransmitter GABA, which binds to postsynaptic/extrasynaptic GABAA and
(sometimes) GABAB receptors, causing inhibition in their targets. Although these
inhibitory neurons can be targeted by other neurons in distant parts of the brain, but they
only synapse on local neurons. Therefore, these inhibitory cortical neurons are also called
interneurons or, more precisely, GABAergic interneurons which excludes the
glutamatergic interneurons.
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Cortical interneurons have a short axon that projects locally, and they often
receive afferent fibers from cortical and noncortical areas. For example, the mediodorsal
nucleus of the thalamus projects to the rat mPFC and synapses on mostly interneurons
over PNs (Rotaru, Barrionuevo, & Sesack, 2005), These axons can arise from the soma or
principal dendrites of the interneuron (The Petilla Interneuron Nomenclature Group,
2008). Beyond that, their morphology can differ dramatically from fellow interneurons
and is not an unambiguous indicator of cell type. Given their wide range of properties,
scientists were driven to categorize different interneurons in order to understand their
collective role in the brain.
However GABAergic interneurons are notoriously difficult to subclassify,
because of the combinations of morphology, expression markers, and physiological
properties that they can possess. But these distinctions are important because different
subsets of interneurons have different roles, and there are some general patterns and
distinctions. The lack of a formal criteria for classification led to formation of a
consortium of scientists, the Petilla Interneuron Nomenclature Group (PING), that was
established to consolidate research and to provide a standard classification of
interneurons for neuroscientists (Batista‐Brito & Fishell, 2009; The Petilla Interneuron
Nomenclature Group, 2008). Although individual labs have their own internal preferred
categorization systems, most classification schemes are similar to PING’s scheme.
Pioneering studies in rodent cortical interneurons have initially grouped all
cortical interneurons into 3 distinct and non-overlapping classes based on expression of
protein markers (Kawaguchi & Kubota, 1997; McCormick, Connors, Lighthall, & Prince,
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1985). These classes are parvalbumin-positive (PV+) interneurons, vasoactive intestinal
peptide-positive (VIP+) interneurons, and somatostatin-positive (SST+ or SOM+)
interneurons. However, in the years since then, a much more complicated portrait
emerged; interneurons are difficult to group into discrete classes because they sometimes
express more than one of those definitive markers, or apparently don’t express any of
those markers (Markram et al., 2004; Parra, Gulyas, & Miles, 1998). The variability in
interneuronal properties could obfuscate results of experimental error (Markram et al.,
2004). Nevertheless, the conventional categorization scheme provides useful (though
flawed) heuristics for inferring properties based on distinct cell markers.
The proportions of each group to the total interneuron population in the
somatosensory cortex are roughly as follows: 40% for PV+ interneurons; 30% for SST+
interneurons; and 30% for the serotonin receptor 5HTa3R+. The latter group
encompasses VIP+ interneurons and, some have argued, is a more parsimonious
interneuronal marker than VIP (Bernardo Rudy, Fishell, Lee, & Hjerling-Leffler, 2011).
The subdivisions of interneurons could be further divided into groups based on the
presence or absence of other markers, and they can have alternative cell markers (Kubota
& Kawaguchi, 1997; Bernardo Rudy et al., 2011; Taki et al., 2000; The Petilla
Interneuron Nomenclature Group, 2008). Cortical interneurons are often described in
very literal terms; a given neuron might be described as “fast-spiking” during
electrophysiological studies or “parvalbumin-positive” (PV+) during ICC studies - even
though the properties tend to be mutually inclusive (i.e., fast-spiking neurons are almost
always PV+, and vice versa).
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Cortical interneurons have numerous properties that distinguish them from PNs.
Experiments in the hippocampus show that many of these differences maximize their
speed and reliability. Some cortical interneurons, such as PV+ basket cells, also innervate
other interneurons of the same type through both electrical and chemical synapses
(Galarreta & Hestrin, 1999, 2002; Gibson, Beierlein, & Connors, 1999; Juszczak &
Swiergiel, 2009). These adaptations are predicted to enable interneurons to synchronize
reliably and orchestrate network activity that are important for executive function (for
review, see Miles (2000)) (Miles, 2000). The importance of synchronization will be
discussed later.
The presence of the µOR and endogenous opioids within interneurons have been
reported extensively with ICC in studies of the hippocampus and neocortex (Arvidsson et
al., 1995; Suzanne B Bausch & Chavkin, 1995; S. B. Bausch et al., 1995; Drake &
Milner, 1999, 2002, 2006; Taki et al., 2000). These experiments also allow us to predict
which categories of neurons are most likely to express the µOR, and further allow us to
predict how this relates to the effects of the µOR given the groups that the µOR is found
in.
1.10 µOR-expressing cortical interneurons
The rate of expression of the µOR has usually been determined through ICC stains of
neocortical or hippocampal slices. However, antibodies generated for the µOR have
shortcomings for reasons that I will address later. Another confounding feature is that
different methods of localizing the µOR produces slightly different rates of expression.
Finally, the hippocampal formation and the neocortex appear to show some differences
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distributions of the receptor. While obviously neocortical data is more applicable to
experiments of the µOR in the neocortex, a great deal of data about cortical µORs is
derived from studies done in the hippocampal formation. These points of disagreement
will be commented on throughout this literature review.
Yet despite the limitations of primary antibodies for the µOR, they can still
provide a useful starting point for understanding how often (and where) the receptor may
be found; in the neocortex, ICC data and an experiment with a fluorescent ligand
suggests that it is expressed by only 5-20% of neocortical interneurons (or 3-5% of all
neurons) (M. C. Lee, Cahill, Vincent, & Beaudet, 2002; Taki et al., 2000).
Researchers have also delved further to identity of these µOR+ neurons (µOR+
are neurons “positive” for the µOR) based on their coexpression of different markers for
interneurons. ICC data on rat neocortical slices show that about 97% of µOR+ produce
GABA, showing that µOR are mostly GABAergic. The majority (92%) of µOR+ had
also expressed VIP indicating that the VIP+ pool of interneurons is the biggest
contributor to the µOR+ interneurons. Inversely, 70.2% of VIP+ neurons showed
presence of the µOR. Meanwhile, 8.2% showed presence of PV; and 2.9% showed
presence of SST. Inversely, only 1.1% of PV+ neurons and 0.6% of SST+ neurons
showed the presence of µOR puncta suggesting that these neurons rarely express the
µOR – or at least not in their somata; this technique may not be relied upon to identify
axonal expression of the µOR due to equipment and practical limitations (Taki et al.,
2000).
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But electrophysiology-based experiments (which probably also include sampling
bias towards certain interneurons) show much higher estimates than ICC experiments in
neocortical slices; one group found a DAMGO response in 2/3rds of the neocortical
interneurons that they surveyed with electrophysiology (while none of 18 PNs showed a
response) (Witkowski & Szulczyk, 2006).
Another electrophysiology-based experiment that also utilized sc-PCR tested
various neocortical neurons for µOR mRNA and probed for a response to DAMGO; they
found a DAMGO response (indicated by hyperpolarization and a decrease in input
resistance) in 86 interneurons out of 169 recorded neurons. However, they only detected
presence of µOR mRNA in 62.5% of the neurons that had responded to DAMGO,
indicating that the DAMGO exposure was the more sensitive technique for detecting the
receptor. Most of their responders were regular or irregular-spiking and had a high
incidence of expression of VIP. They did not appear to sample neurons randomly, for
example, only 98 of 360 recordings were PN, despite constituting 80% of the neurons of
the cortex. All DAMGO responders tested positive for GAD65 or GAD67 mRNA, and
none of the PNs hyperpolarized to the DAMGO application or showed presence of µOR
mRNA (Férézou et al., 2007).
Interestingly the Ferezou et al. (2007) noted an exceptionally high rate of
DAMGO responders were found in the Layer 1 of the cortex and conformed to the
NGFCs morphology. This indicates that these neurons likely express high rates of the
µOR (Férézou et al., 2007). This receptor has been observed in the NGFCs of the
hippocampus as well (Krook-Magnuson, Luu, Lee, Varga, & Soltesz, 2011; C. J. Price,
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Scott, Rusakov, & Capogna, 2008). Taken together, these studies indicate that cortical
neurogliaform neurons are likely to express this receptor.
Although hippocampal studies can often be applied to neocortical studies (in that
the neuron types are strongly similar), the electrophysiology and ICC experiments in both
locations has raised some debate over the localization of the µOR in the PV+ neurons of
the neocortex. As I’ll explain next, several groups have observed the µOR in the PV+
interneurons hippocampus, but other research groups have failed to find it in the PV+
interneurons of the neocortex. While this may be pedantic, PV+ interneurons are the
largest group of neocortical interneurons and are important to the regulation of
neocortical PNs. Thus, their susceptibility to opioidergic activity is not a trivial matter
and could be very consequential to neocortical activity.
Expression of the µOR has been reported extensively in the somata of PV+
interneurons of hippocampal cortex, as indicated by immunostaining (Bartos & Elgueta,
2012; Suzanne B Bausch & Chavkin, 1995; Drake & Milner, 1999, 2002, 2006; Stumm
et al., 2004; Torres-Reveron et al., 2009). Studies have also shown that some PV+
interneurons of the hippocampus have also found a stereotypical hyperpolarizing
response to DAMGO (Glickfeld, Atallah, & Scanziani, 2008; K. R. Svoboda, Adams, &
Lupica, 1999). These experiments have led some to infer that they are also expressed by
PV+ interneurons in the neocortex as well (Volk et al., 2012). However, the best current
information suggests that this is rare (Taki et al., 2000). Additionally, in the report I
described earlier, there was a lack of reported DAMGO responses in fast-spiking
interneurons, even though 38 were tested for it (Férézou et al., 2007). Yet recent work
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using electrophysiology and optogenetics in the mPFC cortices of mice found that the
µOR regulates the amplitude and duration of inhibitory postsynaptic potentials in PNs
with PV+ presynaptic terminals (C. Jiang et al., 2019). An even more-recent study
likewise reported similar results in some parts of the OFC (Lau et al., 2020). Taken
together, it appears likely that the µOR+ is sometimes found in PV+ neurons in the
neocortex - as it is in the hippocampus. However, there does not appear to be perisomatic
expression of the µOR in PV+ neurons of the neocortex (as there is in the hippocampus,
to a high degree), which makes the frequency of colocalization in PV+ neurons difficult
to determine. With the lack of perisomatic expression of the µOR+, there may not be a
characteristic hyperpolarizing DAMGO response from recordings made in the somata of
fast-spiking (mostly PV+) interneurons of the neocortex.
So, it appears that neocortical expression of the µOR may be found in many VIP+
neurons, neurogliaform neurons, and likely PV+ terminals as well, but ICC perhaps is not
the best way to definitively determine its localization, due to nonsomatic expression and
the general difficulties of producing antibodies for GPCRs (Jo & Jung, 2016).
Furthermore, efforts using OPRM1-driven (the gene for the µOR) expression of
fluorescent proteins may not be a reliable indicator for the same reason (Erbs et al., 2015;
Gardon et al., 2014). To address this problem, efforts are underway to leverage the
Cre/Lox recombinase system to reliably localize this receptor (Bailly et al., 2020). Until
then, it appears that electrophysiology is the most sensitive technique for finding this
receptor.
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While the pattern of expression can be roughly deduced from the combination of
ICC and electrophysiology data shown here, it does not explain what these neurons do in
circuits or an intact brain. To understand the effects of the µOR in the neocortex, I must
next explain the roles of the PV+, VIP+, and neurogliaform neurons. From that
information, we can make more informed predictions on the net result of µOR
application on neuronal networks.
1.11 Roles and features of µOR+ interneurons: PV+ and VIP+
The PV+ interneurons of the neocortex are powerfully involved in the regulation of the
excitation/inhibition (E/I) balance in this region. Their inhibitory control over PNs is
illustrated by data that show nearly every PV+ interneuron synapses with every nearby
PN (Packer & Yuste, 2011). PV+ have strong control over the firing of PNs, and their
synchronized network carefully controls the timing of PN neuron spiking (Agmon &
Connors, 1991). These neurons are implicated in executive function of the neocortex
(David A Lewis, 2014), and are hypoactive in psychiatric conditions, such as
schizophrenia (Glausier, Fish, & Lewis, 2014; Volk et al., 2002) and autism (McNally &
McCarley, 2016; Rojas & Wilson, 2014). Therefore, there is a strong link between the
role of PV+ interneurons and overall cortical function due to their tight regulation of
excitatory activity (B. R. Ferguson & Gao, 2018). For review on the role of PV+
interneurons on neuropsychiatric illnesses, see (B. R. Ferguson & Gao, 2018).
VIP+ interneurons that express the µOR have been shown to express nicotinic
receptors (Férézou et al., 2007) and often also express ChAT (Taki et al., 2000). This
finding is consistent with other research showing that VIP+ interneurons respond to
29

acetylcholine (Fu et al., 2014). On a larger scale, there is a relationship between the
nicotine and the endogenous opioid system, namely, that nicotine seems to stimulate
release of these endogenous opioids (Mandillo & Kanarek, 2001; Mathieu-Kia, Kellogg,
Butelman, & Kreek, 2002; Pomerleau, 1998).
VIP+ interneurons have been shown to inhibit nearby interneurons(Fu et al.,
2014; Jackson, Ayzenshtat, Karnani, & Yuste, 2016; Pi et al., 2013). Yet this raises an
interesting issue; how can opioids, which suppresses VIP+ neurons, lead to disinhibition
of PNs while high activity of VIP+ interneurons also lead to disinhibition of the PNs?
This question does not seem to be thoroughly addressed in the literature. One of the
explanations may be that, despite the high degree overlap between the µOR and VIP
expression, the influence of other cortical neurons, such as PV+ interneurons and
neurogliaform cells, are more powerful.
1.12 Roles and features of µOR+ interneurons: NGFCs
The neurogliaform cells (NGFCs) are perhaps one of the more idiosyncratic groups of
interneurons. Santiago Ramon y Cajal provided the earliest published description of these
neurons by noting their small soma, short but radiating dendrites, and short axons
(Ramon y Cajal, 1995). They are multipolar interneurons that do not express the classic
interneuronal markers, but usually do express Reelin and Neuropeptide Y (Jasper, 2012;
Niquille et al., 2018). They do also express the serotonin 5-hydroxytryptamine 3A
(5HT3a) receptor. This receptor is not expressed by SST+ or PV+ neurons but is
generally expressed by most all VIP+ neurons and therefore not a specific cell marker for
neurogliaform neurons (S. Lee, Hjerling-Leffler, Zagha, Fishell, & Rudy, 2010).
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NGFCs have unique electrophysiological characteristics. Classically, they are
known for their “late-spiking” firing pattern, i.e., when a sustained depolarizing current is
injected, there is a short delay before firing their first spike (Chu, Galarreta, & Hestrin,
2003; Kawaguchi & Kubota, 1997). Their RMP is typically around -60mV and they have
low input resistances (Tricoire et al., 2010). Although they can most easily be found in
Layer 1 of the neocortex, they are not exclusively found in Layer 1, and nor are they the
only interneurons found in Layer 1 (Férézou et al., 2007; S. Lee et al., 2010; Miyoshi et
al., 2010; Olah et al., 2007).
NGFCs are well-known for producing dense axon terminals in extrasynaptic
spaces and inhibiting targets through tonic GABA secretion (Overstreet-Wadiche &
McBain, 2015). The effects of NGFCs on their targets has unique consequences.
Consistent with their axon terminals in extrasynaptic space, NGFCs secrete a
considerable amount of GABA into the extracellular environment which results in tonic
inhibition of nearby neurons through volume transmission, in addition to the faster
inhibition mediated by synaptic GABAA receptors (Karayannis et al., 2010; Olah et al.,
2009; Tricoire et al., 2010). Conversely, the tonic secretion of GABA may also
desensitize their targets; NGFCs have been observed to produce rapid desensitization
(Karayannis et al., 2010). The lack of spatial and temporal specificity makes the role of
NGFCs difficult to predict (for review, see (Overstreet-Wadiche & McBain, 2015)).
The GABAA receptor is not the only target of NGFCs; NGFCs uniquely secrete
GABA onto GABAB receptors on PNs and interneurons, which can be located both on
somata and glutamatergic terminals (Karayannis et al., 2010; Olah et al., 2009;
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Christopher J. Price et al., 2005; Tamás, Simon, & Szabadics, 2003). NGFCs are the only
neocortical neurons that have been observed to stimulate GABAB receptors with a single
AP - whereas other interneurons usually need trains of APs to activate GABAB receptors
on their targets (Christopher J. Price et al., 2005; C. J. Price et al., 2008; Tamás et al.,
2003). Therefore, the recruitment of these neurons can create long-lasting inhibitory
postsynaptic potentials in interneurons through the stimulation of GABAB receptors (Olah
et al., 2007; Tamás et al., 2003). Consistent with the inhibitory role for µOR and its
localization on neurogliaform neurons, DAMGO has been found to decrease activation of
the GABAB receptor in neocortical neurons (Lafourcade & Alger, 2008; McQuiston,
2008). This effect appears to be partially mediated by voltage-gated calcium channels – a
known target of the µOR, particularly at axon terminals (M. Connor, Schuller, Pintar, &
Christie, 1999; Law, Wong, & Loh, 2000; Rubovitch, Gafni, & Sarne, 2003).
NGFCs frequently interlink with interneurons and PNs through chemical and
electrical synapses (X. Jiang et al., 2015; Olah et al., 2009). While NGFCs are known to
electrically couple with other NGFCs, there is conflicting evidence that they may couple
with non-neurogliaform interneurons as well (Chu et al., 2003; Fukuda, Kosaka, Singer,
& Galuske, 2006; Hestrin & Galarreta, 2005; Anna Simon, Oláh, Molnár, Szabadics, &
Tamás, 2005; Zsiros & Maccaferri, 2005).
NGFCs also show a type of slow integration (perhaps presumptuously) called
retroaxonal barrage firing; in the 10s of seconds following a sustained depolarizing
current, the neurons will fire many action potentials after the stimulus has already ended
(Overstreet-Wadiche & McBain, 2015; Norimitsu Suzuki, Tang, & Bekkers, 2014).
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Documented reports of this type of firing in the neocortex is presently restricted to
NGFCs and PV+ interneurons in slices and in vivo (N. Suzuki & Bekkers, 2010). While a
similar phenomenon has been reported in other neurons before, retroaxonal barrage firing
in the cortex can be blocked with chemical gap junction inhibitors, but not GABAergic or
glutamatergic inhibitors, and therefore implicates gap junctions as transducing this firing
(Overstreet-Wadiche & McBain, 2015; M. E. J. Sheffield, Best, Mensh, Kath, &
Spruston, 2011). To explain the mechanism inherent in its name, some have suggested
that axon terminals of NGFCs can become tonically active during the depolarizing
current injection and conduct APs through the electrically linked network (M. E. J.
Sheffield et al., 2011; Norimitsu Suzuki et al., 2014). Regardless of the mechanism, some
data has shown that DAMGO application reduces retroaxonal barrage firing and provides
additional corroborating data that NGFCs express this receptor and reduces this barrage
firing phenomenon (Krook-Magnuson et al., 2011; Norimitsu Suzuki et al., 2014).
1.13 µOR disinhibition
The ICC and autoradiography data I have discussed mostly indicate that interneurons
express the µOR with some ambiguity about whether PNs do express it. To take a closer
look at function of this receptor, researchers have taken electrophysiological recordings
from neurons and applied µOR-agonists.
In contrast to autoradiography and ICC which simply inform us of the location of
the µOR, electrophysiology gives us a better idea of the effect of the µOR on individual
neurons. The electrophysiology data mostly continue this theme and show that there is
little doubt that some cortical interneurons react to µOR-agonism with inhibition
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(Férézou et al., 2007; Glickfeld et al., 2008; K.-W. Kim et al., 2000; Madison & Nicoll,
1988; Pang & Rose, 1989; K. R. Svoboda et al., 1999; Kurt R Svoboda & Lupica, 1998;
Wimpey & Chavkin, 1991; Witkowski & Szulczyk, 2006; Zieglgansberger, French,
Siggins, & Bloom, 1979). However, there is also some data that suggest that some PNs
are directly excited by µOR-agonism (Przewlocki et al., 1999), while others have
reported inhibition of PNs with µOR agonism (E. Tanaka & North, 1994). Naturally, one
must be cautious about the bias towards reporting positive results, for instance, some
groups have used electrophysiology and sc-PCR to examine the µOR’s effect on PNs and
observed none (Férézou et al., 2007; Witkowski & Szulczyk, 2006).
Researchers have also investigated whether µOR agonists enhance cortical
excitation through disinhibition (that is, creating greater excitatory activity by inhibiting
the suppressive effects of GABAergic interneurons). Several studies indicate that
excitation in PNs is secondary only through inhibiting the nearby GABAergic neurons
(Homayoun & Moghaddam, 2007; C. Jiang et al., 2019; H. K. Lee et al., 1980; Madison
& Nicoll, 1988; Pang & Rose, 1989; Zieglgansberger et al., 1979). However, several
other studies suggest that the µOR upregulates activity of PNs, thereby directly activating
them (Przewlocki et al., 1999; Rola, Jarkiewicz, & Szulczyk, 2008; Schmidt et al., 2003;
Witkowski & Szulczyk, 2006). This matter remains unresolved.
1.14 Excitation/inhibition balance
If the µOR inhibits interneurons and disinhibits PNs – why would that matter? A
continuous loop of excitatory-only neurons could never organize and would likely be
nearly impossible to properly regulate, especially given the afferent pathways that tend to
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converge on any neuroanatomical structure and may compete for control. GABAergic
interneurons fulfill an important purpose: properly regulating the output of brain
structures and enabling flexibility (Isaacson & Scanziani, 2011; Klausberger et al., 2003).
Therefore, persistent conditions that reduce the excitability of GABAergic interneurons
can in turn result in neurological defects (B. R. Ferguson & Gao, 2018).
The excitation of cortical networks is kept in careful balance by inhibition, and
vice versa. This balance must be maintained for the coordinated activity to be sustained
during cognitive tasks (Yizhar et al., 2011). Several psychiatric disorders, including;
autism (Bozzi, Provenzano, & Casarosa, 2018; Nelson & Valakh, 2015; Orekhova et al.,
2007; Rubenstein & Merzenich, 2003), Rett syndrome (V. S. Dani et al., 2005),
schizophrenia (Fazzari et al., 2010; D. A. Lewis, Hashimoto, & Volk, 2005; Yizhar et al.,
2011) and epilepsy (Bozzi et al., 2018; Engel, 1996) are believed to result from an
improper excitation/inhibition E/I balance. These syndromes may appear from
abnormalities during interneuronal migration, dysregulated postnatal apoptosis (Wong et
al., 2018), synaptogenesis (Fazzari et al., 2010; J.-M. Yang et al., 2013), neurotransmitter
release (Bozzi et al., 2018; McNally & McCarley, 2016), or temporary states from drug
use (Berke, 2009; Premoli et al., 2017).
1.15 Cognitive function and band oscillations
The invention of the electroencephalogram allowed researchers to record the mass
activity of neurons firing synchronously due to their effect on the electrical field around
the subject’s head. These band oscillations (BOs) (Berger, 1929; Steriade, 2001).
Eventually, researchers were able to induce large-scale neuronal activity with transcranial
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magnetic stimulation (Barker, Jalinous, & Freeston, 1985). These inventions allow us to
measure brain activity and a limited means to affect that activity. They were also some of
the earliest methods to understand how neurons in specific regions collaborate to fulfill a
collective function.
The activity of neurons produces a measurable electric field that, when graphed
against time, creates a pattern of high-frequency oscillations. Known mammalian
oscillatory frequency can occur between 0.5 MHz and 500 MHz. While a given structure
can have a prevailing frequency depending on their brain state, task and neuroanatomical
structure, a given structure usually has a composite of multiple BOs contributing to the
net oscillation (Steriade, 2001). Slower frequencies of oscillations (which are usually
more widespread) have a strong modulatory role, whereas faster band oscillations are
more confined in space and relatively easily disrupted/modulated (Buzsáki & Draguhn,
2004; Buzsáki, Geisler, Henze, & Wang, 2004; Csicsvari, Jamieson, Wise, & Buzsáki,
2003; Sirota, Csicsvari, Buhl, & Buzsáki, 2003).
The Gamma Band Oscillations (GBOs) are a particularly relevant band oscillation
to the study of cortex. These GBOs are believed to contribute to proper memory,
attention, and sensory binding (which links senses together) (Bragin et al., 1995;
Csicsvari et al., 2003; Fell et al., 2001; Fries, Reynolds, Rorie, & Desimone, 2001; Gray,
1994; Llinás, Ribary, Contreras, & Pedroarena, 1998; Singer, 1993; Varela, Lachaux,
Rodriguez, & Martinerie, 2001). Although the features of these bands may vary by region
and frequency, the GBOs of the hippocampus and neocortex appear to involve both the
PNs and the cortical interneurons interacting to produce BOs as detected through an EEG
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(Blatow et al., 2003; Csicsvari, Hirase, Czurkó, Mamiya, & Buzsáki, 1999; Csicsvari et
al., 2003; Suffczynski, Crone, & Franaszczuk, 2014; Traub, Jefferys, & Whittington,
1997; M. A. Whittington, Traub, & Jefferys, 1995).
A primary role for cortical interneurons is to provide synchronization inhibition
for the PNs, and permit PNs to then synchronize their activity in the transient gaps of
inhibition (Blatow et al., 2003; Cobb, Buhl, Halasy, Paulsen, & Somogyi, 1995;
Hartwich, Pollak, & Klausberger, 2009; Lytton & Sejnowski, 1991; M. A. Whittington et
al., 1995). Perturbations that disrupt the balance of excitation and inhibition can lead to
deleterious consequences to the cognitive ability of mammals. Disorganized BOs is one
of the features of numerous mental illnesses, such as schizophrenia (Cho, Konecky, &
Carter, 2006; Hirano et al., 2015; David A. Lewis et al., 2012; Minzenberg et al., 2010),
which also coincides with abnormalities that downregulate activity of their inhibitory
neurons (Lodge, Behrens, & Grace, 2009). The relationship between BOs and their
symptoms is not presently clear but may be related to their disrupted sensory perception
and reduced cognitive ability (Green & Nuechterlein, 1999). However strong and
persistent GBOs are not always beneficial, for instance these GBOs are particularly
strong in people with chronic pain and tend to be weaker after therapy (Ebrahimian et al.,
2018). The use of opioid drugs disrupts cortical BOs (Gulyás et al., 2010; M. Whittington
et al., 1998; Y. Zhang et al., 2019).
These band oscillations are decent correlates of the task the subject is handling,
but they do not lend a mechanistic understanding of how the µOR is affecting cortical
processes. For instance, while the µOR is shown to increase net cortical excitation, EEGs
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cannot immediately relate that to glutamatergic activity. To accomplish that, I will refer
to a different kind of oscillation: calcium oscillations. Whereas band BOs are phenomena
produced by synchronous depolarizations of massive amounts of neurons in an intact
brain, calcium oscillations are smaller-scale events to visualize glutamatergic activity that
can be seen in neuronal cultures.
1.16 Calcium transients and excitability
Data from microelectrode array experiments in dissociated neurons demonstrate that
interventions that increase excitability of the neurons leads to global coupling and
uniform activity (Nakanishi & Kukita, 1998; Penn, Segal, & Moses, 2016). But to more
easily monitor network activity in many culture neurons at once, calcium-imaging has
been used to visualize excitation as synchronous calcium oscillations (calcium transients)
(Bacci, Verderio, Pravettoni, & Matteoli, 1999; Inglefield & Shafer, 2000; Robinson et
al., 1993). This produces a sporadic “flickering” effect in cultured neurons from the
transient binding of calcium the calcium-indicator dye loaded into neurons. These
flickering events are often synchronized in multiple neurons at once, but this is not
always the case. Several groups have done experiments to determine the cause of these
calcium oscillations, and these oscillations relate to neuronal activity.
To investigate the cause of these calcium oscillations, various groups have
simultaneously recorded electrophysiology and calcium-dye fluorescence to correlate the
two. They found that these oscillations correspond to bursts APs on top of a feature that
resembled an EPSPs (Bacci et al., 1999; Muramoto, Ichikawa, Kawahara, Kobayashi, &

38

Kuroda, 1993; T. H. Murphy, Blatter, Wier, & Baraban, 1992; Przewlocki et al., 1999;
Shen, Piser, Seybold, & Thayer, 1996; Sombati & Delorenzo, 1995).
The oscillations can be prevented by blocking depolarizations with TTX, or by
blocking all glutamate receptors (Dravid & Murray, 2004; Lo, Fallert, Piser, & Thayer,
1992; T. H. Murphy et al., 1992; Nuñez, Sanchez, Fonteriz, & Garcia‐Sancho, 1996;
Przewlocki et al., 1999). Blocking voltage-gated calcium channels generally does little to
weaken the oscillations, which indicates that these channels are not a major route for
calcium entry in this phenomenon (Cao et al., 2014; Dravid & Murray, 2004). In some
instances, inhibition of Phospholipase C abolished the waves indicating that calciuminduced calcium release was a large component of this effect (Dravid & Murray, 2004).
However, groups are split on whether the major source of calcium to activate PLC is
through NMDA receptors that conduct extracellular Ca2+ into the cells, or from the
internal stores by an mGluR coupled to a Gq protein (Dravid & Murray, 2004; Przewlocki
et al., 1999).
The identity of the glutamate receptor responsible for the calcium oscillations, and
the contribution of calcium-induced calcium release has become a point of disagreement
for researchers. This disagreement at least partially stems from the [Mg] used in the
ACSF, with some groups preferring physiological concentrations while others use no-Mg
ACSF to amplify and synchronize the oscillations; some researchers have tested these
oscillations in presence of low [Mg2+] and have proposed that these calcium oscillations
are due to the calcium-conducting properties of the NMDA receptors (Canepari, Bove,
Maeda, Cappello, & Kawana, 1997; Hemstapat, Smith, & Monteith, 2004; Inglefield &
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Shafer, 2000; Lawrie, Graham, Thorn, Gallacher, & Burgoyne, 1993; Nuñez et al., 1996;
Penn et al., 2016; Shen et al., 1996; T. Tanaka, Saito, & Matsuki, 1996; X.-s. Wang &
Gruenstein, 1997), but others have tested these oscillations at physiological [Mg2+] and
argued that calcium oscillations are mostly caused by calcium-conducting AMPA
receptors and Group I metabotropic Glutamate receptors (mGluRs) coupled to calciuminduced calcium release (Bacci et al., 1999; Cao et al., 2014; Dravid & Murray, 2004;
Flint, Dammerman, & Kriegstein, 1999).
Somewhat confusingly, “calcium oscillation” and “calcium wave” are frequently
used interchangeably through the literature I have cited here; a distinction should first be
made regarding the durations of these events and the cell types that they occur in. One
well-known calcium-imaging phenomena are the slow calcium waves which are usually
observed in non-excitable cells (e.g., glia, HEK293 cells), though they can be relayed to
neurons as well (Berridge, 1993; Kawabata et al., 1996). These slow calcium waves
typically have long rise and decline phases; they can take 10s of seconds to rise and can
last for several minutes (J. W. Dani, Chernjavsky, & Smith, 1992). Calcium waves are
believed to be a phenomenon that results from gap junctions and the slow spread of IP3
(which can stimulate the release of Ca2+ from internal stores) through them (Balaji et al.,
2017; Leybaert & Sanderson, 2012). However, calcium waves can be instigated by
glutamatergic activity, thus there may be a causal relationship between the 2 phenomena
(Zur Nieden & Deitmer, 2005). Calcium oscillations are on the shorter scale; they consist
of calcium spikes that can rise in less than a second, and then taper off back to baseline
over the course of a few seconds. These shorter oscillations have been found previously
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in cultured neocortical neurons and correspond to activation of postsynaptic glutamate
receptors through glutamate release. Though IP3 may very well be involved in these
oscillations, there was no evidence that it was spreading through gap junctions in neurons
(Dravid & Murray, 2004; T. H. Murphy et al., 1992).
These calcium oscillations are linked to development and gene expression in
neurons (Dolmetsch, Xu, & Lewis, 1998; Spitzer, Olson, & Gu, 1995). Oscillations may
also have a neuroprotective effect against rising [Ca2+]in that follow neurological trauma
(possibly by dismounting NMDA receptors from the actin cytoskeleton) (Geddes-Klein,
Serbest, Mesfin, Cohen, & Meaney, 2006).
This model has been used previously to study activation of luteinizing hormonereleasing neurons (Terasawa, Schanhofer, Keen, & Luchansky, 1999), and their response
to estrogen (Abe, Keen, & Terasawa, 2008); the effects of the kappa opioid receptor on
glutamate release in spinal cord cultures (Kelamangalath, Dravid, George, Aldrich, &
Murray, 2011); the excitatory effects of nicotine on neocortical neuron cultures (J. Wang
et al., 2016); cannabinoid regulation of glutamate release in the hippocampus (Shen et al.,
1996); HIV-1 envelope protein and cytotoxicity (Lo et al., 1992); environmental toxins
on neurons (Inglefield & Shafer, 2000); and dopamine receptor 4 on hippocampal
cultures (Y.-L. Wang et al., 2017). Efforts are also underway to develop this model to
study seizure-related drugs; the hypersynchrony observed under certain conditions
(including low Mg2+) resemble that of epileptiform patterns (Cao et al., 2015; Pacico &
Mingorance-Le Meur, 2014).
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While the effects of the µOR on network activity is one thing, the receptor’s
mechanism inside the neuron is another. Due to the boom in interest in the µOR, there is
much known about this receptor’s intracellular cascade and target ion channels. However,
there is a great deal that is not known because of the µOR’s vast complexity. In order to
explain the unknown features of this receptor, I will provide more details about the
receptor, its ligands, and its intracellular signaling pathway.
1.17 Opioid receptors
There are 3 known types of opioid receptors the Δ Opioid Receptor (DOR), the µ
Opioid Receptor (µOR), the Κ Opioid Receptor (KOR) (Al-Hasani & Bruchas, 2011). All
these ORs are Gi-coupled Protein Receptors. Several other receptors were initially
proposed as ORs (e.g., sigma and opioid-like receptor 1) but were subsequently ruled out
as classical opioid receptors due to their wide binding profile to non-opioid
neurotransmitters (Sauriyal, Jaggi, & Singh, 2011; Stein, 2016). But these receptors may
still play a modulatory role in the effects of the 3 classical opioid receptors (F. J. Kim et
al., 2010; Kobayashi, Ikeda, Ichikawa, Togashi, & Kumanishi, 1996).
Opioid receptors can be found in both peripheral and central locations; besides the
brain, they can also be found on immune cells, neuroendocrine organs and some
ectodermal cells. Opioid receptors are subjected to alternative splicing posttranslational
modifications to introduce variety in receptor properties. Generally, both the DOR and
µOR can be found throughout most of the neocortex. The KOR can also be found in the
deep layers of the neocortex but is less concentrated than the other ORs (Hiller & Fan,
1996; Merrer, Becker, Befort, & Kieffer, 2009).
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Opioid receptors are also believed to form homodimers or heterodimers with
other ORs in vitro and in vivo, though this view is not universally accepted (Cvejic &
Devi, 1997; Y.-X. Pan, Bolan, & Pasternak, 2002; Prinster, Hague, & Hall, 2005; Rios,
Jordan, Gomes, & Devi, 2001; D. Wang, Sun, Bohn, & Sadée, 2005). While all the
implications of heterodimerization of ORs is not immediately clear, this possibility
introduces more variability into the response of these receptors to agonist binding and the
receptors may therefore mix their signaling pathways.
The KOR earned a lot of attention as a potential target for therapy since it was an
opioid receptor that is not associated with addiction. Unfortunately, the KOR agonists are
not clinically useful for pain relief, though their antagonists might be. The KOR tends to
have the opposite effects of the µOR and DOR. While µOR-acting drugs are euphoric,
hedonic, and addictive; KOR agonists are usually just unpleasant (dysphoric),
hallucinogenic, and dissociative - and therefore not drugs of abuse (Chavkin, 2011;
Shippenberg, 2009). But this aversion and dysphoric is not always seen in KOR-acting
drugs (Butelman & Kreek, 2015). These receptors can be found in the PFC, where they
inhibit dopamine release from VTA afferents there (Tejeda et al., 2013). However, there
is still interest in developing KOR agonists to treat itchiness and opioid abuse (Chavkin,
2011), or KOR antagonists to treat chronic stress and anxiety (Chavkin, 2011; Knoll &
Carlezon, 2010).
The DOR has attracted interest as a potential target for therapy and specific
peptidergic drugs have developed to study this receptor (Gavériaux-Ruff & Kieffer,
2011). However, this receptor has not benefitted from the boom in interest that µOR43

acting drugs have brought to that receptor. DOR knockout mice show relatively subtle
changes in pain response (Martin, Matifas, Maldonado, & Kieffer, 2003). Interestingly,
whereas the µOR is useful for acute pain and acute mood problems, the DOR may be
more useful for chronic pain and depression (Filliol et al., 2000; Gavériaux-Ruff &
Kieffer, 2011; Nadal, Baños, Kieffer, & Maldonado, 2006; Scherrer et al., 2006;
Valentino & Volkow, 2018). However, they tend to also have convulsive effects and
research has progressed only slowly and cautiously (Pradhan, Befort, Nozaki, GavériauxRuff, & Kieffer, 2011; Saitoh & Yamada, 2012).
1.18 µ opioid receptor
The µOR is the principal site of exogenous opioidergic drugs (Valentino & Volkow,
2018). The µOR has benefitted greatly from the surge in interest of opioid receptors.
To discover the role of the µOR in adults, scientists performed gene knockouts in
mice of the µOR and tested their analgesia, addictive tendencies, motivation, and
maternal attachment. Mice that lack the µOR are resistant to morphine addiction and
analgesia (Matthes et al., 1996; Merrer et al., 2009). µOR knockout mice also suffer from
reduced motivation to eat and reduced maternal attachment (Kas et al., 2004; Papaleo,
Kieffer, Tabarin, & Contarino, 2007). Therefore, this specific receptor appears to be the
primary OR in mediating the effects of exogenous opioidergic drugs, as well as the
endogenous means for motivation and pain suppression.
The µOR can be found throughout much of the neocortex, except in visual
regions at the posterior side of the brain. It can be found in a roughly caudal-to-rostral
gradient and, consequently, is more concentrated in frontal regions of the brain. Its
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staining is relatively dense in Layer 3, followed by Layers 1 and 2 (Hiller & Fan, 1996).
The µOR is expressed at birth, but expression gradually increases for the first several
postnatal weeks (Clendeninn, Petraitis, & Simon, 1976; Coyle & Pert, 1976; Garcin &
Coyle, 1977). I have previously alluded to the difficulty of developing antibodies to
GPCRs and the µOR, which I will now explain in more detail.
One of the most remarkably-paradoxical features of the µOR, is that this
expression of this receptor is driven by only one gene – the OPRM1 (oprm1 in rodents,
according to IUPHAR nomenclature) gene – and yet its effects and regulation introduce a
spectrum of features that make it difficult to study (Classification, 2020). This receptor is
extremely variable due to splice variants, RNA editing, post-translational modifications,
presumed multiple agonist binding sites, functional selectivity, and other characteristics
that introduce variability into their structure and binding profile (Groer et al., 2007;
Gavril W. Pasternak & Pan, 2013). Its property of functional selectivity (also called
biased agonism) is a particularly problematic aspect to understand, because this receptor
can respond differently to different agonists.
This variability is on full display with opioid-acting drugs causing vastly different
opioid effects on different patients (Cherny et al., 2001) and rodent strains (Mogil, 1999;
Reith, Sershen, Vadasz, & Lajtha, 1981). In other instances, µOR antagonists are unable
to reverse all µOR agonist effects in patients when they are taken concurrently (Andoh et
al., 2008). The variable states of the receptor may be the factor that allows patients to
cycle drugs to mitigate the effects of opioid tolerance to specific µOR-acting drugs
(Cherny et al., 2001; Moulin, Ling, & Pasternak, 1988).
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Localization of this receptor has primarily been driven by autoradiography and
ICC, but both techniques have shortcomings and points of disagreement due to the nature
of this receptor. The µOR is one of the few receptors known to have distinguishable
agonist and antagonist conformations; radiolabeled antagonists tend to label the receptor
more widely than agonists, and therefore antagonist conformation usually assumed to be
the more stable conformation (Bruno Cauli et al., 1997). These conformations may be
strongly influenced by presence by ions, including Na+ and Mg2+ (G. W. Pasternak,
Snowman, & Snyder, 1975).
Antibodies for the µOR have primarily been limited to C-terminus epitopes for
the µOR because of the receptor’s susceptibility to glycosylation on the external side
(Gavril W. Pasternak & Pan, 2013). However, the C-terminus of the µOR is also the
primary source of variation between splice forms, which prevents primary antibodies
from recognizing all forms of the µOR (Abbadie, Pan, Drake, & Pasternak, 2000; Gavril
W. Pasternak & Pan, 2011). For a review of these characteristics, see (Gavril W.
Pasternak & Pan, 2013).
There are several known splice variants of the OPRM1/oprm1 gene, which have
unique regional distributions through the brains of rodents (Abbadie et al., 2000; Y. X.
Pan et al., 1999), Studies have found OPRM1/oprm1 to be well-conserved in rodents and
humans, which at least lends itself to study in rodent models (J. Xu, Xu, Rossi, Pasternak,
& Pan, 2011).
The µOR shows the properties of ‘biased agonism’ or ‘functional selectivity’ and
makes the µOR’s potential effects more variable. This property allows the receptor to
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respond differently to different agonists. This has implications for trafficking,
desensitization, and intracellular mechanisms of the receptor which will be discussed
later (von Zastrow, 2010). While precise terms (e.g. “full agonist”) has traditionally been
applied to particular ligands, the influence of functional selectivity enables receptors to
have much more varied responses than this general terminology permits (Raehal, Schmid,
Groer, & Bohn, 2011).
1.19 Endogenous opioid ligands
Endogenous opioids are all peptide neurotransmitters that are derived from prepropeptides. These pre-propeptides are processed through posttranslational modifications,
splicing, and proteolytic cleavage to yield several different peptide neurotransmitters
from the same family (McLaughlin, 2013). Although there may be dozens of individual
endogenous opioids, they can be grouped into just a few categories based on a common
epitope. Enkephalins (µOR and DOR) are mostly derived from preproenkephalin-A gene,
dynorphins (KOR) are derived from the Dynorphin-A gene, and β-endorphins (µOR and
DOR) are derived from the prohormone proopiomelanocortin (POMC) (McLaughlin,
2013; McLaughlin & Zagon, 2013; Spampinato, Bedini, & Baiula, 2013; Taki et al.,
2000). However, POMC is not transcribed in the neocortex and therefore will not be
discussed here further (Gee, Chen, Roberts, Thompson, & Watson, 1983). There is also a
fourth group of opioid peptides – the endomorphins which are products of a presentlyunidentified pre-propeptide. Endomorphins 1 and 2 (µOR) are especially powerful and
specific agonists for the µOR. These peptides are a product of an unknown precursor
(Terskiy et al., 2007).
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The Pre-proenkephalin A gene produces 6 peptides from the 2 major varieties of
enkephalin (Enk); Met-enkephalin (Met-Enk) and Leu-Enkephalin (Leu-Enk). This gene
produces multiple forms of Met-Enk, including an octapeptide and heptapeptide, but only
one form of Leu-Enk (McLaughlin, 2013). Meanwhile Pre-prodynorphin A transcripts,
which mostly produces KOR-acting peptides, also contains a sequence for Leu-Enk on a
decapeptide. Although this Leu-Enk can stimulate the µOR, other dynorphins products do
not (Spampinato et al., 2013). Pre-prodynorphin and Pre-proenkephalin proteins have
been observed extensively in both interneurons and some PNs, but mostly interneurons
(Alvarez‐Bolado, Fairén, Douglass, & Naranjo, 1990; Fallon & Leslie, 1986; Olenik &
Meyer, 1997). Interestingly, these pre-propeptides are often produced by the same
neurons that express the µOR, suggesting that these are autocrine and paracrine
regulators as well (Férézou et al., 2007; Taki et al., 2000).
Enkephalins are highly expressed in the neocortex by several types of neurons,
though localizing it to specific neurons has been a problem despite its high expression
there. As pointed out by Férézou et al. (2007), the concentration of enkephalins in the
neocortex is 4 times more than the concentration of VIP – which is considered to be a
major marker for many interneurons (Crawley, 1985; Lindberg, Smythe, & Dahl, 1979;
Rossier et al., 1977). Yet experiments generally show relatively restricted expression of
the precursor to µOR+ neurons; ICC experiments in the neocortex show a very high
degree (80-90%) of overlap between expression of the µOR and pre-proenkephalin
within the same interneurons (Taki et al., 2000). On the other hand, experiments that used
colchicine treatment – as well as Ferezou et al.’s own sc-PCR data – show that PNs do
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often have low levels of the neurotransmitter which may not be detectable with the ICC
experiments used extensively (F, van der Kooy, & Bloom, 1984; Férézou et al., 2007).
Genetic deletion of pre-proenkephalin A in mice produces offspring that are
surprisingly healthy and seemingly normal – they even have normal stress-induced
analgesia. However, they are also hyper-aggressive and anxious (König et al., 1996).
These knockout mice, interestingly, are also resistant to the effects of chronic stress and
depression (Bilkei-Gorzo, Michel, Noble, Roques, & Zimmer, 2007; Melo, Drews,
Zimmer, & Bilkei-Gorzo, 2014).
Endomorphins 1 and 2 (EM-1 and EM-2) are very highly selective and have high
affinity for the µOR, but less is known about those neurotransmitters (Hackler, Zadina,
Ge, & Kastin, 1997; Martin-Schild, Gerall, Kastin, & Zadina, 1999; Mizoguchi,
Sakurada, & Sakurada, 2013; Terskiy et al., 2007; J. Zadina, Kastin, Ge, & Hackler,
1994; J. E. Zadina, Hackler, Ge, & Kastin, 1997). They are products of an unidentified
precursor protein which unfortunately has made it difficult to localize to particular
neurons (Terskiy et al., 2007). EM-1 can be found abundantly in the cerebral cortex,
while EM-2 is reportedly rarer in the cortex according to ICC data (Gu et al., 2017;
Martin-Schild et al., 1999; Schreff, Schulz, Wiborny, & Höllt, 1998). However, both
endomorphins have been reported in human cortical brain lysates in reportedly high
concentrations, though a direct comparison with other neurotransmitters is difficult to
make with these limited data (Hackler et al., 1997).
Therefore endomorphins 1&2 and enkephalins are the endogenous
neurotransmitters for the (neocortical) µOR. While they have a spectrum of selectivity
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and affinity, and given this wide variety of µOR agonists, efforts were devoted to
selecting a highly selective and high-affinity agonist for the µOR.
1.20 DAMGO
To study the physiological effects of the µOR, obviously, an agonist is needed. While
there are many opioid peptides, they have varying levels of specificity and affinity for the
µOR. The endogenous forms of enkephalins have off-target binding to other ORs (mostly
to the DOR) (Merrer et al., 2009; Takahashi, 2016). Considering that endogenous opioids
already consist as many different peptides, efforts were made to produce a specific,
stable, high-affinity µOR agonist that was structurally derived from the endogenous
peptide and therefore had similar receptor effects as endogenous forms of enkephalins
(Handa et al., 1981).
The synthetic peptide [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO) was
discovered to be a selective agonist for the µOR and is used extensively for µOR-related
research ranging from brain slices (Bushell et al., 2002; Chiou & Huang, 1999; Faber &
Sah, 2004; Férézou et al., 2007; Finnegan, Chen, & Pan, 2006; McQuiston, 2008; Qu et
al., 2015; K. R. Svoboda et al., 1999; Witkowski & Szulczyk, 2006), to in vivo testing
(Castro & Berridge, 2014; Helmstetter et al., 1998; Kekesi et al., 2011; Ma et al., 2020;
Newman, Pascal, Sadeghian, & Baldo, 2013; Selleck et al., 2015), to cell culture (Patel et
al., 2006; Piros, Prather, Law, Evans, & Hales, 1996; Piros et al., 1995; Przewlocki et al.,
1999; Rubovitch et al., 2003; E. Tanaka & North, 1994). The currently favored
pharmacological antagonist for the µOR is CTAP D-Phe-Cys-Tyr-D-Trp-Arg-Thr-PenThr-NH2 (CTAP) for its specificity and low promiscuity (Carrero, Kaigler, Hartshorn,
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Fadel, & Wilson, 2019; B. Chieng, Connor, & Christie, 1996; Falk et al., 2020; Ma et al.,
2020).
1.21 Opioid receptor intracellular cascades
The µOR has a complex intracellular cascade that can terminate with regulation ion
channel proteins, as well as transcription factors. Unfortunately, due to the complexity of
this receptor, the details for its mechanism in regulating potassium channels are not
completely well-understood. However, experiments done in heterologous systems and
neurons show some key components that will be discussed here. I will outline its basic
intracellular cascade in this section. But later, I explain its interaction with specific ion
channels.
The superfamily of opioid receptors is composed of seven transmembrane
spanning (7TM) segments and signal through Gi/Gs signaling pathways. They are
categorized as class A (Rhodopsin) Gi/Go G-protein coupled receptors with an
extracellular N-terminal and an intracellular C-terminal end (Katritch, Cherezov, &
Stevens, 2013). They are usually coupled to pertussis toxin-sensitive heterotrimeric Gi/Go
proteins (Law et al., 2000). Binding of agonists results in activation of both α and βγ
subunits of the G-protein complex, which can interact with separate signaling pathways
and can itself deactivate some ion channels through a direct interaction. The Gβγ subunits
interacts with calcium channels directly (more about ion channels later), while the Gαi
subunit typically inhibits adenylyl cyclase and suppresses cAMP formation (Zamponi &
Snutch, 2002). Diminished levels of cAMP can downregulate PKA and lead to decreased
levels of phospho-CREB, which then causes upregulation or downregulation of different
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genes (Nonnemacher et al., 2017; Purves, 2008). While this may cause acute effects, the
most consequential gene regulation changes may occur when cellular tolerance creates
chronic hyperactivation of PKA and cAMP, which then causes gene expression changes
(Bilecki & Przewlocki, 2000; Noble & Cox, 1996; Terwilliger, Beitner-Johnson,
Sevarino, Crain, & Nestler, 1991). However, the route to ion channel regulation is more
convoluted.
The downregulated PKA releases Phospholipase AA (PLA2) from inhibition (Zor
& Reiss, 1991). Activated PLA2 metabolizes the esterified form of arachidonic acid,
found in cell membranes, and the metabolized product can participate in at least 3
pathways; the cyclooxygenase, lipoxygenase and expoxygenase (cytochrome p450
pathway) (Piomelli & Greengard, 1990; Vaughan, Ingram, Connor, & Christie, 1997).
The cyclooxygenase pathway leads to formation of prostaglandins, prostacyclin, and
thromboxane A2. The lipoxygenase pathway results in formation of 12-lipoxygenase
products. Inhibition of the cyclooxygenase and 5-lipoxygenase pathways potentiated the
µOR’s neurophysiological inhibition of hippocampal neurons, while inhibition of 12lipoxygenase blocked much of it (Vaughan et al., 1997). These data suggest that the 12lipoxygenase pathway likely mediates some of the µOR’s inhibitory effect in
hippocampal interneurons. The authors also found that inhibition of PLA2 likewise
blocked the effect of DAMGO and it appears that PLA2 was the enzyme that was
cleaving arachidonic acid (Vaughan et al., 1997). This pathway likely also contributes to
the synergistic effects of NSAIDs (which block the cyclooxygenase pathway) and opioid
drugs by directing AA metabolites towards the 12-oxygenase pathway (MacDonald J
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Christie, Connor, Vaughan, Ingram, & Bagley, 2000; M. J. Christie, Vaughan, & Ingram,
1999).
There is also strong evidence that Gβγ subunits from Gi receptors can activate
phospholipase C (PLCβ). This mobilizes intracellular calcium release and increase
Protein Kinase C activity and IP3 levels, even though this mechanism is typically
associated with Gq receptors rather than Gi receptors (C. L. Huang, Feng, & Hilgemann,
1998; Law et al., 2000; Rubovitch et al., 2003; Smart & Lambert, 1996; Smart, Smith, &
Lambert, 1994; Tsu, Chan, & Wong, 1995; Zimprich, Simon, & Höllt, 1995). While this
finding may be somewhat controversial, a group did find that PKC (and PKA) may
mediate some of the µOR’s inhibitory effects in neocortical interneurons (Witkowski &
Szulczyk, 2006). Other research has shown that DAMGO can upregulate the activity of
PLCβ, and that PLCβ is necessary to mediate the antinociceptive effects of morphine in
mice (W. Xie et al., 1999). Consistent with this, PLCβ I implicated in increasing the
activity of PLA2, which I previously mentioned cleaved arachidonic acid to mediate the
µOR’s regulation of voltage-sensitive K channels in hippocampal neurons (Zor & Reiss,
1991). Additionally, µOR activation of Gαq proteins has also been reported as mediating
some of the supraspinal analgesic effects of opioids as well (Sánchez-Blázquez, GómezSerranillos, & Garzón, 2001).
The µOR may have more direct and indirect interactions with many receptors and
ion channels; it co-immunoprecipitates with the NR1 subunit of NMDA receptors
(Rodríguez-Muñoz, Sánchez-Blázquez, Vicente-Sánchez, Berrocoso, & Garzón, 2012);
the µOR, intracellular calcium, and NMDA receptors may work collaboratively to alter
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gene transcription (Chartoff & Connery, 2014; Hyman, Malenka, & Nestler, 2006;
Konradi, Cole, Heckers, & Hyman, 1994). NMDA receptor antagonism has also been
shown to reverse the effects of morphine tolerance, suggesting some upregulation of
NMDARs occurs, though it may not be clearly demonstrated to occur as a direct
regulation – as opposed to a disinhibitory effect and increase in glutamatergic outflow
(Trujillo & Akil, 1991).
On the topic of biased agonism and functional selectivity, researchers have
observed that different agonists can differentially regulate intracellular signaling
pathways. Application of the label-free integrative pharmacology on-target (iPOT)
approach demonstrated that dozens of µOR agonists could bias the receptor towards
different pathways (Morse, Sun, Tran, Levenson, & Fang, 2013). This has also been
demonstrated on a smaller scale and appears to result from biased activation of different
Gαi/o proteins associated with the receptor (S. Allouche, Polastron, Hasbi, Homburger, &
Jauzac, 1999; Massotte, Brillet, Kieffer, & Milligan, 2002; Raehal et al., 2011). There are
also many studies that have found that different agonists can induce phosphorylation of
the µOR at several different sites (Grecksch et al., 2011; McPherson et al., 2010; Rivero
et al., 2012; Y. Yu et al., 1997).
Naturally, this raises the issue of how these different effects relate to the
intracellular signaling cascade, and eventually, to different neurophysiological effects of
different ligands. Unfortunately, limitations to understanding this phenomenon are
imposed by current technology, different cell types that express the µOR, and the dozens

54

of exogenous and endogenous ligands available to screen. Some of these repercussions
are discussed later.
1.22 Opioid desensitization
In addition to the addictive potential of opioids, the µOR is known to desensitize and
accumulate tolerance to follow-up exposure to agonists. This reduces the effect of opioid
agonists over the course of sequential doses and can ultimately require higher doses to
achieve the same effect. Adaptations that occur over longer-term exposure are usually
classified as tolerance, while shorter term adaptive responses to acute effects are
classified as desensitization. Desensitization can happen within minutes (Stéphane
Allouche, Noble, & Marie, 2014). Tolerance can develop against all actions of opioids,
but it accumulates at different rates for different aspects (Blanchet & Lüscher, 2002;
Gavril W. Pasternak & Pan, 2013). Similarly, different biochemical effects of ORs can
desensitize at different times (Stéphane Allouche et al., 2014).
Studies using in vitro models to research the µOR report a wide variety of
desensitization properties. With DAMGO, desensitization is sometimes visible by 5
minutes of exposure with observable reductions in DAMGO effects, but usually takes 1020 minutes – or even longer than that (Koch et al., 2005; Law et al., 2000; Raehal et al.,
2011). This varies system-to-system, and agonist-to-agonist. Morphine is highly
desensitizing, while DAMGO is less desensitizing; co-applying DAMGO with morphine
can reduce morphine-alone desensitization, suggesting that this principle may have
clinical applications (Finn & Whistler, 2001; Ma et al., 2020). Different pathways can
also desensitize along different timelines, for instance; the presynaptic effects
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(interactions with voltage-sensitize calcium channels) is stable for at least 15 minutes
after exposure to DAMGO, but the postsynaptic effects are significantly reduced at that
timepoint (Blanchet & Lüscher, 2002).
Many explanations and mechanisms for the development of desensitization (and
ultimately tolerance) revolve around the trafficking and regulation of the µOR after it has
bound a ligand, therefore the endocytic cycling process will be discussed next.
1.23 µOR endocytic cycling
Opioid receptors, like many GPCRs, can be rapidly endocytosed by clathrin-coated pits.
β-arrestin, which binds to activated ORs, facilitates this process (S. S. Ferguson et al.,
1996; Goodman et al., 1996). Endocytosis can also be facilitated by phosphorylation by
GRKs (Kovoor, Celver, Abdryashitov, Chavkin, & Gurevich, 1999). Consistent with the
functional selectivity of the µOR, this process is remarkably influenced by the ligand;
morphine usually does not lead to internalization of the receptor, but DAMGO (including
in cultured rat neocortical neurons), etorphine, methadone, and fentanyl all do rapidly
(Finn & Whistler, 2001; L. He, Fong, Von Zastrow, & Whistler, 2002; Keith et al., 1998;
Keith et al., 1996; Schulz et al., 2004; Trafton & Basbaum, 2004). DAMGO can also
recruit β-arrestins more consistently than morphine is able to (Bohn, Dykstra, Lefkowitz,
Caron, & Barak, 2004; Whistler & Von Zastrow, 1998, 1999; Jie Zhang et al., 1998).
Recruitment of β-arrestins does not halt all of the intracellular signaling pathway, though
some branches of the pathway may stop (Williams et al., 2013). Failing to induce rapid
internalization of the µOR may lead to quick desensitization of the receptor (Williams et
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al., 2013). For a review of the µOR, functional selectivity and desensitization, see
(Raehal et al., 2011) or (Williams et al., 2013).
Once endocytosed, the ligand dissociation can occur and the receptor can be
sorted to its new destination; the µOR can potentially be shuttled back to the cell
membrane, or to a lysosome for destruction (von Zastrow, 2010). Trafficking it back into
the membrane can promote resensitization by enabling it to activate again, while the
lysosome will lead to its proteolytic destruction (Ma et al., 2020; von Zastrow, 2010).
Numerous factors can influence this fate, for instance ubiquitylation has been shown to
exert an influence on the fate of endocytosed ORs (J.-G. Li, Haines, & Liu-Chen, 2008),
or the splice variant of the µOR (Tanowitz, Hislop, & von Zastrow, 2008; Tanowitz &
von Zastrow, 2003). Coactivation of other receptors can influence recycling of the
receptor, for instance, the NK1 neurokinin receptor (activated by substance P) can reduce
arrestin activity and receptor endocytosis (Y. J. Yu, Arttamangkul, Evans, Williams, &
Von Zastrow, 2009).
Some have proposed that agonist-induced endocytosis enhances sensitivity and
allows drugs like DAMGO (which promotes endocytosis) to be less desensitizing than
drugs like morphine, which typically does not promote endocytosis (Finn & Whistler,
2001; Ma et al., 2020). Others have argued against this view by claiming endocytosis is
not the causal factor, though this may be a heuristic to relate endocytosis to
desensitization (Finn & Whistler, 2001; Gavril W. Pasternak & Pan, 2013).
Although the existence of µOR/DOR dimers has not been proven, there is
evidence that these dimers may promote the development of tolerance. Heterodimers of
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the mu/delta opioid receptors are suspected to play a role in development of tolerance (S.
Q. He et al., 2011). DOR agonism promotes µOR desensitization (S. Q. He et al., 2011),
while disrupting µOR domains suspected of linking µOR/DOR dimers also disrupts
tolerance (S. Q. He et al., 2011). Some have pointed out that the DOR appears to have the
opposite tolerance/trafficking pattern of the µOR; endocytosing the DOR correlates with
greater tolerance (Scherrer et al., 2006; von Zastrow, 2010). For a review of opioid
heterodimers and tolerance, see (Gavril W. Pasternak & Pan, 2011).
1.24 Basics of neurophysiology
Ohm’s Law states that V=IR and therefore generation of a voltage requires a current to
move through a resistor. Neurons use their plasma membrane (PM) is a natural resistor
and conduct ionic currents through the plasma membrane, which then produces its
membrane voltage (Vm). Different ion currents can create different voltage magnitudes
and polarities; therefore, a neuron can modulate its Vm by controlling which (and when)
ions can cross the PM. When a neuron sends its signal, it does so by rapidly changing its
polarity, and then rapidly repolarizing to its initial starting point. It does this by rapidly
changing the identity of the dominant ion that can pass through the PM. This
depolarization is called an Action Potential (AP). Neurons normally start off with a
negative polarity compared to their extracellular environment. During an AP (also called
a spike), their polarity rapidly shifts from negative to positive. They can do this by
rapidly altering the permeability of their PM to different ions and therefore change the
rapidly ionic current through their PM.
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Differential distributions of ions on the inside and outside of cells creates an ion
gradient. Given the opportunity (permeability through the PM), the ions will diffuse
down their concentration gradient. Sodium and calcium ions are highly concentrated on
the outside of the cells and therefore will diffuse into the inside of cells through sodium
ion channels and calcium ion channels. This creates a depolarizing effect on the neuron
and a transiently-positive Vm during an AP. Importantly, these depolarizations also allow
calcium ions to enter and interact with various biochemical pathways – for instance, by
enhancing neurotransmitter release at synaptic terminals or activating gene transcription
and synaptogenesis. Potassium is highly concentrated on the inside of the cells. The
outward potassium current has a hyperpolarizing effect on cells. Neurons at rest (not
during an action potential) have a relatively high permeability to potassium and therefore
restricts their excitability. Neurons have very high resistance and therefore can maintain
and alter their polarity with very little current (very little ion flow).
Each cell has a resting membrane potential (RMP) produced to the slow outward
K current and a little inward sodium current. GPCRs, such as the µOR, can add or
subtract leak channels from the membrane. In the µOR’s case, it can make the RMP more
negative (more hyperpolarized) by opening more leak channels. The details and identities
of these channels will be given later, but the µOR is also implicated in trafficking
voltage-sensitive channels, which are more complex.
GPCRs can move voltage-sensitive ion channels (VSICs) that are mostly not open
at rest. These VSICs but can open/close in response to a change in Vm. After opening,
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they may rapidly inactivate. But others do not inactivate and simply stay open until the
Vm moves out of their preferred range.
These voltage-sensitive ion channels, which affect Vm, can themselves also be
triggered by changes in Vm, and this sets up a potential positive feedback loop. Voltagesensitive sodium channels, for instance, are activated by depolarized Vm, but themselves
also create a more-depolarizing Vm before they inactivate and close. These Voltagesensitive sodium channels create sharp APs (spikes) as they open and then inactivate.
Voltage-sensitive calcium channels act similarly but are even more depolarizing, and the
calcium ions they conduct can interact with biochemical pathways. Voltage-sensitive
potassium channels, meanwhile, can dampen this chain reaction (dampen APs or smaller
depolarizations that don’t rise to the level of an AP) by activating at depolarized Vm but
conduct an outward potassium current to repolarize the membrane and, thus, they
counteract the sodium and calcium channels by maintaining a strongly negative Vm and
preventing the sodium and calcium channels from opening.
There are also receptors, such as the NMDA and AMPA receptors that bind the
excitatory neurotransmitter glutamate and allow sodium (and sometimes calcium) to enter
and produce a transient depolarization. The NMDA receptor, though, is occluded by a
Mg2+ ion and frequently requires the AMPA receptors to depolarize the cell and dislodge
that ion. Therefore, they are channels that can initiate the process of an AP by binding
glutamate and causing a transient depolarization. The NMDA receptor (and some AMPA
receptors) can conduct calcium, and therefore also can cause gene transcriptional and
biochemical changes in the neuron.
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On the other side of the spectrum are the GABAA and GABAB receptors, which
are usually inhibitory and bind the inhibitory neurotransmitter GABA. GABAergic
interneurons activate these. These receptors, respectively, conduct an inward chloride
current, or an outward potassium current which both hyperpolarize the neuron and
counteract glutamatergic excitation. GABAA receptors are faster to open than GABAB
receptors, because GABAB receptors are GPCRs, that act indirectly – like the µOR does.
To put this together as an example, a typical resting neuron may receive
numerous, transient excitatory postsynaptic potentials (EPSPs) a result of their NMDA
and AMPA receptors and inhibitory postsynaptic potentials (IPSPs) from activation of
their GABAA and GABAB receptors. The outcome of those 2 forces depends on the
activity of the neuronal network as the. But eventually that Vm may become so positive
that it triggers a critical amount of voltage-dependent sodium channels to open causing a
spike (an AP). Voltage-sensitive potassium channels, which are slower to open, then
bring the Vm back down to a hyperpolarized Vm value, ending the AP. Neurons have
axons that these APs can be conducted along, and at the terminal ends of axons are
neurotransmitter vesicles which could contain glutamate, GABA, or other
neurotransmitters depending on the identity of the neuron. At the axon terminals, voltagedependent calcium channels can open during APs and allow calcium stimulate release of
neurotransmitter onto the next neuron. They will then release their glutamate, GABA,
enkephalins, and the cycle continues into the next neuron.
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1.25 Hyperpolarization by the µOR
The µOR has been observed to be strongly inhibiting on neurons with the receptor by
hyperpolarizing the neuron and diminishing its capability to fire APs, including with the
synthetic agonist DAMGO (Brunton & Charpak, 1998; B Chieng & Christie, 1994;
Childers, 1991; Ikeda, Kobayashi, Kumanishi, Niki, & Yano, 2000; Kovoor, Henry, &
Chavkin, 1995; Stein & Machelska, 2011; Stein & Zöllner, 2009). This is also observed
in cortical neurons as well with DAMGO (Férézou et al., 2007; Glickfeld et al., 2008;
Krook-Magnuson et al., 2011; K. R. Svoboda et al., 1999; Wimpey & Chavkin, 1991;
Witkowski & Szulczyk, 2006). This is normally one of the µOR’s faster responses (Law
et al., 2000). For a review of OR coupling with GIRK channels, see (Ikeda, Yoshii, Sora,
& Kobayashi, 2003).
Much of this hyperpolarizing effect has been attributed to G-protein coupled
inwardly-rectifying channels (GIRK or Kir3 channels), which are open at rest and
provide the cell membranes with a constant hyperpolarization and decreased input
resistance (A. M. Brown & Birnbaumer, 1990; Harris & Williams, 1991; Ikeda et al.,
2000; Kobayashi et al., 1996; Lüscher & Slesinger, 2010; Nockemann et al., 2013; R
Alan North, 1989; Signorini, Liao, Duncan, Jan, & Stoffel, 1997). Activation of these
channels is believed to be mediated by the Gβγ subunits of the G-protein complex (Raveh,
Cooper, Guy-David, & Reuveny, 2010). The µOR-mediated upregulation of GIRK
channels is the first interaction to desensitize, with significantly reduced upregulation of
GIRK channels occurring around 15 minutes (Blanchet & Lüscher, 2002). Tis subunit’s
regulation of GIRK channels is believed to be a direct interaction and can be terminated
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when the Gβγ subunit re-associates with the Gαi/o-GDP protein (Schreibmayer et al.,
1996).
There are 4 GIRK channels (GIRK1-GIRK4) but only GIRK1-GIRK3 are highly
expressed in the neocortex; GIRK4 is restricted to deeper layers and only found in small
amounts (Karschin, Dißmann, Stühmer, & Karschin, 1996; Murer et al., 1997). GIRK
channels form tetramers, and typically heterotetramers (Lüscher & Slesinger, 2010).
To understand the colocalization of the µOR and GIRK channels (GIRK1
specifically) researchers have used ICC with antibodies to both proteins in various parts
of the brain, including the neocortex. They found a high degree of overlap between these
2 proteins there in the soma and proximal dendrites of cortical neurons. However, the
overlap was not complete; distal puncta (presumed to be axon terminals) occasionally
stained for the µOR, but not GIRK1, indicating that the µOR’s inhibitory effect in distal
processes are not associated with hyperpolarization there (Suzanne B Bausch & Chavkin,
1995). Unfortunately, it appears that similar studies have not been attempted with GIRK1
or GIRK3.
Another important issue to address is whether µOR+ interneurons always
hyperpolarize when they are exposed to the µOR agonist, DAMGO. This is difficult to
answer since electrophysiology seems to be the most sensitive technique, for instance
Férézou et al. (2007) (Férézou et al., 2007) found µOR mRNA in only 20 out of 32
neurons (with sc-PCR) that hyperpolarized with DAMGO (Férézou et al., 2007).
According to Wimpey & Chavkin (1991) (Wimpey & Chavkin, 1991), most of their
DAMGO responders in the CA1/subiculum region of the hippocampal formation did not
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hyperpolarize, but instead activated unidentified voltage-sensitive K channels (VSKCs)
(Wimpey & Chavkin, 1991). It appears that while electrophysiology is still the most
sensitive technique, but hyperpolarization may not be the only indicator of a DAMGO
response (Férézou et al., 2007). It should also be noted that the GIRK1/µOR
colocalization study discussed earlier analyzed at least 20 different brain regions and
found the greatest degree of discordance of coexpression in the hippocampal formation
and therefore the neocortical µORs may be more likely to induce somatic
hyperpolarization than hippocampal µORs (Suzanne B Bausch & Chavkin, 1995).
In summary, it appears that a strong hyperpolarization may not be the only
indicator of a response to DAMGO and neurons. In addition to Wimpey & Chavkin
(Wimpey & Chavkin, 1991), there are numerous reports that cortical and noncortical
µORs can upregulate VSKCs in response to DAMGO (Faber & Sah, 2004; Finnegan et
al., 2006; Vaughan et al., 1997; Wimpey & Chavkin, 1991) and Met-Enk (Vaughan et al.,
1997) which is the next topic.
1.26 Voltage-sensitive K channels
Voltage-sensitive K channels (VSKCs) can be divided into several different groups based
on their shared properties. VSKCs can mediate either A-type current, which activates and
deactivates rapidly, or delayed rectifier current that activate slowly and deactivate slowly
or do not inactivate at all. They are also grouped into families based on their genetic
similarity; channels within the family typically generate the same type of current, but
sometimes they do not. These channels are expressed widely throughout the brain,
including the neocortex.
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The Shaker (Kv1) family of Kv channels comprise the largest group of voltagesensitive K channels. They are constituted of 4 α-subunits and sometimes auxiliary β
subunits. There are 6 known members expressed in the brain and are numbered Kv1.1Kv1.6. These peptides may homotetramerize with identical subunits, or they more form
heterotetramers with each other which can lead to various combinations of properties.
They are typically slower to inactivate, and they deactivate slowly, or not at all. They
tend to be triggered at more negative potentials when compared to other VSKCs (B Rudy
et al., 2009). These channels can be blocked with 4-aminopyridine (4-AP). The protein
αDendrotoxin (αDTX) selectively blocks Kv1.1, Kv1.2 and Kv1.6 subunits; possession
of even a single Kv1.1, Kv1.2 or Kv1.6 subunit in heterotetramers will result in channel
blockade. Their current is called D-type (ID) current due to their susceptibility to
dendrotoxin (B Rudy et al., 2009). The tendency of these channels to heterotetramerize,
complex with auxiliary subunits, and capability to undergo post-translation modifications
in their α and auxiliary subunits makes the function and properties of ID current extremely
variable. While the Kv1 channels are usually delayed rectifiers, Kv1.4 channels and other
Shaker modified Kv1 channels may mediate A-type current (Carrasquillo, Burkhalter, &
Nerbonne, 2012). The αDTX-sensitive current in has been reported to modulate threshold
voltage for action potentials, afterhyperpolarization, spike frequency, and small effects on
the AP repolarization kinetics rat visceral sensory neurons (Glazebrook et al., 2002).
This Shaker class of channels is believed to exert a strong influence over the
excitability of neocortical PVBCs (X. Li, Surguchev, Bian, Navaratnam, & SantosSacchi, 2012). The high sensitivity to voltage of these channels allows them to control
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repeated firing (J. Connor & Stevens, 1971). These channels can be found in neocortical
PNs to restrict firing rates, however expression of Kv1 channels tends to be strongly
influenced by layer and region (Bekkers & Delaney, 2001; Martina, Schultz, Ehmke,
Monyer, & Jonas, 1998). The αDTX-sensitive subset of Shaker channels is also
implicated in duration of afterhyperpolarizations in hippocampal PNs (Golding, Jung,
Mickus, & Spruston, 1999).
The Shab (Kv2) family of Kv channels has two known members: Kv2.1 and
Kv2.2, and they typically function as delayed rectifiers, but in some instances, they can
influence the repolarization phases of APs (A-type) (Liu & Bean, 2014). These channels
can likewise heterotetramerize and undergo posttranslational modifications to alter their
kinetics (B Rudy et al., 2009). These channels can be found at axon initial segments of
hippocampal PNs (Sarmiere, Weigle, & Tamkun, 2008) and is generally a common
feature of both interneurons and PNs (Murakoshi & Trimmer, 1999).
The Shaw family (Kv3) are a group of A-type channels that typically activate and
deactivate quickly. They also tend to be activated ay more depolarized voltages than the
previously mentioned channels. It’s believed that this channel manages the duration and
repolarization phases of action potentials due to these fast kinetics, but unfortunately this
family is difficult to investigate due to the lack of specific blockers for Kv3 channels
(Labro, Priest, Lacroix, Snyders, & Bezanilla, 2015; B Rudy et al., 2009). RT-PCR
results from hippocampal experiments show that these channels are expressed in at least
some types of interneurons and a minority of PNs (Martina et al., 1998). Blocking these
channels with the non-specific channel blocker 4-aminopyridine reduces their firing rates
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(Martina et al., 1998). These channels can be found in Layer 1 interneurons (Weiser et
al., 1994) They can enable cortical neurons to repolarize more quickly, and fire more APs
(Cao et al., 2014).
The Shal (Kv4) family of K channels are another group of A-type channels that
are similar to the Shaw family, but are generally capable of activating at more
hyperpolarized voltages. They are believed to modulate repolarization phases of action
potentials and possibly interspike intervals. Although Shal Kv channels do tend to
inactivate quickly, they are believed to recover from inactivation relatively rapidly.
Immunofluorescence of rat visual cortex shows that Kv4 channels can be found in both
cortical interneurons and PNs. This includes GABAergic post-synaptic sites, somata,
dendrites and dendritic spines (Burkhalter, Gonchar, Mellor, & Nerbonne, 2006). These
channels are believed to modulate the duration and frequency of APs in neocortical PNs
(Carrasquillo et al., 2012).
Finally, the Kv7 (KCNQ) channels are a group of channels that mediate the IM
current, which is targeted by many neuropeptides. This current is active between RMP
and threshold for APs. While it is somewhat slow to activate, it either does not deactivate
or deactivates very slowly. Therefore, these channels are unlikely to influence individual
APs, but may suppress spike frequency adaptation and interspike interval (D. Brown,
1988; Storm, 1987). This IM current is believed to be modulated specifically by Gq
Coupled Protein Receptors, like the eponymous muscarinic receptor that the current is
named after. The likely mechanism is through mobilization of PLCβ and regulation of
PIP2 (B Rudy et al., 2009). These channels are found in hippocampal PNs and
67

interneurons and regulate interspike interval (Hu, Vervaeke, & Storm, 2007; Lawrence et
al., 2006). These channels have been demonstrated to show powerful effects on cortical
excitability and performance (Leão, Tan, & Fisahn, 2009; Peters, Hu, Pongs, Storm, &
Isbrandt, 2005).
To summarize, there are many families of potassium channels that can mediate K
currents with slightly different properties. Delayed rectifiers tend to be associated with
ability to fire APs, while the faster A-type current is more likely to modulate the duration
of the spikes. To fully assay the potassium channels in current clamp mode (which
enables APs to happen as they would in neurons) there are several important measures.
Specifically, the firing frequency or interspike interval, the resting membrane potential,
input resistance, repolarization rate or duration of an AP, and the magnitude of
afterhyperpolarization.
1.27 µOR regulation of voltage-sensitive channels
The µOR is a pertussis toxin sensitive Gi coupled receptor that generally acts through two
divergent mechanisms (Al-Hasani & Bruchas, 2011; Ingram & Williams, 1994). Upon
binding of an agonist to an opioid receptor the Gαi and Gβγ subunits dissociate from each
other. The Gαi activates local inhibits adenylyl cyclase, meanwhile the Gβγ inhibits Ca2+
conductance by binding to, and inactivating, local voltage-gated calcium channels
(Capogna, Gähwiler, & Thompson, 1993; M. Connor et al., 1999; Glickfeld et al., 2008;
Rusin, Giovannucci, Stuenkel, & Moises, 1997; Zamponi & Snutch, 2002). Upregulation
of potassium channels appears to be cAMP-dependent in at least some cases (Chen & Yu,
1994), but not in others (Sánchez-Blázquez et al., 2001; Witkowski & Szulczyk, 2006).
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The µOR is also believed to negatively regulate calcium (and some sodium)
currents as well. This includes: suppression of N-type Ca2+ channels (Law et al., 2000;
Rubovitch et al., 2003); suppression of L-type Ca2+ channels (Piros et al., 1996; Piros et
al., 1995); P/Q-type Ca2+ channels and G protein-activated inwardly-rectifying K
channels (M. Connor et al., 1999; Henry, Grandy, Lester, Davidson, & Chavkin, 1995;
Jeong & Ikeda, 1998). µORs are also believed to downregulate activity of NMDARs (C.
W. Xie & Lewis, 1997). µORs have also been reported to regulate a variety of other
channels in DRG neurons, including inhibiting TRPV1 channels (Endres-Becker et al.,
2007; Spahn et al., 2013), inhibiting acid-sensing ion channels (Cai et al., 2014).
Yet not all channels that the µOR modulates in cortical neurons have been
identified. In dorsal striatal neurons, researchers found that multiple K currents were
being modulated by DAMGO (Ponterio et al., 2013). Researchers found that an
unknown, voltage-dependent K current was activated with DAMGO as well in
hippocampal neurons (Wimpey & Chavkin, 1991). Follow-up research with both the
endogenous ligand Met-Enk and DAMGO indicated these agonists were upregulating a K
current that was 4-AP sensitive and likely belong to the Shaker family of K channels
(Vaughan et al., 1997). Limited knowledge of voltage-sensitive K currents at the time
may have prevented further inquiry about the identity of these channels in cortical
neurons, but more recent research from other parts of the brain provides more insight
about the identity these channels.
Findings from the lateral amygdala by Faber et al. (2004)(Faber & Sah, 2004)
indicated that the µOR was upregulating a voltage-sensitive K current to increase spike
69

frequency adaptation – a feature that suppresses the number of evoked action potentials
and increases the time between spikes (interspike interval). They likewise found that this
effect was blocked by inhibiting phospholipase A2 with AACOCF3. Most interestingly
they identified this current as sensitive to both αDTX and Tityustoxin-Kα (TsTx-Kα),
which is a feature of the Shaker-family channel Kv1.2. In a similar study on basolateral
amygdala neurons that project to the central nucleus of the amygdala, Finnegan et al
(2006) (Finnegan et al., 2006) found that DAMGO reduces the amplitude of evoked
IPSCs and reduced the frequency of mIPSCs. They found that 4-AP, αDTX, TsTx-Kα,
and Dendrotoxin-K (blocker of Kv1.1, another Shaker channel). These findings in
amygdalar structures suggest that the µOR upregulates the Shaker channels Kv1.1 and
Kv1.2 to inhibit neurons in a PLA2-dependent manner. These results closely mirrored
findings in cortical neurons that suggested that unidentified VSKCs were being
upregulated by the µOR (Wimpey & Chavkin, 1991).
Therefore, these mechanisms and data collected from the amygdala implicate
αDTX-sensitive current as a target of modulation, which can then modulate the number
of APs that are evoked from µOR+ neurons. The relationship between these αDTXsensitive channels and the µOR has not presently been explored in neocortical neurons
but could be one of the mechanisms that the µOR uses to suppress neocortical them.
1.28 Measures of excitability in individual neurons
Cortical neurons have a variety of mechanisms that they can leverage to modulate their
output. These mechanisms are used to adjust their firing rates, probability of an action
potential (AP), and their neurotransmitter release at synaptic terminals.
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Perhaps the simplest way is for neurons to increase their permeability to
potassium, which moves their Vm closer to EK and hyperpolarizing the cell – moving it
away from its threshold for an action potential. This can be accomplished by opening K
leak channels which provide their PM with a constant hyperpolarization. Therefore, their
RMP will become more negative. Opening more channels also decreases their input
resistance, as measured by a recording electrode. This is potentially more challenging
than measuring RMP, since measuring input resistance necessarily requires inputting a
current. A depolarizing current may cause the neuron to fire, and a hyperpolarizing
current may not fully capture the breadth of voltage-gated channels that would be
activated by a depolarizing current. The µOR is consistently shown the hyperpolarize
neurons.
Neurons may also modulate their threshold for an AP – a voltage range at which
voltage-sensitive Na channels are likely to begin to open and create the positive-feedback
loop that creates an AP. This could be done by utilizing posttranslational modifications or
trafficking of voltage-sensitive K channels to the cell membrane and make them more
likely to open upon a depolarizing stimulus. On the other hand, cells may also
downregulate their voltage-sensitive Na channels to make them less able (by trafficking
or posttranslational modifications) to open upon a depolarizing stimulus. The µOR is not
necessarily known to modulate AP threshold (Faber & Sah, 2004), though it is relatively
easy to measure since the spikes evoked at threshold is normally minimal and can
produced a stable change in Vm.
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Cortical neurons rarely fire only one AP in response to a depolarizing stimulus –
they often fire several. The pattern, frequency, and number of APs is subject to
modulation to alter their excitability. Interspike interval (ISI) – the length in time between
APs – is a property that is inversely related to the frequency of APs. The µOR has been
shown to increase the ISI in amygdalar neurons, which is reversible with αDTX (Faber &
Sah, 2004). Therefore, this is an important aspect to measure. Similarly, the number of
evoked APs is closely related to the ISI.
The duration of an action potential that neurons can modulate too and may lead to
variable physiological effects. For instance, neurons may reduce the activity of their Atype K currents to make APs longer in duration. This may slow down the rate of APs –
because the Vm will take longer to reset down to RMP and allow the VSNCs channels to
shift into the closed conformation. However, at a presynaptic terminal, the longerduration AP may make it more likely that Ca channels will open and cause release of
neurotransmitter.
1.29 Cortical neurodevelopment and Dlx genes
Discriminating PNs from GABAergic interneurons is a common issue with any testing
preparation of neocortical neurons. This distinction may be important to understanding
how PNs are affected by DAMGO exposure or targeting a specific population for
electrophysiology. Luckily, this obstacle can be overcome with the help of transgenics.
Excitatory and inhibitory neocortical neurons have different embryonic origins.
They therefore are hallmarked by expression of different genes, which can be used to
identify them. Utilizing unique homeobox genes expressed by either excitatory or
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inhibitory neurons allows researchers to identify them in virtually any experimental
system.
All cortical neurons, whether inhibitory or excitatory, are produced from
temporary proliferative zones (the ventricular zone and subventricular zone) and migrate
into the prenatal cortex. The deeper layers of the cortex migrate the earliest and Layer 2
developing the latest – Layer 1 is an exception; the most superficial cortical layer appears
to develop first and develop persistently through the postnatal period (Rakic, 2009)
While PNs migrate radially into the cortex from the pallium, the cortical
interneurons are generated in the prenatal, basal telencephalon (the sub pallium) and
migrate tangentially into the cortex. The subpallium consists of several domains,
including the medial ganglionic eminence (MGE), the lateral ganglionic eminence
(LGE), the preoptic area (POA). The caudal ganglionic eminence (CGE), meanwhile, is
located at a caudal fused area of the MGE and LGE. Fate-mapping experiments show that
interneurons are born in the ventricular zone of these ganglionic eminences, while PNs
are born in the VZ of the cortex (Stewart A Anderson, Marín, Horn, Jennings, &
Rubenstein, 2001). Mouse interneurons begin this migration on about day E12 and the
neurons populate all cortical areas (including hippocampal cortex and neocortex) (Flames
& Marin, 2005). Migration of progenitors from the subcortical telencephalon appears to
be complete by around E17 in rodents – including in rat models (S. A. Anderson,
Eisenstat, Shi, & Rubenstein, 1997; Metin, Baudoin, Rakic, & Parnavelas, 2006; Q. Xu,
Cobos, De La Cruz, Rubenstein, & Anderson, 2004).
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While some researchers have proposed that interneurons are granted their unique
identity based on where they happen to stratify, fate-mapping data suggest that their
identities are determined prior to migration (Stewart A Anderson et al., 2001; BatistaBrito, Machold, Klein, & Fishell, 2008; Butt et al., 2005). The MGE interneuronal pool
gives rise to most PV+ and SST+ interneurons, while the CGE gives rise to other classes
(Butt et al., 2005).
Interneuron migration and development is supported by unique expression of the
homeodomain transcription factors Dlx of the family which can be used to identify
interneurons from PNs (Flames & Marin, 2005; Pla et al., 2017). Six known Dlx
orthologs are known, numbered 1 through 6 are expressed by prenatal cortical
interneurons but data derived from a Dlx 5/6 BAC suggests that expression of Dlx5/6
persists in mature cortical interneurons (Y. Wang et al., 2010). Using transgenic
expression of β-galactosidase, researchers have shown that Dlx5 or Dlx6 are expressed
by only, and all, cortical interneurons. Sc-PCR analyses revealed that these neurons
represent all the major expression categories of neurons (SST+, 5HTr3a+, and PV+) (de
Lombares et al., 2019). Furthermore, experiments using Dlx5/6-Cre mice show that these
neurons differentiate into GABAergic interneurons, while the excitatory neurons are
instead predicted by expression of Emx1 (Batista-Brito et al., 2008; Gorski et al., 2002).
A Dlx5/6-Cre construct has also been used to disrupt the excitatory drive into mouse
interneurons in vivo and thereby create behavioral defects that resemble a schizophrenic
endophenotype (Fazzari et al., 2010).
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Unfortunately, the embryonic lethality of Dlx gene knockout makes it difficult to
determine the exact roles of these genes, but in mature interneurons Dlx5/6 appears to
promote expression of the GABA-synthesizing enzymes GAD65 and GAD67; ectopic
expression of these genes can induce production of GABA (de Lombares et al., 2019).
1.30 Primary neuron culture
The need to conduct experiments on neurons in an accessible environment led to
development of several models to investigate neurons that are grown in vitro. Some
models of neurons are derived from tumors (Biedler, Helson, & Spengler, 1973), but the
primary neuron culture model enables researchers to extract otherwise-normal neurons
from the brains of rodents and culture them in a controlled environment for experiments
(Gordon, Amini, & White, 2013). The present-day neuron culture protocol has evolved
for 100 years (Harrison, 1910) to enhance their validity and study the phenomena
referenced in this literature review. Modern iterations of this technique have developed to
maximize their similarity with neurons in situ.
Primary Neuron Cultures are popular models for use with electrophysiology due
to the ease-of-access and separation from tonic factors secreted by neocortical neurons
(Brewer, Torricelli, Evege, & Price, 1993; Dichter, 1978; Mains & Patterson, 1973). This
simplifies many of interactions between neurons.
Primary neuron cultures, as described above, have been used extensively to study
calcium oscillations for the ease of imaging a network of neurons in a single plane
(Dravid & Murray, 2004; T. H. Murphy et al., 1992; Przewlocki et al., 1999; J. Wang et
al., 2016). These cultures are highly amenable for these studies for their ease of use and
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the ability to resolve single neurons without obfuscation from additional tissue layers.
They can enable the collection of a large volume of data that may be required to sample a
heterogenous population, such as neocortical interneurons.
Primary cultures of rat neocortical neurons have been used extensively to
investigating µOR’s intracellular signaling pathway, mechanisms (Arttamangkul,
Torrecilla, Kobayashi, Okano, & Williams, 2006; M. C. Lee et al., 2002; Junhui Zhang,
Qian, Zhao, Hong, & Xia, 2006), and electrophysiology (E. Tanaka & North, 1994) including the µOR’s disinhibitory effect in non-cortical primary cultures (Crain, Shen, &
Chalazonitis, 1988). Therefore, primary neuron cultures are a powerful tool to investigate
the phenomena outlined in this literature review.

CHAPTER 2: NEOCORTICAL µ OPIOD RECEPTORS ENHANCE
SPONTANEOUS CALCIUM OSCILLATIONS THROUGH
DOWNREGULATION OF GABAA AND GABAB RECEPTORS
2.1 Introduction
The endogenous opioid system of the cerebral cortex mediates antinociception, reward
valuation and reward-seeking behaviors. Dysregulation of this system is believed to
contribute to pathological and compulsive behaviors, such as behaviors eating disorders,
pathological gambling, and drug-seeking (B. Bencherif et al., 2005; Badreddine
Bencherif et al., 2005; Joutsa et al., 2018; Mick et al., 2016; Mitchell et al., 2012; Qu et
al., 2015; Zubieta et al., 1996). Experimentally, impulsive behaviors and binge-eating can
be induced through infusion of the µ opioid receptor specific (µOR) agonist [D-Ala2, N76

Me-Phe4, Gly5-ol]-Enkephalin (DAMGO) into the frontal cortex of animal models
(Mena et al., 2011; Selleck et al., 2015). Blockade of the µOR with naltrexone inhibits
these compulsive behaviors (Bartus et al., 2003; Blasio et al., 2014). These aberrancies
are believed to result from disruption of the activity of cortical networks (Haider, Duque,
Hasenstaub, & McCormick, 2006; M. Whittington et al., 1998; Y. Zhang et al., 2019).
The µOR is believed to suppress GABAergic release through its expression
primarily on cortical GABAergic interneurons, and therefore lead to overactivity of the
targets of their inhibition, the glutamatergic Pyramidal Neurons (PNs) (Drake & Milner,
1999, 2002, 2006; Férézou et al., 2007; Huo et al., 2005; Madison & Nicoll, 1988;
Stumm et al., 2004; Taki et al., 2000; Witkowski & Szulczyk, 2006; Zieglgansberger et
al., 1979). But some research suggests that the µOR µOR may localize to PNs and
directly activate them as well (Przewlocki et al., 1999; Rola et al., 2008; Schmidt et al.,
2003; Witkowski & Szulczyk, 2006). Therefore, it is unclear whether excitatory effects
of µOR agonism is due to disinhibition or excitation of Pyramidal Neurons, or whether
the µOR can perform both functions. These conflicting results have presented a challenge
to understanding how the µOR exerts its effects on cortical circuits. Furthermore, several
lines of evidence suggest that the µOR suppresses the neurogliaform class of neurons,
which uniquely activate GABAB receptors on excitatory Pyramidal Neurons (KrookMagnuson et al., 2011; Olah et al., 2007; Tamás et al., 2003) – whereas other cortical
interneurons generally activate only GABAA receptors. This positions µOR+
interneurons to play an important role on slower-acting and longer-lasting inhibition on
cortical networks by regulating postsynaptic activity of GABAB receptors.
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The dynamics of excitatory and inhibitory network activity have been explored in
cultured neurons, where neurons engage in frequent spontaneous activity and
synchronized depolarizations due to synaptic interlinkage (Canepari et al., 1997;
Chiappalone, Bove, Vato, Tedesco, & Martinoia, 2006; Nakanishi & Kukita, 1998). To
easily monitor network activity in many culture neurons at once, calcium-imaging has
been used to visualize large-scale network events in cultured neurons; excitation in
cultured neurons can be visualized as spontaneous synchronized calcium oscillations
(SCOs) resulting from synchronized activation of glutamatergic receptors (Bacci et al.,
1999; Muramoto et al., 1993; Nakanishi & Kukita, 1998; Robinson et al., 1993). These
oscillations can be prevented by blocking depolarizations with TTX, or by blocking
glutamate receptors (Dravid & Murray, 2004; Kelamangalath et al., 2011; T. H. Murphy
et al., 1992; Nuñez et al., 1996; Przewlocki et al., 1999). Within individual neurons, these
calcium transients correspond with excitatory postsynaptic potentials as well as bursts of
action potentials (Muramoto et al., 1993; T. H. Murphy et al., 1992). Some researchers
have used this model in low concentrations of Mg2+ and found that these calcium
oscillations and bursts of action potentials are due to the calcium-conducting properties of
the NMDA receptors (Canepari et al., 1997; Penn et al., 2016; Przewlocki et al., 1999; T.
Tanaka et al., 1996), but others argue that calcium oscillations in physiological [Mg2+]
are actually caused by calcium-conducting AMPA receptors and mGluRs coupled to
calcium-induced calcium release (CICR) (Dravid & Murray, 2004; Flint et al., 1999). Yet
other authors have suggested that voltage-sensitive calcium channels play a large or
predominant role in generating SCOs (Bacci et al., 1999; Dravid & Murray, 2004;
Inglefield & Shafer, 2000). Although there is disagreement over the identity of the
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glutamatergic receptor or ion channel based on the type of neuronal culture and
experimental condition, these calcium oscillations appear to be related to activity in
excitable cells.
The effect of DAMGO on SCOs was explored in previous experiments by another
lab, and it was suggested that the µOR directly stimulates NMDA receptors on
hippocampal Pyramidal Neurons (Przewlocki et al., 1999), which may throw doubt on
the view that the µOR excites cortical networks by suppressing interneurons. On the
other hand, electrophysiological experiments done by our lab (Dutkiewicz & Morielli,
2020), and another lab (Férézou et al., 2007), suggest that neocortical interneurons are
suppressed by DAMGO stimulation. Although these mechanisms are not mutually
exclusive, these lines of evidence have presented a challenging research issue, whether
the µOR’s role in exciting cortical networks is mainly driven by suppressing cortical
interneurons, or by directly activating the Pyramidal Neurons. Furthermore, the evidence
that the µOR localizes to neurogliaform neurons also raises the possibility that DAMGO
stimulation may reduce GABA release onto both GABAA and GABAB receptors, and
thus DAMGO-induced disinhibition may be more consequential to network activity than
previously considered.
We hypothesized that the µOR’s excitatory effect on cultured neurons was
primarily by suppressing subsets of GABAergic interneurons (i.e., disinhibition) rather
than by directly exciting the PNs themselves. We further predicted that DAMGO would
suppress GABA release onto both GABAA and GABAB receptors due to the research
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suggesting that neurogliaform neurons express the µOR. We therefore tested DAMGO in
the presence of GABAR-blockers to prevent the DAMGO-induced SCO changes.
2.2 Materials and methods
2.2.1 Cell cultures
All procedures were authorized by the Institutional Animal Care and Use Committee
(IACUC) at University of Vermont. We dissected CD® IGS Sprague-Dawley (Charles
River) pregnant rat dams to harvest neocortical neurons from the frontal cortices of E21
rat embryos. Brain cortices were rinsed in Hibernate A (Gibco, Grand Island, NY),
dissociated with papain (Worthington, Columbus, OH) and mechanically separated
through gentle trituration with a pipette. Dissociated cortical neurons were and cultured
on round 12mm glass, PEI-coated (Sigma-Aldrich, St. Louis, MO) coverslips at an
approximate density of 3x104 cells/cm2. We maintained the neurons in Neurobasal A,
B27, Penicillin-Streptomycin and Glutamax (All from Gibco), in a humidified 37° C
incubator with 5% CO2. For experiments where we utilized the interneuron marker, we
transformed those cultures on DIV0 with AAV-mDlx-NLS-mRuby2, which was a gift
from Viviana Gradinaru (Addgene viral prep # 99130-AAV1);
http://n2t.net/addgene:99130; RRID:Addgene_99130).
2.2.2 Calcium imaging
We removed coverslips for their growth media and incubated them in the dark, at
ambient temperature in a combination of a 1:50 dilution of B27 and Hibernate A. We
prepped the fluo-4 AM dye (Molecular Probes, Eugene OR) by combining 2uLs of a 1
µg/µL (in DMSO) stock solution with 2µLs of 20% Pluronic F-127 (Molecular Probes).
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After ensuring the dye was dissolved in the Pluronic F-127, we combined this with the
neuron’s Hibernate A (Gibco) buffer at a final concentration of 1 µg fluo-4, AM/1 mL of
Hibernate A+B27. The neurons were incubated in this solution for 1 hour before imaging.
The drugs were purchased from two main sources: [d-Ala2,N-Me-Phe4,Gly5-ol]Enkephalin] (DAMGO), D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP),
picrotoxin, and CGP55845 were purchased from Sigma (St. Louis, MO); 6-Cyano-7nitroquinoxaline-2,3-dione disodium (CNQX) and D-(-)-2-Amino-5-phosphonopentanoic
acid (dAP5) were from Tocris (Bristol, United Kingdom).
After dye loading, we transferred them into a recording chamber and perfused
them with ACSF (in mM): NaCl, 126; KCl, 5; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1;
NaHCO3, 26; Glucose, 20; and pyruvate, 5(Férézou et al., 2007). The ACSF was warmed
to 30oC and constantly bubbled with a mixture of 95% O2 and 5% CO2. Neurons were
visualized and recorded on a Nikon Eclipse E600 fluorescence microscope. We used a
40x objective dipping lens and acquired an imaging area with at least 15 neurons. During
image capture, we illuminated the neurons with an X-Cite 120 fluorescence illuminator to
activate green fluorescence (Excelitas, Waltham, MA). In instances where we used redfluorescent interneurons, we captured red fluorescence (mRuby2) with one image prior to
recording the green (fluo-4) channel. Fluorescence was captured with a Photometrics
CoolSnapES Monochrome Camera (Roper Scientific, Sarasota Florida) and imaged with
an exposure time of 250ms with either Metavue 6.1 (Molecular Devices, San Jose, CA)
software or µManager (Edelstein et al., 2014).
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Our preliminary experiments indicated that we could capture at least 125s of
images at 4 frames/second before significant bleaching occurred. Therefore, we recorded
two 62.5s stacks; one before the drug (slot 1) and one after the drug (slot 2).
Although previously published studies by other labs have sometimes opted to use
low or no [Mg2+] ACSF, which enhances spontaneous synchronized calcium oscillations
(SCOs), we observed spontaneous calcium oscillations in the presence of physiological
levels (1 mM Mg2+), which has also has been reported previously in rodent cortical
cultures (Dravid & Murray, 2004; T. H. Murphy et al., 1992). We therefore continued to
use 1mM Mg2+ ACSF.
For the first dataset (Figure 7), we recorded .tiff image timestacks under a predrug condition, and then applied the drug buffer for 62.5s and subsequently recorded an
image time stack for the post-drug condition while continuously applying the drug
(Figure 5). However, the drug sequence varied depending on which data set it was
collected from; in the first dataset, slot1 always corresponded with vehicle ACSF (saline),
and timeslot 2 always corresponded to a combined drug bolus. This drug combination is
indicated on the graphs.
In the second dataset (Figure 11), picrotoxin and CGP55845 were preincubated
for 15-25 minutes before exposure to DAMGO, such that DAMGO was applied in a
background of those drugs. In the case of Figure 12, CGP55845 was similarly applied in
a background of picrotoxin.
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2.2.3 Calcium-imaging analyses
Data initially were contained in the form a brightfield image and a stack of 250 greenchannel images. Cell counting and image analyses were done on ImageJ 1.52p
(Schindelin et al., 2012) prior to running the Python script. We used ImageJ to draw ROIs
separately around nonred or red (where applicable in the second data set) with the Timer
Series Analyzer V3 plugin, which produced a table of calcium-indicator fluorescence
over the 250 images. That table was copied over onto separate Microsoft Excel
Spreadsheets into labelled data folders. Those labelled folders and the spreadsheets
therein served as the data input for the calcium-imaging Python scripts. These Excel
spreadsheets were analyzed directly by the ca_transient_peak_finder_14.5.py script. in
the first dataset (for Figure 6 and Figure 7) which was programmed to generate xy plots
for the peaks (Figure 1 and Figure 2).

Figure 1. Representative example of calcium peaks in one neuron.Spontaneous calcium oscillations were
captured in each neuron over 62.5s (4 frames / second) and graphed on xy plots. The y axis represents
relative proportional units of calcium indicator fluorescence ((F-F0)/F0), where the highest peak in the
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timestack (including all of the neurons/ROIs not shown here) is set to an amplitude of 1.00, and these peaks
are scaled against the tallest peak. X axis represents frames at (4 frames/sec). On the calcium peaks: yellow
lines denote the base of each recognized peak, green horizontal lines are the measures of halfwidth for the
peaks, and the red dot at the tips of the peaks are noting that the peak has been successfully culled for
analysis by the Python script.

The data for the second dataset (for Figure 11) utilized the
auto_mask_red_cell_v2.5.py script to automatically generate ROIs in neurons. It created
two spreadsheets, one for red neurons and one for nonred neurons. These spreadsheets
were then analyzed separately in the same manner as described above.
We observed that groups of neighboring neurons captured within imaging frames
tended to experience apparently synchronous SCOs, and therefore opted not to use
individual neurons as members of the sample (Figure 2). Instead, we measured all SCOs
occurring in all neurons within the imaging frame and derived median values of the SCOs
in each neuron within the frame. We then further determined the mean value of these
median values, to calculate the average SCO from each imaging stack. Through these
calculations, we compared the SCOs before and after various drug treatments to
determine how the drugs impacted the average SCO occurring within the imaging frame.
Thus, each member of our sample represented the average (mean of median) SCO
occurring in the imaging frame during the 62.5s recording.
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Figure 2. Neurons in image field have synchronous spontaneous calcium oscillations. A temporal
alignment of all neurons in an imaging field (Left) before DAMGO, and the same neurons (Right) after
DAMGO. Y axis shows calcium indicator fluorescence with each separate neuron arranged in a separate
row. Each neuron’s highest peak is set to a value of 1.00 to standardize the scale across neurons. X axis
represents a period of 80s in each of the two conditions. We observed that neurons in the imaging field had
synchronized spontaneous calcium oscillations (SCOs). Therefore, we derived median peak values for each
neuron, and then derived the mean of the median values across all the neurons in the field for each of the 2
conditions, in order to derive the average peak value before and after the drug. DAMGO’s enhancement of
calcium peak halfwidth is also evident from these graphs.

2.2.4 Validation for auto_mask
To validate the auto_mask script that automatically drew ROIs in the second dataset, we
hand-drew ROIs in 214 spreadsheets that were also analyzed using the auto_mask script.
85

We performed a bivariate correlation in IBM SPSS 27.0.0.0. to correlate the mean SCO
amplitude, halfwidth, and number between the script-drawn and manually drawn ROIs.
Measure
Bivariate Correlation
Amplitude
R = 0.790, p < 0.001
Halfwidth
R = 0.909, p < 0.001
Number
R = 0.856, p < 0.001
Table 1. Validation for auto_mask ROI generator. To determine whether the automatic generator could
derive values positively correlated with hand-drawn ROIs (in ImageJ), we utilized the script and handgenerated ROIs on 214 image stacks across all drug conditions. We determined that all measures featured
here were positively and significantly correlated with each other, indicating that the auto_mask script ROIs
were consistent with the manually drawn ROIs.

2.2.5 Whole-cell recordings
Patch pipettes with resistances of 5-10MΩ were fabricated from borosilicate glass
capillaries and filled with intracellular saline containing (in mM) K-gluconate, 144;
MgCl2, 3; ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, 0.5; 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, 10 (Férézou et al., 2007). The pH was
adjusted to 7.2 with potassium hydroxide and confirmed for an osmolarity of 285/295
mosm. Whole-cell recordings were made with an Axopatch 200B (Axon Instruments)
amplifier and Clampex 9.2.1.9 (Molecular Devices) software. Signals were sampled at
10kHz with a Digidata 1322a (Axon Instruments) DA converter. Calcium-imaging was
aligned with electrophysiology through a green light emitting diode that was linked to the
Digidata 1322a converter and controlled by the Clampex software; the LED emitted a
start sequence of light flashes which were visible in the first 16 seconds of recording and
removed prior to analysis.
2.2.6 Sample sizes and statistics
Sample sizes were initially calculated based on preliminary data on DAMGO’s effect in a
large test group of 21 saline and 21 DAMGO recordings. This test group was used to
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determine future sample sizes and the polarity of DAMGO effects for statistical testing
(one-tailed versus two-tailed). Although we measured several properties of SCOs, we
focused on DAMGO’s effect on SCO halfwidth, since preliminary data indicated that it
was the most frequent DAMGO effect, and also the only persisting effect in the presence
of picrotoxin. In this large pool of preliminary recordings, we found that fold changes of
halfwidth in the DAMGO recordings (N = 21, M = 1.80, SD = 0.78) were significantly
greater (t(40) = 4.68, p < 0.001) than the fold changes in saline controls (N = 21, M =
0.97, SD = 0.78). A posthoc analysis of that preliminary data pool revealed that the effect
size d was a value of 1.44. We used G*Power software (Faul, Erdfelder, Buchner, &
Lang, 2009; Faul, Erdfelder, Lang, & Buchner, 2007) to determine that the required
sample size was an n = 12 for a one-tailed t test. For the first dataset, we therefore used
groups of n = 12 for each group. In the second dataset, we used an n = 13 to provide a +1
sample number in case of technical difficulties, which did not occur, and we thus used all
13 recordings.
The mean scores for calcium peak halfwidth, number of peaks, and amplitude in
all drug conditions were graphed and analyzed in GraphPad Prism version 8.4.3 for
Windows, GraphPad Software, San Diego CA, USA www.graphpad.com. Statistical
testing on the first dataset commenced by testing for a normal distribution with a
D’Agostino-Pearson’s omnibus test. When data within a group were significantly
different from a normal distribution (p < 0.05), then that group was compared with a
Mann-Whitney U test. Data that were not significantly different from normal
distributions were instead tested with a one-tailed unpaired t-test. Statistical testing on
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(Figure 11), where 4 groups were included, we instead tested with ordinary one-way
ANOVAs and Sidak’s test for multiple comparisons in GraphPad Prism.

2.3 Results
2.3.1 Measuring synchronized spontaneous calcium oscillations
To measure spontaneous calcium oscillations, we directed our analyses on 3 basic
properties of the calcium spikes to comprehensively analyze SCOs: peak height, duration,
and the number of calcium peaks. Respectively, these represent the y dimension of the
calcium peak, the x dimension, and the quantity of SCO peaks (Figure 1).
2.3.2 SCOs require neuronal activity and glutamatergic signaling
Other labs have reported SCOs similar to our observations (Figure 1) and found that these
oscillations correspond to excitatory postsynaptic potentials and bursts of action
potentials in the neurons (Bacci et al., 1999; T. H. Murphy et al., 1992; Przewlocki et al.,
1999; Robinson et al., 1993). To investigate whether SCOs in our preparation correlated
with neuronal activity, we counted SCOs in a variety of conditions designed to prevent
glutamatergic drive and action potentials,
Other labs have found that SCOs are produced by activation of postsynaptic
glutamate receptors (Bacci et al., 1999; Dravid & Murray, 2004; T. H. Murphy et al.,
1992; Przewlocki et al., 1999). To test this in our preparation, we counted calcium
oscillations occurring during pharmacological blockade of glutamatergic receptors. We
therefore applied the combination of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
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acid receptor (AMPA) and kainate blocker 6-Cyano-7-nitroquinoxaline-2,3-dione
(CNQX; 20 µM) and the N-methyl-D-aspartate (NMDAR) inhibitor D-(-)-2-Amino-5phosphonopentanoic acid (AP5; 50 µM), which eliminated all SCO activity (Figure 3).
The finding that, SCOs depend on intact glutamatergic signaling is in agreement with
previous reports of SCOs in primary cortical cultures (Cao et al., 2015; Dravid & Murray,
2004; Inglefield & Shafer, 2000; T. H. Murphy et al., 1992; Nuñez et al., 1996;
Przewlocki et al., 1999; Shen et al., 1996).
To test whether SCOs were dependent on spontaneous action potentials, we
applied 1 mM of the sodium channel inhibitor tetrodotoxin (TTX) to block them. We
found that this drug also prevented SCOs from occurring (Figure 3). These findings were
again consistent with previous research from other labs which have found TTX
suppresses SCOs (Dravid & Murray, 2004; T. H. Murphy et al., 1992; Przewlocki et al.,
1999; Shen et al., 1996) (Inglefield & Shafer, 2000).
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Figure 3. Neuronal activity and glutamatergic signaling required for SCOs. We counted calcium peaks
occurring in a 160s period in 3 groups: saline controls; voltage-sensitive sodium channel inhibitor
tetrodotoxin (TTX; 1 µM); and the combination of (20 µM) AMPA/kainate blocker 6-Cyano-7nitroquinoxaline-2,3-dione (CNQX) and the NMDAR inhibitor (50 µM) D-(-)-2-Amino-5phosphonopentanoic acid (AP5). In the saline condition, neurons exhibited a median of 6.93 oscillations
(range 0.25 to 12.66) per neuron, per minute. In the TTX condition, neurons exhibited a median of 0.00
(range 0.00 to 0.10). In the CNQX+AP5 condition, neurons exhibited a median of 0.03 oscillations (range
0.00 to 0.24) per neuron, per minute. We found that the number of calcium oscillations in the TTX (t(11) =
1.45, p = 0.17) and CNQX+AP5 (t(11) = 2.19, p = 0.05) condition were not significantly different from a
test value of 0 (one-sample t tests), while the saline group was significantly different from a test value of 0
(t(11) = 10.01, p < 0.0001). Therefore, spontaneous calcium oscillations are virtually undetectable in TTX
and the combination of CNQX+AP5.

We next performed simultaneous electrophysiology and calcium imaging to
determine whether the SCOs corresponded to neuronal activity, and thus determine
whether SCOs could be used to indicate bursts of activity (Figure 4). Previous studies on
SCOs have found that they correlate with large depolarizations, which appear to be
excitatory postsynaptic potentials, and bursts of action potentials - but not single, isolated
action potentials (Bacci et al., 1999; T. H. Murphy et al., 1992; Przewlocki et al., 1999;
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Robinson et al., 1993). We similarly found that the SCOs correlated with large
depolarizations that resembled excitatory postsynaptic potentials. Importantly, we also
found that these SCOs do not correspond to isolated action potentials, but instead bursts.
We found that depolarizing current injections (Figure 4) were capable of causing
calcium peaks, spontaneous bursts of activity were sometimes greater. Thus, bursts of
action potentials were correlated with SCOs.

Figure 4. SCOs correspond to bursts of activity. We simultaneously performed electrophysiology and
recorded calcium indicator fluorescence, in order to correlate the SCOs with bursts of activity. Every 3
seconds, we applied a 1s suprathreshold current to induce action potentials, to determine whether the bursts
of activity were causal or correlation. (Red Line) Vm over time, showing action potentials and RMP. (Gray
line) Applied current over time. (Blue line) Calcium indicator fluorescence. This image indicates that
calcium peaks are generally produced through spontaneous activity in this neuron.

Taken together, SCOs were dependent on intact spontaneous glutamatergic
signaling and action potentials, and thus necessarily dependent on excitatory drive and
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spontaneous neuronal activity. Our observations of the simultaneous electrophysiology
and pharmacological experiments were consistent with previous experiments of other
labs; we similarly saw large depolarizations and bursts of action potentials that
corresponded to synchronized SCOs. These large depolarizations appeared consistent to
previous descriptions that suggested that they were excitatory postsynaptic potentials.
Having found that the SCOs in our preparation were correlated with bursts of activity,
and that they are dependent on spontaneous APs and availability of glutamatergic
receptors, we next conducted a series of pharmacological experiments to elucidate the
nature and mechanism of DAMGO’s effects on SCOs.
2.3.3 First dataset experimental design
To assay the effects of drugs on the SCOs, we designed an experiment to measure SCOs
before and after drug combinations to determine how drugs altered SCOs (Figure 5).
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Figure 5. Timecourse of experiment. We recorded calcium transients during an 80s period before exposure
to the drug (slot 1) and after exposure to the drug or drug combination (slot 2) to study the effects of these
drugs on SCOs. To measure the change in the properties of these calcium oscillations, we divided the
postdrug value by the predrug value to calculate the fold-change in that property due to the drug.

2.3.4 µOR agonism enhances spontaneous Ca2+ oscillations Given our result that SCOs
correlate with neuronal activity, we next applied DAMGO and measured SCOs before
and after this drug to find whether µOR-agonism enhanced their SCO amplitude, duration
(halfwidth), and/or frequency. This finding would support the µOR’s known role in
exciting cortical circuits and could provide a basis for determining whether the effect of
DAMGO was disinhibitory or providing direct excitation to cortical cultures.
We found that DAMGO (3 µM, 80s) induced a significant increase (t(22) = 2.74,
p = 0.006) in SCO amplitude (M = 1.80, SD = 0.94) when they were compared to
negative controls (M = 0.93, SD = 0.58). We also found a significant (t(22) = 2.69, p =
0.007) increase the halfwidths of DAMGO-exposed neurons (M = 1.71, SD = 0.69) when
compared to saline controls (M = 1.09, SD = 0.42). However, we did not find significant
changes (U = 43, p = 0.050) in the number of calcium transients in the DAMGO (Mdn =
1.17) condition versus the control (Mdn = 0.71). In summary, we found that DAMGO
enhances the duration and magnitude of these calcium oscillations, but not their number.
Although these findings substantiated the µOR’s known role in enhancing the activity of
neuronal circuits, it was unclear whether DAMGO was directly activating excitatory
neurons or inhibiting GABAergic neurons. For instance, our finding that DAMGO
enhanced the duration (halfwidth) of SCOs could suggest that µORs directly (on
Pyramidal Neurons) were inducing release of glutamate over a longer period, or it could
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also suggest that µOR+ inhibitory neurons were slower in being recruited to suppress
excitatory neurons, which in turns allows the PNs to release glutamate over longer
periods before being sufficiently inhibited to cease secretion of glutamate. However, in
the latter (disinhibitory) scenario, GABA antagonists could prevent inhibitory
interneurons from intervening during the DAMGO challenge.
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Figure 6. DAMGO enhances calcium oscillation duration and amplitude. We measured the average
amplitude, halfwidth, and number of calcium transients after incubation with (n = 12) vehicle saline or (3
µM; n = 12) DAMGO. (Top Row) Amplitude numerical values are taken as a proportion of the tallest peak
in the predrug recording of the timestack. (First column) Real values of saline controls for a) amplitude, e)
halfwidth, and i) average number of peaks before and after vehicle saline. (Second column) Real values of
DAMGO-exposed neurons in (b) amplitude, (f) halfwidth, and (j) average number of peaks before and after
DAMGO. (e,f) Frames measured in 4 frames/second. To visualize the change in these properties in
individual neurons, we graphed the fold change from baseline in these same properties. We found
significant DAMGO-induced increases (p < 0.05) in (c) amplitude and (g) halfwidth of calcium transients
relative to the change in the saline group. However, we did not find a significant DAMGO-induced change
(p > 0.05) in (k) number of peaks relative to the saline controls. (d,h,l) Validation for the specific effect of
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DAMGO by combining it with the µOR-specific antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2
(CTAP) successfully blocked the effect of DAMGO relative to fold changes in saline controls (p > 0.05)
PARAMETER

Mean Difference
(DAMGO-Saline)

P value

95% Confidence Interval for Difference

Lower
Upper
Amplitude
0.88
0.006
0.21 1.54
Halfwidth
0.63
0.007
0.14 1.11
Number
0.33
0.050
-0.20 0.86
Table 2. DAMGO enhances amplitude and halfwidth of SCOs. We found that DAMGO enhanced the
amplitude and halfwidth of SCOs in cultured neurons. However, the number of SCOs occurring within
imaging frames were not significantly impacted by DAMGO. Statistical testing was performed with
unpaired t-tests that compared fold changes in the DAMGO group with fold changes in the saline control
group, after first being tested for normality with D’Agostino-Pearson’s test. Peak Number was significantly
different from a normal distribution, and therefore tested with a Mann-Whitney U test.

2.3.5 The effect of DAMGO is mediated through both GABA receptors
Prior investigations by other groups (Drake & Milner, 1999, 2002, 2006; Férézou et al.,
2007; Huo et al., 2005; Madison & Nicoll, 1988; Stumm et al., 2004; Taki et al., 2000;
Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979) and our own lab (Dutkiewicz
& Morielli, 2020) into the mechanism of the µOR have suggested that the µOR acts
primarily by inhibiting activity of inhibitory interneurons. However, other groups have
indicated that the µOR is found on excitatory neurons as well (Rola et al., 2008; Schmidt
et al., 2003; Witkowski & Szulczyk, 2006), including a series of experiments that used
the SCO model in cultured hippocampal neurons (Przewlocki et al., 1999). Therefore, it
was unclear whether DAMGO was suppressing inhibitory neurons and enhancing SCOs
through disinhibition, or whether DAMGO was directly promoting the activity of
excitatory neurons and enhancing SCOs through a more direct mechanism.
Our previous study showed that µOR inhibits primary culture neocortical
interneurons (Dutkiewicz & Morielli, 2020). We therefore predicted that DAMGO
augmented spontaneous calcium oscillations by through its effects on GABAergic
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interneurons. In this disinhibitory model, we anticipated that blocking GABA receptors
would prevent DAMGO from exerting its effects on SCOs. In contrast, if DAMGO acts
by directly enhancing the activity of PNs, GABA receptor inhibitors should fail to
prevent DAMGO from enhancing the calcium oscillations.
We tested this first by applying the GABAA antagonist, picrotoxin; if DAMGO
was inhibiting release of GABA onto GABAA receptors, this drug should mimic
DAMGO in polarity. Picrotoxin alone (M = 2.31, SD = 1.64) significantly enhanced SCO
amplitude (t(22) = 2.76, p = 0.006) when compared to the saline controls (M = 0.93, SD =
0.58). Picrotoxin also significantly enhanced calcium oscillation halfwidth compared to
the change in control. However, picrotoxin (Mdn = 0.69) did not significantly (U = 62, p
= 0.295) enhance SCO number compared the change in control (Mdn = 0.71). Therefore,
the effects of picrotoxin were similar in polarity to the effects of DAMGO and could
suggest that the µOR downregulated GABAA receptors. To test this, we coapplied
DAMGO and picrotoxin together to determine whether DAMGO had an additive effect
(Figure 6). Effects of DAMGO with picrotoxin would suggest that DAMGO’s effects
were not solely mediated by downregulated GABAA receptors.
We found that the combination of picrotoxin and DAMGO (M = 1.81, SD = 1.08)
did not result in a significantly different (t(22) = 0.89, p = 0.192) change in SCO
amplitude versus picrotoxin alone (M = 2.31, SD = 1.64). However, the combination of
picrotoxin and DAMGO (M = 4.51, SD = 2.10) did significantly (t(22) = 1.86, p = 0.039)
enhance SCO halfwidth compared to the fold change in picrotoxin alone (M = 3.10, SD =
1.61). This result suggested that other factors may be involved than reduced GABA
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release onto GABAA receptors, which picrotoxin should have blocked. The combination
of picrotoxin and DAMGO (M = 0.55, SD = 0.26) did not significantly (t(22) = 0.89, p =
0.191) change SCO number when compared to picrotoxin alone (M = 0.68, SD = 0.42).
Therefore, neither the µOR nor GABAA receptors do not to appear to alter the number of
SCOs (Figure 6k and Figure 7e).
Picrotoxin with DAMGO failed to completely block the DAMGO effect; this
could mean that the µOR directly excites PNs, or that the effect of DAMGO is mediated
through both GABAA and GABAB receptors. We hypothesized that blocking both
GABAA and GABAB receptors would block the DAMGO effect based on studies by
other labs that suggest that the µOR is expressed by GABAB-stimulating neurogliaform
neurons (Lafourcade & Alger, 2008; Olah et al., 2007).
To determine whether DAMGO was mediating its excitatory effect through
downregulation of GABAA + GABAB receptors or direct excitation of PNs, we tested
DAMGO in combination of picrotoxin and the GABAB antagonist CGP55845. We found
that this combination of GABAA receptor blockade and GABAB receptor blockade
DAMGO (M = 2.65, SD = 1.04) did not result in significantly different (t(22) = 1.71, p =
0.51) fold change in halfwidth versus CGP55845 and picrotoxin themselves (M = 2.04,
SD = 0.65), which indicated that this drug combination could block the DAMGO effect
where picrotoxin alone did not (Figure 7c,d). This finding was consistent with our
hypothesis, that DAMGO was mediating its SCO-enhancing effect by suppressing
interneuronal release of GABA onto both GABAA and GABAB receptors, and not
GABAA receptors alone.
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The combination of CGP55845 + picrotoxin + DAMGO (M = 1.76, SD = 0.65)
also did not result in a significantly different change (t(22) = 1.28, p = 0.106) in SCO
amplitude versus CGP55845 + picrotoxin (M = 2.25, SD = 1.14; Figure 7b). This was
consistent with Figure 7a, because picrotoxin (without CGP55845) itself could prevent
this DAMGO effect that we observed. Unexpectedly, we also found that CGP55845 +
picrotoxin + DAMGO (M = 0.40, SD = 0.24) resulted in a significantly fewer (t(22) =
2.03, p = 0.027) SCOs versus CGP55845 and picrotoxin alone (M = 0.82, SD = 0.68).
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Figure 7. Blockading both GABARs prevents DAMGO-enhancement of SCOs. We tested for the effect of
DAMGO when GABA receptors were blockaded. (Left column) We co-administered (100 µM) picrotoxin
with DAMGO. We found that picrotoxin alone produced significant increases in (a) peak amplitude and (c)
halfwidths of calcium peaks. Co-administering DAMGO with picrotoxin blocked the effect of DAMGO in
(a) amplitude not in (c) halfwidth. (Right column) We therefore coapplied DAMGO with both picrotoxin
and the GABAB antagonist CGP55845 and found that this drug combination blocked the DAMGO effect (p
in both (b) amplitude as well as (d) halfwidth. (e,f) Meanwhile, we found no significant effects in number
of calcium peaks in either condition. (First and Second column) Lines connect the same neuron’s pre and
postdrug value for each individual replicate. (Third and Fourth column) Edges of the boxes are drawn at the
1st and 3rd quartiles while the “whiskers” connect the largest and smallest values for that group. We tested
the data with D’Agostino-Pearson omnibus K2 test (p > 0.05) to ensure a normal distribution. Figure (d)
was analyzed with Mann-Whitney U test (one-tailed) due to a nonnormal distribution, while the rest of the
comparisons were executed with unpaired t tests (one-tailed).
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for the peaks, and the red dot at the tips of the peaks are indicating that the peak has been successfully
culled for analyses by the Python script.

2.3.6 Interneurons and Pyramidal Neurons
Our results suggested that interneurons were being downregulated by DAMGO, which
caused the PNs to become hyperactive in response to reduced activity of GABA
receptors. If this is true, we might expect activity of interneurons to decrease, as activity
of excitatory neurons to increase. However, the data described so far did not discriminate
between inhibitory and excitatory types of neurons, and we could not determine if
activity of interneurons in this preparation was decreasing despite the net enhancement of
SCOs. We therefore separately labelled interneurons to determine whether their SCOs
were differentially regulated from PNs by the drugs in this model.
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Figure 9. Cultured neurons transformed with AAV-mDlx-NLS-mRuby2. Brightfield image of cultured rat
neurons. (Top Right) Fluorescence of mRuby2 in red. (Bottom) Overlay of both images to show the
neocortical interneurons in the field. Neurons at DIV (40x magnification).

Neocortical interneurons only constitute 10-25% of all neocortical interneurons,
while excitatory neurons constitute the remaining proportion (Beaulieu, 1993; Jones,
1993; Meyer et al., 2011; Ren, Aika, Heizmann, & Kosaka, 1992). We therefore expected
that interneurons in these cultures would comprise a similar proportion. To identify
interneurons in our model, we exposed the cultured neurons to an AAV that induces
expression of a red fluorescent protein in interneurons by using the interneuron-specific
enhancer Dlx5/6. We manually counted neurons in 110 images across 3 independent
cultures and found that interneurons constituted 432 neurons out of a total of 2428
neurons (17.8%). We also used a separate approach with a Python script that
automatically enumerated neurons and found that interneurons constituted 1037 out of
6461 neurons (16.1). Collectively, these data show that interneurons in our culture system
comprised the expected 10-25% range (Beaulieu, 1993; Jones, 1993; Meyer et al., 2011;
Ren et al., 1992).
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2.3.7 Second dataset experimental design
In our first dataset, we observed that picrotoxin alone could significantly enhance SCO
halfwidth and amplitude (Figure 7) and its effect outweighed the effects of DAMGO.
While this was expected, the magnitude of picrotoxin’s effect in that model made the
effect of DAMGO difficult to separate from the larger effect of picrotoxin. To address
this, we instituted a change in the drug exposure protocol by applying picrotoxin for 1525 minutes before applying DAMGO (i.e., a “background” of picrotoxin). While this
drug application procedure did depart from our earlier method, it also conferred the
benefit of testing these effects in a slightly different way to reinforce their validity.
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Figure 10. Second dataset experimental design. For our next dataset, we administered a preincubated
background of (100 µM) GABAA-specific inhibitor picrotoxin or picrotoxin + the GABAB specific
inhibitor CGP55845 (10 µM), and then applied (3 µM) DAMGO. This mitigated the more drastic effects of
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combining DAMGO with the GABAR blockers, in order to further isolate the effect of DAMGO from the
effects of picrotoxin and CGP55845.

2.3.8 Changes similar in interneurons and excitatory neurons
Based on our data, we believed that interneurons were specifically being suppressed,
which allowed excitatory PNs to enhance their activity. We therefore hypothesized that
interneurons would have diminished SCOs when compared to enhanced SCOs in PNs. To
determine whether DAMGO was differentially affecting inhibitory versus excitatory
neurons, we tested for DAMGO effects we previously found in here separately in the
populations of neurons (Figure 11).
Post-hoc comparisons using Tukey’s multiple comparisons test revealed that
significant effects of DAMGO on SCO halfwidth could be found in both interneurons (M
= 1.98, SD = 0.58) and noninterneurons (M = 1.72, SD = 0.64) relative to inhibitory and
excitatory controls exposed to vehicle saline (M = 1.09. SD = 0.25; M = 1.20, SD = 0.35).
Therefore, the effect of DAMGO was not significantly different between excitatory and
inhibitory neurons. Unexpectedly, the SCOs in interneurons and PNs were similarly
upregulated, and augmentation of SCO halfwidth could be found in both neuronal types.
We next investigated whether this DAMGO enhancement of SCO halfwidth was
again distinguishable in picrotoxin, and absent in the presence of picrotoxin and
CGP55845. These findings would replicate our conclusion that DAMGO suppressed
GABA release onto GABAA and GABAB receptor. Consistent with this, administering
DAMGO in a background of picrotoxin resulted in significantly larger halfwidths in both
interneurons (M = 1.33, SD = 0.39) and noninterneurons (M = 1.49, SD = 0.41) relative to
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their no-DAMGO vehicle controls (M = 0.99, SD = 0.16; M = 1.13, SD = 0.14). This
showed again that the effect of DAMGO was not solely mediated by downregulation of
GABAA receptors. We therefore tested whether DAMGO-enhancement of SCO
halfwidth was blocked in a background of picrotoxin and CGP55845.
The effect of DAMGO was blocked only in the presence of both picrotoxin and
CGP55845 in both interneurons (M = 1.01, SD = 0.29) and excitatory neurons (M = 1.15,
SD = 0.27) in comparison to their respective controls (M = 1.25, SD = 0.56; M = 1.28, SD
= 0.56).
In summary, found that interneurons and excitatory neuronal SCO durations were
similarly enhanced in response to DAMGO. However, we also found here that DAMGO
enhancement of SCO halfwidth was still present in a background of picrotoxin, but not a
background of picrotoxin + CGP55845. Therefore, we were able to replicate our main
finding from the first dataset – that DAMGO’s effects were mediated through cortical
interneurons and both GABAA and GABAB receptors.
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Figure 11. DAMGO enhancement of SCOs observed in both neuron types. To test whether DAMGOinduced changes in SCOs were similar in both neuronal types, we tested DAMGO in the presence of
GABAergic blockade. (Left column) Changes in a background of saline. (Middle column) Changes due to
DAMGO in a 10-minute preincubation with the GABAA-antagonist picrotoxin. (Right column) Changes
due to DAMGO after a 10-minute preincubation with picrotoxin and the GABAB-antagonist CGP5845. We
found DAMGO enhanced (d) SCO halfwidth, and not (g) number of SCOs. Unlike the previous dataset,
however, there were not significant differences in SCO amplitude in this dataset. (e) In the presence of
picrotoxin, DAMGO again enhanced SCO halfwidth, and failed to enhance their (b) amplitude and (h)
number which recapitulated our earlier dataset. In the presence of picrotoxin and CGP55845, DAMGO
once again failed to change (c) amplitude (g) halfwidth, and (j) number, which also recapitulated our earlier
findings. All groups include the same number (n = 13) trials. Mean fold changes were tested by comparing
mean fold changes in properties relative to other cell types and the same cell type in the vehicle condition.
Statistics were analyzed using Sidak’s test for multiple comparisons.
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2.3.9 Effect of DAMGO in picrotoxin similar to GABAB blockade
Our data had indicated that DAMGO still enhances SCO halfwidth in the presence of
picrotoxin in both datasets, and that the DAMGO enhancement was found in both
excitatory and inhibitory neurons. We next investigated whether CGP55845 in a
background of picrotoxin resemble the effect of DAMGO in the same background, which
would be consistent with our hypothesis that DAMGO reduces activity at both GABAA
and GABAB receptors.

Change in Amplitude

a)
Blank (Excitatory)

ns

✱

Blank (Interneuron)

ns

ns

CGP55845 (Excitatory)

2.
0

1.
5

1.
0

0.
5

0.
0

CGP55845 (Interneuron)

Fold change from baseline

b)

Change in Halfwidth

Blank (Interneuron)

ns

✱✱✱

CGP55845 (Excitatory)

✱✱✱

ns

Blank (Excitatory)

4

3

2

1

0

CGP55845 (Interneuron)

Fold change from baseline

c)

Change in Number of Peaks

✱✱✱

ns

CGP55845 (Excitatory)

✱✱✱

ns

Blank (Excitatory)
Blank (Interneuron)

1.
5

1.
0

0.
5

0.
0

CGP55845 (Interneuron)

Fold change from baseline

Figure 12. Effect of GABAB inhibition. We found that application of the GABAB antagonist CGP55845 in
a background of picrotoxin resulted in no significant changes in (a) SCO amplitude. However, we found
significant increases in (b) SCO halfwidth after CGP55845 in both interneurons and excitatory neurons. We
also found significant reductions in (c) SCO number after CGP55845 in both neuronal types. Mean fold
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changes were tested by comparing mean fold changes in properties relative to other cell types and the same
cell type in the vehicle condition. Statistics were analyzed using Sidak’s test for multiple comparisons.

In a background of picrotoxin, CGP55845 produced no significant change in SCO
amplitude in interneurons (M = 0.57, SD = 0.24) or excitatory neurons (M = 0.82, SD =
0.23) relative to their vehicle controls (M = 0.50, SD = 0.25; M = 0.81, SD = 0.39). We
found that addition of CGP55845 produced a significant increase in SCO halfwidth
relative in both interneurons (M = 1.80, SD = 0.65) and excitatory neurons (M = 1.91, SD
= 0.81) relative to controls (M = 0.98, SD = 0.17; M = 1.04, SD = 0.14). These effects
were consistent with our DAMGO findings in a background of picrotoxin (Figure 7c),
which showed that DAMGO produces an increase in SCO halfwidth.
We observed a consistent and significant trend towards fewer SCOs upon
application of CGP55845 (Figure 11c). While SCO number did not generally change
throughout our previous experiments, the number of SCOs was significantly reduced in
both interneurons (M = 0.60, SD = 0.28) and excitatory neurons (M = 0.58, SD = 0.21)
versus their respective controls (M = 0.96, SD = 0.21; M = 0.96, SD = 0.21) under this
condition.
Taken together, these results (Figure 11) do show similar effects of DAMGO in a
background of picrotoxin; enhancement of SCO halfwidth but not amplitude, which is
further evidence that DAMGO reduces GABA release onto both GABAA and GABAB
receptors in neocortical cultures.
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2.4 Discussion
We report here that µOR agonism upregulates spontaneous activity in primary
neocortical cultures; on average, we observed that DAMGO enhanced SCO duration by
63% (Table 2). These results therefore strongly suggest that the µOR excites neocortical
circuits, in part by enhancing durations of bursts of activity being indicated by SCOs. In
addition, our results also implicate the µOR in a disinhibitory role by suppressing the
activity of interneurons, as shown by our findings that the µOR’s enhancement of SCO
can be blocked by coapplication with GABA inhibiters (Figure 7), or in a background of
GABA inhibitors (Figure 11). Given the ambiguity in the field about whether DAMGO
provides disinhibition, or direct excitation to PNs, these experiments provide additional
evidence that the main network effect of µOR stimulation is due to inhibition of
interneurons.
We speculate that this enhancement may indicate that cortical interneurons were
slower in counteracting bursts of action potentials (being indicated by the SCO), which
allowed pulses of excitatory activity to continue for longer before being suppressed by
interneurons. This finding could suggest that the µOR may make the cultured networks of
interneurons less responsive and able to provide feedback inhibition to local excitatory
neurons. Therefore, these results may suggest that this receptor dysregulates networks of
interneurons by reducing their ability to respond quickly to bursts of glutamatergic
activity.
A previous study by another lab has found that DAMGO enhances SCOs in
hippocampal cultures, but our findings contract it in 2 major ways (Przewlocki et al.,
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1999). We performed simultaneous GABAA and GABAB receptor blockade to show that
effects of DAMGO are ameliorated only when both receptors are blocked, and GABAA
blockade fails to do that. Therefore, our main conclusions that DAMGO disinhibits
neocortical networks appears to be well-supported in both datasets (Figure 7 and Figure
11). Our results also departed from those earlier findings in another way – we obtained
fairly inconsistent results on DAMGO enhancement of SCO amplitude, but instead we
observed that DAMGO consistently enhanced the duration (halfwidths) of the SCOs.
Our electrophysiological recordings indicate that SCOs generally are not caused
by isolated APs, which appear to correspond to no detectable SCO activity (Figure 4).
Instead SCOs generally correspond to longer-lasting depolarizations that appear to be
excitatory postsynaptic potentials. Our results therefore are similar to previous reports
that used simultaneous electrophysiological recordings to show that SCOs correspond to
excitatory postsynaptic potentials (Bacci et al., 1999; T. H. Murphy et al., 1992;
Przewlocki et al., 1999). In addition to that, we also found that depolarizing current
applications are capable of causing calcium peaks, though spontaneous activity could
trump those induced calcium peaks (Figure 4). This suggests that the causal arrow could
point both ways; bursts of action potentials can cause SCOs, while our data discussed to
this point also suggest that EPSPs themselves can induce both bursts of action potentials
and SCOs that correlate with them. We also observed a possible refractory period (Figure
4) towards the end of the calcium indicator fluorescence traces, which could suggest that
CICR phenomena may be involved with the calcium peaks being induced by the current
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application. In summary, SCOs correspond to bursts of activity, but SCOs can be
proximally caused by different phenomena.
We investigated whether this model can be used to show inhibition of
interneurons and overactivity of PNs upon application of DAMGO. Yet, our results
showed uniformly that the SCOs were not significantly different between the two types in
various drug conditions. How do we reconcile this with disinhibition? On one hand, some
authors show that SCOs are constituted of a voltage-sensitive calcium channel
component (Bacci et al., 1999; Dravid & Murray, 2004; Inglefield & Shafer, 2000).
However other authors show that SCOs are mostly a result of glutamatergic input (Cao et
al., 2015; Dravid & Murray, 2004; Inglefield & Shafer, 2000; T. H. Murphy et al., 1992;
Nuñez et al., 1996; Przewlocki et al., 1999; Shen et al., 1996). Our own results support
the latter model – that the SCO is a result of excitatory drive being input into each
neuron, which would explain why SCOs are similar in interneurons and excitatory
neurons, because nearby neurons receive the same input. This explanation would further
suggest that interneurons are unable to provide adequate inhibition despite the increase in
excitation going into both neuronal types; electrophysiological experiments from
neocortical interneurons show that DAMGO reduces frequency and duration of action
potentials elicited by same-magnitude depolarizations from an electrode(Dutkiewicz &
Morielli, 2020; Férézou et al., 2007). Therefore, these electrophysiological data are
consistent with the notion that interneurons are downregulated, despite experiencing
greater glutamatergic input being indicated by the SCOs. Although GABAA receptors are
the main cortical GABA receptor, our results indicated that the DAMGO-enhancement of
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duration calcium oscillations was successfully blocked only by combined GABAA and
GABAB receptor inhibitors and failed to be blocked by only GABAA blockade in both of
our datasets (Figure 7 and Figure 11). While cortical GABAA receptors are plentiful,
GABAB receptors are confined to synaptic and extrasynaptic spaces in neurons that are
most strongly activated by neurogliaform neurons (Olah et al., 2007; Tamás et al., 2003).
These neurogliaform neurons are shown to express high rates of the µOR in the cortex
(Férézou et al., 2007) and hippocampus (Krook-Magnuson et al., 2011). Therefore, our
data that µOR+ neurons release GABA onto GABAA and GABAB receptors are
consistent with previous experiments by other labs (Olah et al., 2007; Tamás et al., 2003)
and consistent with studies that suggest that neurogliaform neurons are µOR+ (Férézou et
al., 2007; Krook-Magnuson et al., 2011). These experiments suggest that this
phenomenon can be reproduced in the SCO model.
We found that picrotoxin blocked the DAMGO-enhancement of calcium
oscillation amplitude, even though the DAMGO effect of picrotoxin on duration
(halfwidth) persisted. One possible reason is that picrotoxin had so profoundly amplified
the intensity of calcium oscillations, that DAMGO did little to add to the height of the
calcium peaks. This may happen, for instance, if the picrotoxin condition fully recruited
the NMDA receptors by sufficiently releasing glutamatergic neurons from enough
inhibition to promote glutamate release, which itself may in turn further activate other
glutamatergic neurons. Previous experiments by other labs have related SCO amplitude
to the activity of NMDA receptors, which is expected to promote greater Ca2+ entry
during postsynaptic potentials (Bacci et al., 1999; Inglefield & Shafer, 2000; T. H.
111

Murphy et al., 1992; Nuñez et al., 1996; Przewlocki et al., 1999; Shen et al., 1996). This
can potentially pose a limitation to this study, because any potential positive regulation of
NMDA receptors may be overlooked by the overwhelming enhancing effect of picrotoxin
on SCO amplitude (Figure 7a), though this does not appear to mask the effect of
DAMGO on SCO halfwidth (Figure 7c and 11e).
There were several effects that we found in our first data set (Figure 6 and Figure
7) but were not found when a similar experiment was repeated in the second dataset
(Figure 11). Firstly, we initially found an effect on SCO amplitude due to DAMGO
(Figure 6c), however this effect was not present in the second data set (Figure 11a).
DAMGO’s effect on SCO amplitude appeared to be weaker and less frequent than its
effect on SCO halfwidth, which may have led to the inconsistent results. Secondly, we
initially found a statistically significant reduction in SCO number in the first dataset
(Figure 7f). We initially believed that DAMGO’s effect under the combination may be
limited to cortical interneurons and suppressed SCO number in interneurons, however the
effect was not found in interneurons (nor in noninterneurons) in the second dataset
(Figure 11i). Therefore, it seems more likely that this was a statistical anomaly. While the
failure to replicate these findings present a more complicated picture of DAMGO’s
effects, the repetition of these experiments at least may provide more validity and insight
for follow-up studies. For example, the effect of DAMGO on SCO amplitude may be less
consistent. However, both datasets show clearly that DAMGO shows a picrotoxinresistant enhancement of SCO duration (Figure 7c and Figure 11e), and that all effects of
DAMGO are blocked by coapplication (Figure 7d) or preincubation (Figure 11f) with a
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combination of picrotoxin and CGP55845. Therefore, our conclusions that DAMGO
promotes excitation secondary to inhibition of interneurons appears to be well-supported
by our data, and by data from other labs in different models that suggests µORs localize
to GABAergic interneurons (Drake & Milner, 1999, 2002, 2006; Férézou et al., 2007;
Huo et al., 2005; Madison & Nicoll, 1988; Stumm et al., 2004; Taki et al., 2000;
Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979).
One lingering issue is the neurophysiological mediators of SCO amplitude and
duration (halfwidth). Previous experiments on SCOs, which generally use low ACSF
[Mg2+], have consistently linked SCO amplitude with activity of various postsynaptic
glutamate receptors (Bacci et al., 1999; Nuñez et al., 1996; Przewlocki et al., 1999; Shen
et al., 1996). SCO duration (halfwidth, in our experiment) has only occasionally been
quantitatively analyzed but, it too, may be modulated by NMDAR activation because
[Mg2+] manipulations can modify it (T. H. Murphy et al., 1992). Our data show that
GABAB receptors modulate SCO duration, though the mechanism requires some
speculation. One conceivable explanation is that the prolonged glutamatergic stimulation
indicated by the SCO activates cortical interneurons which provide an immediate GABA
release. However, the background of picrotoxin prevented GABAA receptors prevented a
quick counterbalance, and the eventual termination of the SCO was brought about
through the slower action of GABAB receptors. This explanation is corroborated by our
data that show that DAMGO or CGP55845 in a background of picrotoxin both
significantly enhance the SCO halfwidths (Figure 11 and Figure 12), and support our
main conclusion that DAMGO is downregulating GABA release onto both GABAA and
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GABAB receptors, which is consistent with their known role in suppressing the GABABstimulating neurogliaform neurons of the neocortex (Craig & McBain, 2014; Olah et al.,
2007; C. J. Price et al., 2008).
The downstream physiological origin of these Ca2+ oscillations is presently
unknown, and the various mechanisms proposed to contribute to the calcium transients
may be responsible for this uncertainty. Calcium transients have previously been linked
the development and gene expression in neurons (Dolmetsch et al., 1998; Spitzer et al.,
1995). They are also believed to confer a neuroprotective role against trauma (GeddesKlein et al., 2006).

CHAPTER 3: µ OPIOID RECEPTORS MODULATE ACTION POTENTIAL
KINETICS AND FIRING FREQUENCY IN NEOCORTICAL INTERNEURONS

3.1 Introduction
The endogenous opioid system of the cerebral cortex mediates antinociception and
reward valuation (Choi et al., 2016; Ong et al., 2019; Qiu et al., 2009; Zubieta et al.,
2001). Dysregulation of this system is believed to contribute to pathological and
compulsive behaviors such as eating disorders, pathological gambling, and drug-seeking
(Ashok et al., 2019; B. Bencherif et al., 2005; Giuliano & Cottone, 2015; Joutsa et al.,
2018; Mick et al., 2016; Mitchell et al., 2012; Qu et al., 2015; Zubieta et al., 1996).
Experimentally, impulsive behaviors and binge-eating can be induced through infusion of
the µ opioid receptor (µOR) specific agonist [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin
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(DAMGO) into the frontal cortex of animal models (Mena et al., 2011; Selleck et al.,
2015). Blockade of µORs with naltrexone inhibits compulsive behaviors (Bartus et al.,
2003; Blasio et al., 2014). These aberrancies are believed to result from the disruption of
activity within cortical networks by µORs (Haider et al., 2006; M. Whittington et al.,
1998; Y. Zhang et al., 2019). More specifically, µORs appear to dysregulate cortical
networks by suppressing GABAergic activity and thereby altering the balance of
excitation and inhibition in the cortex (David A. Lewis et al., 2012; Shi et al., 2020; Volk
et al., 2012). The µOR is believed to suppress GABAergic signaling through its
expression primarily on cortical interneurons. This leads to overactivity of the targets of
their inhibition, the glutamatergic Pyramidal Neurons (PNs) (Drake & Milner, 1999,
2002, 2006; Férézou et al., 2007; Huo et al., 2005; Madison & Nicoll, 1988; Stumm et
al., 2004; Taki et al., 2000; Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979).
However, some research suggests that µOR may activate PNs directly as well (Rola et al.,
2008; Schmidt et al., 2003; Witkowski & Szulczyk, 2006). Immunohistochemical
experiments have found high rates of expression of µOR in interneurons that express
vasoactive-intestinal peptide (VIP+) (Taki et al., 2000). Electrophysiological and sc-PCR
data in neocortical neurons have supported this finding (Férézou et al., 2007) and have
also implicated neurogliaform neurons as expressing this receptor (Férézou et al., 2007;
Lafourcade & Alger, 2008; McQuiston, 2008). Evidence for µOR expression in somata
of parvalbumin-positive (PV+) interneurons of the hippocampal formation is fairly clear
(Bartos & Elgueta, 2012; S. B. Bausch et al., 1995; Drake & Milner, 1999, 2002, 2006;
Stumm et al., 2004; Torres-Reveron et al., 2009), however perisomatic expression of this
receptor in neocortical PV+ neurons has been investigated but, to our knowledge, has not
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been reported (Férézou et al., 2007; Taki et al., 2000), though recent evidence shows that
µORs are sometimes found in PV+ axon terminals of the frontal cortex (C. Jiang et al.,
2019; Lau et al., 2020) and insular cortex (Yokota et al., 2016). Therefore, neocortical
VIPergic, neurogliaform, and some PV+ interneurons are generally believed to express
µORs – though not necessarily in their somata.
In addition to the uncertainty surrounding the µOR’s localization, there is also
some mystery surrounding its mechanism by which µORs affect interneuron activity. The
µOR is a G-protein coupled receptor and has been shown to activate potassiumconducting inwardly rectifying K (GIRK) channels (Henry et al., 1995; Ikeda et al., 2000;
Loose & Kelly, 1990; Marker, Lujan, Loh, & Wickman, 2005). Regulation of GIRK
channels and hyperpolarization are characteristic features of various ORs (Ikeda et al.,
2003). Agonist-induced hyperpolarization has been found in cortical µOR+ neurons
(Férézou et al., 2007; Glickfeld et al., 2008; Madison & Nicoll, 1988; E. Tanaka & North,
1994) non-cortical µOR+ neurons (Grudt & Williams, 1993; Harris & Williams, 1991;
Johnson & North, 1992; Kelly, Loose, & Ronnekleiv, 1990; Lagrange, Ronnekleiv, &
Kelly, 1994; Lagrange, Rønnekleiv, & Kelly, 1995; Loose & Kelly, 1990; R. A. North,
Williams, Surprenant, & Christie, 1987; Sugita & North, 1993), and is also a feature of
other opioid receptors as well (B Chieng & Christie, 1994; Chiou & Huang, 1999; Grudt
& Williams, 1993; Johnson & North, 1992; Loose & Kelly, 1990; Loose, Ronnekleiv, &
Kelly, 1990; Madison & Nicoll, 1988; R. A. North et al., 1987; Sugita & North, 1993).
However, hyperpolarization does not always occur in response to DAMGO (Faber &
Sah, 2004; Wimpey & Chavkin, 1991), possibly due to an incomplete overlap between
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GIRK channel expression and µORs, which may be the case in the cortex (S. B. Bausch
et al., 1995). Additionally, reductions in spontaneous APs with µOR-agonism is also
found in various parts of the brain, though not all µOR+ neurons fire spontaneously
(Loose & Kelly, 1990; Mitrovic & Celeste Napier, 1998; Ponterio et al., 2013).
Hyperpolarization and decreased spontaneous activity are both commonly found in
response to the activation of µOR and other opioid receptors, and the two effects often
coincide (Chiou & Huang, 1999; Elghaba & Bracci, 2017; Kelly et al., 1990; Loose &
Kelly, 1990; R. A. North et al., 1987). While it is possible that hyperpolarization could
induce a decrease in spontaneous APs by increasing the distance to Vm threshold for
action potentials, some studies in cortical neurons have found reductions in spontaneous
APs with only small accompanying hyperpolarization (Krook-Magnuson et al., 2011; M.
E. Sheffield et al., 2013; M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al., 2014).
Therefore, the µOR may induce hyperpolarization of varying magnitude along with
reductions in tonic APs, and one effect could occur independently of the other.
In addition to hyperpolarization and reductions in spontaneous APs, research from
other parts of the brain suggests that µORs modulate αDendrotoxin-sensitive channels;
αDTX inhibits Kv1.1, Kv1.2, and Kv1.6 channels (Ponterio et al., 2013). Experiments
have found that µORs modulates αDTX-sensitive channels in the basolateral amygdala
(Finnegan et al., 2006), periaqueductal gray (Vaughan et al., 1997), as well as
thalamocortical terminals within the frontal cortex (Lambe & Aghajanian, 2001).
Although these channels are known to be expressed by several families of neocortical
interneurons (Casale, Foust, Bal, & McCormick, 2015; Goldberg et al., 2008; Golding et
117

al., 1999; T. Li et al., 2014; Porter et al., 1998), they have not been directly investigated
for mediating the µOR’s inhibitory effect in the neocortical interneurons. We therefore
predicted that µORs activate αDTX-sensitive channels to inhibit neocortical interneurons.
Several studies have investigated the role of the αDTX-sensitive channels by
analyzing its effects on action potentials. While Kv1.1, Kv1.2, and Kv1.6 channels have
been shown to modulate spike frequency and AP threshold, (Bekkers & Delaney, 2001;
Faber & Sah, 2004; Finnegan et al., 2006), and some studies have suggested that they
contribute to AP shape as well. Specifically, researchers have found that αDTX-sensitive
channels hasten repolarizations and shorten durations of APs (Geiger & Jonas, 2000;
Pathak, Guan, & Foehring, 2016), including in neocortical interneurons (Casale et al.,
2015). We therefore predicted that part of the mechanisms by which the µOR act in
neocortical interneurons is through one or a combination of these αDTX channelmediated electrophysiological effects. To investigate this, we cultured neocortical
neurons and performed patch-clamp electrophysiology on interneurons in current-clamp
mode to stimulate and measure their APs. To measure the kinetics of APs, we created
Python scripts to measure 54 membrane properties, AP kinetic properties, and ratios. We
were primarily interested in 7 properties that have previously been implicated in
mediating DAMGO or αDTX effects in neurons. We predicted that DAMGO and αDTX
would modulate (in opposite polarity) resting membrane potential, AP threshold, number
of evoked APs, interspike interval, AP halfwidth, maximum repolarization rates,
amplitude of afterhyperpolarizations.
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3.2 Materials and methods
All procedures were authorized by the Institutional Animal Care and Use Committee
(IACUC) at University of Vermont. We dissected CD® IGS Sprague-Dawley (Charles
River) pregnant rat dams to harvest neocortical neurons from the frontal cortices of E21
rat embryos. Brain cortices were rinsed in Hibernate A (Gibco, Grand Island, NY),
dissociated with papain (Worthington, Columbus, OH) and mechanically separated
through gentle trituration with a pipette. Dissociated cortical neurons were and cultured
on round 12mm glass, PEI-coated (Sigma-Aldrich, St. Louis, MO) coverslips at an
approximate density of 3x104 cells/cm2. We maintained the neurons in Neurobasal A,
B27, Penicillin-Streptomycin and Glutamax (All from Gibco), in a humidified 37° C
incubator with 5% CO2. Cultures were transformed on day in vitro 1 with an AAV-mDlxNLS-mRuby2 to induce expression of a red fluorescent protein in cortical interneurons.
Culture media was half-replaced every 3 days. Experiments commenced between day in
vitro 16-37. AAV-mDlx-NLS-mRuby2 was a gift from Viviana Gradinaru (Addgene
viral prep # 99130-AAV1); http://n2t.net/addgene:99130; RRID:Addgene_99130).
3.2.2 Whole-Cell Recordings
Cultured neurons were transferred from their growth media into a chamber perfused with
ACSF (in mM: NaCl, 126; KCl, 5; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1; NaHCO3, 26;
Glucose, 20; and pyruvate,5 (Férézou et al., 2007). The ACSF was warmed to 30oC and
constantly bubbled with a mixture of 95% Oxygen and 5% CO2. When indicated, both
CNQX (20 µM; Sigma-Aldrich) and dAP5 (50 µM; Sigma-Aldrich) were included in the
ACSF, which was then constantly perfused through the recording chamber. Saline
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controls were done alternately with drug condition recordings throughout the course of
the experiments. α-Dendrotoxin (αDTX) was purchased from Alomone Labs (Jerusalem,
Israel).
Patch pipettes with resistances of 5-10MΩ were fabricated from borosilicate glass
capillaries and filled with intracellular saline containing (in mM) K-gluconate, 144;
MgCl2, 3; ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, 0.5; 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, 10 (Férézou et al., 2007). The pH was
adjusted to 7.2 with potassium hydroxide and confirmed for an osmolarity of 285/295
mosm. Whole-cell recordings were made with an Axopatch 200B (Axon Instruments)
amplifier and Clampex 9.2.1.9 (Molecular Devices) software. Signals were sampled at
10kHz with a Digidata 1322a (Axon Instruments) DA converter. Passive membrane and
AP kinetics measurements were automated using a custom Python program
(cc_analysis.py) the source code for which is available at
https://github.com/moriellilab/cc_analysis_46.
All 7 measures that we investigated in the hypotheses were manually testedagainst script generated values. In all 7 cases, they significantly and positively correlated
to values determined manually with the threshold peak-detector of Clampfit 10.7
(Molecular Devices). All analyses used measurements generated by the cc_analysis
program, with the exception of spiking pattern, which was always determined manually.
Measure
RMP
AP Threshold
Number of APs
ISI

Correlation
r(7) =0.998, p < 0.001
r(7) = 0.982, p < 0.001
r(7) = 1.000, p < 0.001
r(7) = 0.999, p < 0.001
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Halfwidth
Maximum AP Repolarization Rate
AHP Amplitude

r(7) = 0.963, p < 0.001
r(7) = 0.998, p < 0.001
r(7) = 0.921, p < 0.001

Table 3. Manual measurements positively correlate with script-derived values. We validated the scriptderived values by randomly selecting 3 recordings for validation by using all 3 of their timeslots.
Therefore, an N = 9 files were analyzed in the script and with manual measurements using Clampfit 10.7.
In all 7 measurements, values derived with the script were significantly and positively correlated with
manual measurements. Values compared with a bivariate correlation and tested for significance (two-tailed;
α = 0.05).

3.2.3 Current-clamp protocol
We selected neurons for recording that were fluorescent (red), reflecting their exposure to
AAV-mDlx-NLS-mRuby2 during culturing. We adjusted membrane potentials for a
junction potential of -11mV. Only neurons with a healthy appearance were selected for
recording. We generally used neurons that were more hyperpolarized than -45mV for
recording, though primarily the inclusion criterion was primarily the ability to fire APs
from their natural RMP after the application of a depolarizing current.
A diagram of the experiment is illustrated on Figure 15. Upon acquiring a wholecell configuration, we recorded for 3 minutes to ensure that the RMP was stable and more
hyperpolarized than -45mV, and that the neuron was capable of firing APs with a
depolarizing current from its RMP. The 20 current steps (1s duration) we used to elicit
APs were adjusted for each recording during this waiting period, because neurons had
slightly different RMPs, thresholds, and resistances that required modulating the current
magnitude. Once calibrated for the neuron, we kept that setting constant for all 3 drug
conditions for all timeslots for that neuron. We subsequently made the pre-drug
recording, and then we applied these drugs through bath perfusion for 80s to ensure the
concentration and response was stable. We then made the “post-DAMGO” (slot 2)
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recording after these 80s of incubation, then applied the next drug buffer for 80s (a
combination of DAMGO and αDTX), and then made the post-αDTX+DAMGO
recording (slot 3). Neurons were passively recorded from between timeslots for Vm
changes, but these data were not considered in the analyses. Coverslips were discarded
and replaced after a single use.
We quantified spontaneous APs by counting APs that occurred outside of the 1s
current pulse. This comprised a noncontiguous period totaling 60 seconds in each
timeslot. Spontaneous APs were not analyzed beyond counting them because most
DAMGO-responders stopped firing spontaneous APs after DAMGO.
3.2.4 Measurements of AP and membrane properties
APs were evoked with a 1s current pulse of varying amplitude. These pulses occurred 3s
apart. Resting membrane potential (RMP) was determined from the median Vm measured
during a 330 ms period immediately before the 1s current pulse. when the 1s current
pulse was not being applied. This was composed of a noncontiguous period surrounding
the current pulse, totaling 6.6s.
AP Threshold was determined from steady-state Vm at the first current
application that induces an action potential. Mean interspike intervals were likewise
derived from measuring the mean value for the space between spikes. Number of evoked
APs was measured by averaging the number of APs also during episodes 15-18. The
remaining parameters were likewise determined from the average value of episodes 1518.
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AP kinetic values (halfwidth and maximum repolarization rates) were also
derived from episodes 15-18 of the 20 current steps. We averaged the values for APs 3-5
on each of the 4 current steps, and then averaged across the current steps to derive the
final value. The halfwidth was determined as the width (in ms) of each AP at half the
height of the AP.

Figure 13. Sample AP diagram. AP kinetics were measured by the script and an example is shown here to
illustrate the derivation of the measurements (Upward-facing blue arrow) Start of the AP demarcated at
10% of the maximum depolarization rate. Vm at this point represents AP threshold. (First Green Circle)
Maximum rate of depolarization of the AP. (Second Green Circle) Maximum rate of repolarization of the
AP. (Downward-facing blue arrow) 10% of maximum rate of repolarization, marking the end of the AP.
(Yellow Diamond) Lowest point of the afterhyperpolarization. Afterhyperpolarizations were measured as
the difference between the y value of the start of the AP with the lowest point of the afterhyperpolarization,
out to a maximum distance of 2ms from the point where the repolarization phase returns to the same V m as
the start of the AP at the upward blue arrow. (Pink Horizontal Line) The halfwidth of the AP was measured
at half the height of the AP from the threshold V m of the AP at the upward blue arrow.

3.2.5 Data Display
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The cc_analysis.py analysis program produced a Microsoft Excel spreadsheet with all
measurements. To render the spreadsheet compatible with SPSS, we sorted the rows of
recordings by filename and added in a row of column labels. SPSS syntax is compatible
with the master spreadsheet included here. Additional columns were added to the excel
spreadsheet that divided the post-DAMGO (or post-saline) scores by their initial (predrug) condition for each particular measure, which were ultimately graphed on box-andwhisker plots throughout this text. Every change in the post-DAMGO condition was
some factor of 1 (initial) to show the fold change. Thus, the changes from baseline were
determined for the DAMGO recordings and saline controls. While we had either 11 (Hresponders) and 10 (S-responders), we randomly selected a group of comparable size to
compare changes in the drug condition with entropic changes in the saline controls to
identify the drug effect. In the box-and-whisker plots where a subset of 10 or 11 saline
controls were required, we used Excel’s built-in random number generator function was
used to sort the saline recordings for comparison groups.
3.2.6 Statistics
Sample sizes were initially chosen under the expectation that only 5-20% of neurons
would show a hyperpolarizing effect with DAMGO. We estimated that around 55
DAMGO recordings should enable us to record from ~10 DAMGO responders. We also
recorded from 21 saline controls to enable us to compare the changes in DAMGOexposed neurons to negative controls; groups are not of matching sizes because we
expected that the whole DAMGO group would not be compared to the saline controls
since responders would only compose some of the DAMGO-exposed neurons.
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Since we were examining for DAMGO or αDTX effects in 7 variables at a time,
we first tested the combined variables in mixed-model repeated measures MANOVA
tests first to mitigate the high (30.1%) family-wise error rate to an α = 0.05. If the
omnibus test failed to produce significant results, we did not test each of the 7 variables
individually (main hypotheses). However, we made exceptions for data in the post-hoc
analyses of Table 12, since posthoc tests come with some assumptions of false positives.
All mixed-model repeated measures MANOVAs were conducted through IBM
SPSS 27.0.0.0. We defined the independent variable as the timeslot (within-subject
variable), and the between-subjects factor as the drug group (either saline or the DAMGO
sequence). For these tests, we compared the 11 DAMGO H-responders (or 10 SResponders) against all 21 saline-controls. For DAMGO effects we tested timeslot 1 and
2 data. For αDTX effects, we analyzed timeslot 2 and 3 data. We only reported
Slot*Group interaction effects; the effect of Slot (time) most likely reflected entropic
decay of the neurons over the course of the recording, while the effect of Group likely
reflected stochastic differences of the neurons between the 2 groups of neurons – neither
of which were a topic of these analyses. Therefore, in our experimental design, only the
Slot*Group interaction was relevant to whether DAMGO or αDTX effects were present.
In instances where the Slot*Group interaction was significant, we followed up by
individually testing each of the 7 measures.
Post-hoc analyses (Table 12) were executed similarly with mixed repeated
measures MANOVAs by testing sets of related variables to provide organizational and
analytical grouping. APs analyzed in these tests were also measured in episodes 15-18,
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but first, second, and average (of APs 3-5) were analyzed separately. For instance, the
first APs in episodes 15-18 were averaged across the episodes and analyzed separately
from the other (second and later) APs in that episode. We excluded the 7 variables
previously discussed in the main hypotheses to limit the posthoc analyses to data that
were not previously analyzed. Results of their individual omnibus tests are noted in the
figure legend for thoroughness, but we provided posthoc analytical data for individual
with-subject contrasts regardless of whether their omnibus test was significant.
Statistical testing portrayed on the box-and-whisker plots and summary tables
were conducted through in GraphPad Prism version 8.4.3 for Windows, GraphPad
Software, San Diego CA, USA www.graphpad.com. Statistical testing on fold changes
proceeded by first testing for skewness and kurtosis using D’Agostino-Pearson omnibus
K2 test in GraphPad Prism. When the statistic was not significantly different from normal
(p > 0.05), we conducted an unpaired t-test (one-tailed) to compare the fold changes in
the DAMGO group with the saline group. When the distribution of either group was
nonnormal (p < 0.05) we instead did the comparison with a one-tailed Mann-Whitney Utest.
3.3 Results
3.3.1 Identifying responders
Cortical µOR is expressed only in certain subcategories of interneurons; some studies
have estimated that only around 3-5% of all neocortical neurons, or 15-25% of
GABAergic interneurons, express µORs (Férézou et al., 2007; M. C. Lee et al., 2002;
Taki et al., 2000), though some have reported as many as 2/3rds of prefrontal GABAergic
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neurons respond to µOR-agonism (Witkowski & Szulczyk, 2006). To identify and target
GABAergic interneurons in culture, we transformed neurons with an AAV (see Methods)
that drove expression of the red fluorescent protein mRuby2 under the interneuronspecific Dlx5/6 enhancer (Batista-Brito et al., 2008; de Lombares et al., 2019; Fazzari et
al., 2010).

Figure 14. Cultured neurons with AAV-mDlx-NLS-mRuby2. (Top Left) Brightfield image of cultured rat
neurons. (Top Right) Fluorescence of mRuby2 in red. (Bottom) Overlay of both images to show the
neocortical interneurons in the field. Neurons at DIV 19 at 40x magnification.

Neocortical interneurons generally only constitute between 10-25% of all
neocortical neurons (with the balance being glutamatergic Pyramidal Neurons),
depending on the model and methods used to measure the proportions (Beaulieu, 1993;
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Jones, 1993; Meyer et al., 2011; Ren et al., 1992). To determine whether proportions of
interneurons occurring in the culture model used here fell within this range, we manually
counted the number of red and nonred neurons across 110 images in 3 independent
cultures. We found that red neurons constituted 432 out of 2428 neurons (17.8%). In a
second approach, we utilized a Python script that automatically counted the neurons. This
automated approach gave similar results, with red neurons constituting 1037 out of 6461
neurons (16.1%). With either counting method, our estimations of the proportions of
interneurons to non-interneurons in these dissociated neuronal cultures are typical for
previous reports of intact or sliced animal neocortex.
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Figure 15. Time course for patch-clamp recordings. Upon achieving whole-cell configuration, we
calibrated the amplitude of the current injections to that particular neuron (to factor in its RMP and input
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resistance) during the waiting and calibration period. (20 µM) CNQX and (50 µM) D-AP5 were constantly
perfused to block glutamatergic receptors. We performed the “Initial” (slot 1) recording after this period
and applied (3 µM) DAMGO for 80s of incubation and perfusion. We then performed the “post-DAMGO”
recording (slot 2) and applied (100 nM) αDTX+DAMGO for another 80s of incubation. After that, we
finally collected the “post-αDTX+DAMGO” (slot 3) recording. To evaluate for DAMGO effects, we
compared slot 2 with slot 1. To look for αDTX effects in background of DAMGO, we examined the change
between slot 3 and slot 2. We also collected recordings from neurons under a saline-control condition to
account for the effects of time in the drug group. We recorded from these neurons in an identical fashion
(the timeline is the same), but the saline-control neurons only received vehicle buffer, and not DAMGO or
αDTX.
Within-Subjects Factor (Slot)
Group
Slot 1
Slot 2
Slot 3
BetweenSaline (N = 21)
Saline
Saline
Saline
Subjects Factor
Drug Sequence (N =
Saline
DAMGO
αDTX+DAMGO
(Group)
55)
Table 4. Control and drug groups for electrophysiology. We included 2 groups in the experimental design;
a saline-only control and the experimental group that received the sequence of drugs. In both cases, slot 1
recordings are always pre-drug conditions. Slot 2 is synonymously referred to as “post-DAMGO” or as
“pre-αDTX” depending on whether we are testing for the effects of (3 µM) DAMGO or (100 nM) αDTX in
that particular analysis; the αDTX was always delivered in a background of DAMGO. To detect drug
effects, we analyzed the changes between 2 timeslots in the drug group and compared it to the changes in
the saline group: slot 1 versus slot 2 for DAMGO effects, and slot 2 versus slot 3 for (100 nM) αDTX
effects.

Overall, the DAMGO-exposed neurons (N = 55, M = 1.03, SD = 0.05) were
significantly more (t(74) = 3.14, p = 0.001) hyperpolarized than saline controls (N = 21,
M = 0.99, SD = 0.99), which tended to slightly depolarize. However, the µOR is only
expressed by a subset of cortical interneurons, and therefore was expected to be
represented in only some of the red-fluorescent Dlx5/6-mRuby2 neurons that we
recorded from. We anticipated that most neocortical interneurons would be unresponsive
to DAMGO. Combining data from all interneurons would thus obscure the effects of
DAMGO (3 µM) and αDTX (100 nM) in neurons that did express had µORs. We
therefore screened interneurons for responsiveness to DAMGO prior to subsequent
analyses. Hyperpolarization is a common response to DAMGO in neurons expressing
opioid receptors (B Chieng & Christie, 1994; Chiou & Huang, 1999; Grudt & Williams,
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1993; Johnson & North, 1992; Loose & Kelly, 1990; Loose et al., 1990; Madison &
Nicoll, 1988; R. A. North et al., 1987; Sugita & North, 1993), and in particular those
expressing µORs (Férézou et al., 2007; Glickfeld et al., 2008; Harris & Williams, 1991;
Kelly et al., 1990; Lagrange et al., 1994; Lagrange et al., 1995; Madison & Nicoll, 1988;
E. Tanaka & North, 1994). We therefore first identified responders by detecting a
hyperpolarizing change in resting membrane potential (RMP) after exposure to DAMGO
(Figure 16). By comparing the DAMGO-exposed group’s changes in RMP to the changes
in saline controls, we established a cutoff level to separate neurons most affected by
DAMGO. We refer to the DAMGO-exposed neurons above this cutoff as
“hyperpolarizing responders” (H-responders, N = 11). These H-responders
hyperpolarized significantly (t(20) = 7.61, p < 0.001) when they (N =11, M = 1.10, SD =
0.03) were compared to a group of random saline controls (n = 11, 𝑥̅ = 0.98, s = 0.04).
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Figure 16. H-responders hyperpolarize. The efforts to identify DAMGO-responders and measure the
change of RMP in the H-responders began by graphing resting membrane potential (RMP) after the 80s
period of incubation with either (3 µM) DAMGO or vehicle saline (a) We plotted the RMP each salinecontrol neuron (N = 21) individually and (b) each DAMGO-exposed neuron (N = 55) individually.
However, these graphs were ineffective in identifying the neurons that hyperpolarized the most under the
DAMGO condition. To isolate the change (hyperpolarization), we graphed the fold change in RMP instead
of the raw value (c) We plotted the change in RMP (defined as slot 2 RMP/ slot 1 RMP) in saline and
DAMGO controls and found a significant hyperpolarization in the DAMGO group compared to the saline
group (p < 0.05). To identify true DAMGO responders, we established a cutoff at the most hyperpolarized
saline control (vertical dotted line). DAMGO hyperpolarizers (to the right of the cutoff) are hereafter called
“H-responders” (N = 11). (d) We extracted these H-responders and a comparison group of random saline
controls (n = 11) onto a new plot. This represents the change in RMP among the H-responders, which was
significantly (p < 0.05) more hyperpolarized than the random controls. (e) Subset of random saline controls
for comparison (n = 11) showing little general trend towards depolarization or hyperpolarization during the
slot1 to slot 2 period. (f) A plot of the H-responders (N = 11) RMP in their actual values showing a trend
towards hyperpolarization. (g) The RMP of the nonresponders (N = 34) during the same period. (a,b,e,f,g)
Dots are values for interneurons and lines connect the same neurons before and after saline or the DAMGO
(c,d) Edges of box are 1st and 3rd quartiles for values, dots are the change in RMP for the individual
neurons, and whiskers extend to the largest and smallest values. Statistical testing performed with unpaired
t tests (one-tailed) after confirming their data had a normal distribution with a D’Agostino-Pearson
omnibus K2 test (p > 0.05).

During the recording process, we observed that only 3 of the H-responders were
firing spontaneously at rest and, not surprisingly, their rate of spontaneous APs decreased
after DAMGO. However, we observed that a sub-population of interneurons in which
DAMGO failed to produce an above cut-off level of hyperpolarization nevertheless
underwent reductions in spontaneous APs after DAMGO. We found that 50.0% (22 out
of 44) of neurons that fell below the H-responder cut-off level exhibited spontaneous AP
activity before DAMGO (Figure 17). Application of DAMGO resulted in a dramatic
reduction in the number of spontaneous APs in 45.5% (10 out of 22) of those neurons.
We define this group of spontaneous AP DAMGO-responders (S-responders) by using an
arbitrary cutoff of a 50% reduction in spontaneous APs after DAMGO (N = 10).
Spontaneous APs were measured during a noncontiguous period (cumulative of 60s) in
between current pulses.
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Figure 17. Spontaneous APs after DAMGO or saline. Out of the remaining pool of 44 (3 µM) DAMGOexposed neurons, 22 were spiking spontaneously. Out of the 21 saline controls, 11 were spiking
spontaneously. (a) Rate of spontaneous APs after 80s of vehicle saline show no general trend. (b) Rate of
spontaneous APs in the remaining (non-H-responder) DAMGO-exposed neurons, which appeared to show
some neurons had reductions in spontaneous APs, and others had not. (c) We therefore graphed the fold
change in spontaneous APs after DAMGO or vehicle saline. We established a 50% reduction (vertical
dotted line) in spontaneous APs as a somewhat arbitrary cutoff to distinguish nonresponders from Sresponders. (d) Rate of spontaneous APs in S-responders (N = 10) which had fell below the cutoff, and
therefore were classified as S-responders. (e) Rate of spontaneous APs in the remaining pool of
nonresponders (N = 12), which had not achieved that 50% cutoff. Figures (d) and (e) are therefore subsets
of (b).

Figure 17 depicts the fold change in number of spontaneous APs (slot 2/slot 1) in
the saline group (N = 11) and the DAMGO-exposed group (N = 22). Because a saline
control dropped spontaneous APs to zero, we could not use a “real datapoint” cutoff as
we did with the H-responders. We therefore established a 50% reduction (0.50; at the
vertical dotted line in Figure 17c) as a cutoff point for S-responders and nonresponders.
All DAMGO-exposed neurons to the left of that cutoff were considered to be “S132

responders” (N = 10). We did not analyze the effect of DAMGO on spontaneous APs
beyond counting them, because 8 out of 10 S-responders had simply stopped firing
spontaneous APs after DAMGO. Collectively, 21 out of 55 (38.2%) neurons fell into at
least one of the two responder categories. Hyperpolarizing responders had an average
RMP of -54.0 mV (range -50.1 to -62.9 mV). The H-responders had, on average,
hyperpolarized by -5.6 mV (range -3.5 to -8.6 mV) during the 80s period from slot 1
(saline) to slot 2 (DAMGO). Most H-responders were silent at rest, with only three firing
spontaneous APs. On average the S-responders fired around 2.8 APs/s before DAMGO
when unstimulated. This ranged from 0.17 APs/s to 12.1 APs/s. After DAMGO, 8 out of
10 S-responders simply stopped firing spontaneous APs, however 2 continued to fire
spontaneous APs at lower rates after DAMGO. A neuron that was firing spontaneous APs
at 12.1 APs/s reduced its spiking to 5.75 APs/s after DAMGO, whereas the remaining the
remaining neuron underwent a nearly four-fold reduction in spontaneous APs (Figure
17d).
To further explore whether the H and S-responder classes of DAMGO-responsive
cells represent distinct cell populations, we determined the pre-drug spiking pattern based
on the Petilla Interneuron Nomenclature Group’s suggested categorization scheme (The
Petilla Interneuron Nomenclature Group, 2008). Categorization of H and S-responders
was determined for based on their firing pattern during the 1s suprathreshold current
application (Figure 18). Although we characterized their spiking pattern around their
threshold Vm for the first AP, we observed that discharge patterns could change at higher
current applications. For instance, fastspiking neurons typically had low firing rates
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around threshold, but increased at more-depolarizing current steps, which has been
reported before (Golomb et al., 2007).

Figure 18. Representative Examples of Firing Patterns. We classified the spiking characteristics of
interneurons by observing the pattern of AP discharges that occurred around their V m threshold for an AP.
Note that there is some variability here in their threshold and RMP, which manifests as threshold V m
sometimes occurring at different episodes for each neuron. Firing patterns are arranged by row, and their
episodes by column. (Top row) Adapting neurons tended to fire more frequently at the beginning of the
current pulses and had steadily increasing interspike intervals through the current application. This pattern
stayed stable even at high current applications (E-15 and E-20). (Second Row) Irregular spiking neurons
fired irregular APs, or irregular bursts of APs, at suprathreshold current application. However, this firing
pattern often transitioned to more evenly spaced APs at higher current applications. (Third row) Fastspiking neurons tended to have more distance between their RMP and AP threshold. Most of their APs
were evenly spaced throughout the current application. At higher current applications (E-15 and E-20) this
firing pattern tended to fire more frequently, and correlate with the amplitude of the current injection.
(Fourth Row) Nonadapting, nonfastspiking neurons had evenly spaced spikes throughout the current
application. This firing pattern tended to have a stable discharge pattern regardless of the current
application; unlike the neurons we classified as fastspiking which tended to increase their AP frequency
when more-depolarizing currents were applied.

We found that S-responders and non-responders were roughly equivalent in their
distribution of firing patterns. H-responders, in contrast, were notable in having a
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relatively high frequency of Adapting neurons, a relatively low frequency of nonadapting neurons and a lack of fast-spiking neurons. Collectively, these data suggest that
the µOR effects might be heterogeneous and could vary between neuron populations.

Pattern

H-responders (N = 11)
Count (% of column)

S-responders (N = 10)
Count (% of column)

Nonresponders
(N = 34)
Count (% of
column)
8 (23.5%)
16 (47.1%)

Fastspiking
0 (0%)
2 (20%)
Nonadapting,
3 (27.2%)
6 (60%)
nonfastspiking
Adapting
6 (54.5%)
1 (10%)
4 (11.8%)
Irregular Spiking
2 (18.2%)
1 (10%)
6 (17.6%)
Table 5. Responder groups demonstrate different proportions of spike patterns. We used the PING
classification system to categorize each group (by hand) based on their spiking pattern in response to a 1s
depolarizing current at 2-3 steps above threshold, where the trace stabilizes, and multiple APs occur. While
the proportions of spiking patterns in each pool (in parentheses) are relatively similar, it appears that
adapting firing patterns are roughly 5 times as common in the H-responder group as S-responders and nonresponders. We did not find fastspiking neurons in the H-responder group, though they were found
sometimes in S-responders and nonresponders. The PING nomenclature also designates “Intrinsic Burst
Spiking” and “Accelerating” spike patterns; however, we did not observe these patterns in the sample (N =
55).

3.3.2 DAMGO effects on action potential activity and kinetics
Modulation of AP kinetics can affect neurotransmitter release by influencing the kinetics
and amplitude of calcium influx (Y.-M. Yang & Wang, 2006). Features of AP kinetics
are shaped by multiple types of ion channels (B Rudy et al., 2009). We therefore evoked
APs before and after DAMGO and αDTX to assess a potential role of µOR in regulating
αDTX-sensitive ion channels as a means of governing AP kinetics.
We analyzed 54 AP parameters, ratios, and membrane properties (Tables 7 and
9). Of those, seven have been reported to be affected by activation of µORs or αDTX in
other studies, though not necessarily both. Hyperpolarization was the first measure,
which is often found with DAMGO stimulation (Loose et al., 1990). Secondly, αDTX135

sensitive channels are shown to modulate Vm threshold for an AP (AP threshold)
(Bekkers & Delaney, 2001; Glazebrook et al., 2002; Kirchheim, Tinnes, Haas, Stegen, &
Wolfart, 2013; Pathak et al., 2016), though the µOR may not change it (Bekkers &
Delaney, 2001; Faber & Sah, 2004; Glazebrook et al., 2002; Kirchheim et al., 2013;
Pathak et al., 2016). Both the µOR and αDTX-sensitive channels also suppresses evoked
AP discharges, and so we investigated whether it decreases the number of evoked APs
and increases their temporal spacing (interspike interval; ISI) (Faber & Sah, 2004; Mo,
Adamson, & Davis, 2002). The AP halfwidth (duration) and the AP maximum
repolarization rate were also measured because there is some evidence to support their
modulation by αDTX-sensitive channels (W. Wang, Kim, Lv, Tempel, & Yamoah,
2013). Finally, since many voltage-sensitive K channels contribute to the
afterhyperpolarization (AHP), we measured the magnitude of afterhyperpolarizations as
well (W. Wang et al., 2013).
3.3.3 DAMGO alters AP waveform and pattern of evoked APs in H-responders
To reduce family-wise errors from running sets of 7 analyses simultaneously, we first
tested the combined 7 dependent variables (RMP, AP threshold, interspike interval,
number of evoked APs, AP halfwidth, maximum repolarization rate, and
afterhyperpolarization amplitude) in the H-responders (N = 11) versus the saline controls
(N = 21) for a significant Slot*Group interaction (see Table 4) in a mixed-model repeated
measures MANOVA. When the Slot*Group interaction was significant, we tested the
changes in the dependent variables individually.
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We found that the H-responders had statistically significant (F(7,20) = 19.32, p <
0.001, Wilks’ λ = 0.871) Slot*Group interaction in the 7 combined variables that we were
tested, which suggested a possible DAMGO effect in those parameters. We therefore
carried out specific analyses of RMP, AP threshold, number of evoked APs, interspike
interval, AP halfwidth, max repolarization rate, and afterhyperpolarization magnitude in
H-responders.
The αDTX-sensitive channels can modulate Vm threshold for an AP, however the
µOR does not necessarily change this property (Faber & Sah, 2004; Finnegan et al.,
2006). We analyzed their change in Vm threshold for the first AP (Figure 19a,b,c). We
found no significant difference (t(20) = 0.42, p = 0.338) in the change in AP threshold for
the H-responders (M = 0.99, SD = 0.07) versus the saline controls (𝑥̅ = 0.98, s = 0.07)
after DAMGO. This shows that neocortical µORs do not modulate AP threshold in the Hresponders.
We then investigated the patterns of AP discharges to determine whether how
DAMGO had influenced the number of evoked APs and their temporal spacing between
APs (Figure 19). These H-responders (N = 10, M = 1.35, SD = 0.36) had significantly
increased interspike intervals (t(18) = 3.01, p = 0.004) when compared to the saline-only
controls (n = 10, 𝑥̅ = 0.98, s = 0.12). The H-responders (N = 11, Mdn = 0.98) also had
significantly reduced numbers of evoked action potentials (U = 12, p < 0.001) after
application of DAMGO when compared to saline controls (n = 11, Mdn = 0.98). These
data show that DAMGO reduced the number of APs evoked by suprathreshold currents.

137

b

Vm Threshold for an AP
in H-responders

0

0

-20

-20

mV

-40

AP Threshold

DAMGO

ns

-40

Saline

-60

-60

c

1.
2

Post

1.
1

Pre

Post

1.
0

Pre

0.
9

-80

-80

0.
8

mV

Vm Threshold for an AP
in Saline Controls

0.
7

a

Fold Change From Initial
Higher Threshold

Number of Evoked APs
in Saline Controls

Number of Evoked APs
in H-responders

e

f

Evoked APs

30

Number of APs

20

10

***
10

Saline

Pre

Post

2.
0

Post

1.
5

0

Pre

1.
0

0

DAMGO

20

0.
5

Number of APs

30

0.
0

d

Fold Change From Initial

Mean Interspike Interval
in Saline Controls

h

Mean Interspike Interval
in H-responders

Mean ISI

0.20

Seconds (s)

0.15
0.10
0.05

DAMGO

**

0.10
Saline

0.05

Post

2.
5

Pre

2.
0

Post

1.
5

0.00

Pre

1.
0

0.00

0.15

0.
5

Seconds (s)

0.20

i

0.
0

g

Fold Change From Initial

Figure 19. Spike frequency altered in H-responders. We tested whether H-responders had discernible
changes after (3 µM) DAMGO AP threshold and frequency by comparing them to saline controls. (Left
column) The saline controls (N = 21) show little systematic changes in their (a) AP threshold, (d) number
of evoked APs, (g) and mean interspike interval during exposure to vehicle saline. (Middle column)
Meanwhile the H-responders (N = 11) show little change after (3 µM) DAMGO in (b) AP threshold,
however they generally show reduced numbers of (e) evoked APs, and (h) larger interspike intervals after
DAMGO. (Right column) To illustrate and test these changes more precisely, we measured the fold change
in those parameters against a random group of saline controls (n = 11). We found that (c) AP threshold
change was unaffected by the DAMGO compared to the change in saline controls, but we found
significantly decreased (p < 0.05) number of (f) evoked APs in H-responders after DAMGO and
significantly increased (i) mean interspike interval. One H-responder is excluded because it became singlespiking after DAMGO (Left and Middle columns) connecting lines bridge the same neuron after an 80s
period of vehicle or DAMGO incubation. Y axes are true values for those particular measures (Right
column) isolates the fold change (slot 2/slot1; postdrug/initial) after vehicle saline or DAMGO. Edges of
the boxes are drawn at the 1st and 3rd quartiles while the “whiskers” connect the largest and smallest values
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for that group. We performed statistical testing of ISI and AP threshold with unpaired t-tests (one-tailed)
after first testing for skewness and kurtosis with D’Agostino-Pearson omnibus K2 test (p > 0.05). Only
number of evoked APs was significantly different from a normal distribution (p < 0.05) and therefore tested
with a one-tailed Mann-Whitney U test.

We next analyzed the H-responder group to determine whether AP waveform was
being altered by DAMGO (Figure 20). Among hyperpolarizing DAMGO-responders, we
found several significant changes in action potential waveforms against the saline-only
controls; we found significant reductions in AP halfwidth (U = 11, p < 0.001) in the
DAMGO H-responders (Mdn = 0.91) versus the saline controls, which trended slightly
towards widening APs over that time period (Mdn = 1.05). The 11 DAMGO Hresponders had increased their maximum repolarization rates (M = 1.29, SD = 0.44)
significantly (t(20) = 2.91, p = 0.004) compared to the saline controls (𝑥̅ = 0.89, s = 0.11)
which trended towards slower repolarizations by slot 2. These results show that DAMGO
was hastening the maximum rates of AP repolarization, and shortening the duration of the
APs. Lastly, we compared the magnitude of afterhyperpolarizations (AHPs) in the saline
controls (𝑥̅ = 0.94, s = 0.07) versus the H-responders (M = 1.10, SD = 0.30) and found
that DAMGO had significantly increased (t(20) = 1.78, p = 0.045) the AHPs in the H-
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Figure 20. AP kinetics are altered in H-responders. We analyzed AP kinetics and afterhyperpolarization
(AHP) amplitude before and after DAMGO or vehicle saline to determine whether DAMGO altered these
properties. (Left column) Saline controls (N = 21) before and after an 80s period of exposure to the vehicle
saline. In the saline group, there was little trends in (a) AP halfwidth, and (d) maximum repolarization rates
(Middle column) DAMGO-exposed H-responders (N = 11) generally show reduced (b) halfwidths and (e)
larger maximum repolarization rates after DAMGO, but (h) AHP amplitudes are generally stable. (Right
column) To isolate and statistically test the change after DAMGO, we plotted the fold change after
DAMGO or vehicle saline. We found that DAMGO exposure in H-responders resulted in significantly
reduced (c) halfwidths compared to random saline controls (n = 11). This corresponded with significantly
increased (f) maximum AP repolarization rates. We also found significantly larger (i) AHP amplitudes in
H-responders relative to controls. (Left and Middle columns) connecting lines bridge the same neuron after
an 80s period of vehicle or DAMGO incubation. Right column isolates the fold change (slot 2/slot1;
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postdrug/initial) after vehicle saline or DAMGO. Edges of the boxes are drawn at the 1 st and 3rd quartiles
while the “whiskers” connect the largest and smallest values for that group. We performed statistical testing
for maximum repolarization rate and AHP amplitude with unpaired t-tests (one-tailed) after testing for
skewness and kurtosis with D’Agostino-Pearson omnibus K2 test. AP halfwidth change (for saline group)
was nonnormally distributed (p < 0.05) and therefore tested with Mann-Whitney U tests.

PARAMETER

Mean Difference
(DAMGOSaline)

P value

95% Confidence Interval for
Difference

Lower
Upper
RMP
0.12
<0.001
0.09
0.16
AP Halfwidth
-0.21
< 0.001
-0.32
-0.10
AP Max Repolarization
0.40
0.004
0.11
0.68
Rate
Interspike Interval
0.37
0.004
0.11
0.62
Number of Evoked APs
-0.35
< 0.001
-0.56
0.14
AP Threshold
0.01
0.338
-0.05
0.08
Afterhyperpolarization
0.16
0.045
-0.03
0.35
Amplitude
Table 6. Summary of DAMGO effects in H-responders. We compiled a statistical summary and effect sizes
for H-responders in all 7 measures that we were primarily investigating. The change in each property was
derived by dividing post-DAMGO/pre-DAMGO values (i.e., slot 2/slot 1) to calculate the fold change.
Here, these fold changes in the saline group (expected to represent the change due to time) was subtracted
from the fold change in the DAMGO group to derive the effect of DAMGO. Each mean difference is a
proportion of one (e.g., a mean difference of -0.21 is a reduction of 21% in the DAMGO condition over the
saline control). Comparisons of the change in saline and DAMGO group were tested first for normality
with the D’Agostino-Pearson omnibus K2 test. Normally distributed data were tested for significance (α =
0.05) with one-tailed unpaired t-tests and nonnormally-distributed data were tested with one-tailed MannWhitney U tests.

We classified the H-responders by spiking pattern after DAMGO to determine if
µORs could change the pattern of discharges, since there were changes in evoked AP
number and ISI in these neurons (Table 7). Although most H-responders had a stable
spiking pattern after DAMGO, we did notice a few changes. Three H-responders had
shifted spiking categories, however the majority (8 out of the 11) H-responders had
remained in the same spiking pattern after DAMGO. In 2 out of 3 cases where the Hresponder shifted pattern, the neurons transitioned into an Adapting patten, which was
consistently the prevailing spiking pattern in H-responders.
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Pre-DAMGO Pattern
Post-DAMGO Pattern
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Adapting
Irregular Spiking
Irregular Spiking
Irregular Spiking
Irregular Spiking
Adapting
Non-adapting, Non-fastspiking
Non-adapting, Non-fastspiking
Non-adapting, Non-fastspiking
Non-adapting, Non-fastspiking
Non-adapting, Non-fastspiking Adapting
Table 7. Few H-responders shift spiking patterns after DAMGO. We identified the spiking patterns of Hresponders based on PING categories before and after DAMGO. Neurons are ordered by row arbitrarily.
Boldtype rows are neurons that change firing type. The majority of the neurons remained the same spiking
patterns, though 3 had changed after DAMGO.

3.3.4 αDTX counteracts µOR-agonism in H-responders
Having found that DAMGO was altering AP waveform and pattern of discharge,
particularly in hyperpolarizing DAMGO responders, we investigated whether αDTXsensitive channels were involved in this effect; µOR elsewhere in the brain has
previously been found to modulate an α-Dendrotoxin-sensitive channels (Faber & Sah,
2004; Finnegan et al., 2006). We therefore exposed the neurons to a combination of
DAMGO + αDTX (3 µM and 100 nM, respectively) after their prior exposure to (3 µM)
DAMGO to determine if the addition of αDTX could reverse the effects. We once again
compared this drug group against saline-only recordings to account for stochastic effects
and the effects of repeated stimulation, and thereby detect the true impact of αDTX in a
background of DAMGO. For the following comparisons we also isolated the change by
dividing the post αDTX+DAMGO/pre αDTX-DAMGO; slot 3/slot 2. In this case, the
post-DAMGO (slot 2) measurements that had been used as the “after-DAMGO”
recording were used here as the “pre-αDTX+DAMGO” recording (see Figure 15).
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We tested for a significant Slot*Group interaction in the H-responders versus the
controls in timeslots 2 to 3 (DAMGO → αDTX+DAMGO). This interaction was
significant indicating a potential αDTX effect on the 7 variables (F(7,19)= 2.57, p =
0.048, Wilks’ λ = 0.486). We therefore conducted further analysis on each measure. We
had previously found significant DAMGO effects in all the measures for H-responders,
except for AP threshold and afterhyperpolarization amplitude (see Table 6), but we
expected that αDTX’s effects may not be as extensive as DAMGO’s effect, since this
channel may only mediate some of the µOR’s inhibitory mechanisms.
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Figure 21. αDTX reverses DAMGO effects on ISI and AP number. We tested for αDTX effects in the Hresponders by applying αDTX in a background of DAMGO and examined these parameters for changes
that were in opposite polarity as DAMGO. These change ratios were calculated by dividing
postDTX/preDTX (i.e., slot 3/slot 2). Thus, αDTX in a background of DAMGO. (Left column) Real values
for saline controls during this period which show stochastic changes in each measure. (Middle column)
Real values for H-responders before and after exposure to αDTX. (Right column) isolates the fold change
in a subset (n = 11) of saline controls and the (N = 11) H-responders from their pre-DTX condition.
Statistical testing was performed by comparing the changes in saline controls (n = 11) with the changes in
H-responders (N = 11) after αDTX. We found no significant effects of αDTX on (a) RMP, (e,f) AP kinetics
(halfwidth and max repolarization rate). However, we did find significant effects of αDTX on H-responders
in a background of DAMGO in (d) interspike interval (c) number of evoked APs, as well as (g)
afterhyperpolarization amplitude. We also found that αDTX lowered (b) AP threshold, which had not been
modulated by DAMGO. One neuron was excluded from graph (c), but not statistical comparison, due to a
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14-fold increase in evoked APs. Edges of the boxes are drawn at the 1st and 3rd quartiles while the
“whiskers” connect the largest and smallest values for that group. We performed statistical testing with
unpaired t-tests (one-tailed) after testing for skewness and kurtosis with D’Agostino-Pearson omnibus K2
test (p > 0.05).

We found no significant effect (t(20) = 0.33, p = 0.374) of αDTX on the RMP of
H-responders (M = 0.98, SD = 0.03) when compared to saline-controls (𝑥̅ = 0.98, SD =
0.04). This indicates that although DAMGO had hyperpolarized these neurons, αDTXsensitive channels were not responsible for this effect. However, we did find a significant
(U = 32, p = 0.033) effect of αDTX on the AP Vm threshold of H-responders (Mdn =
1.04) when compared to the saline controls (Mdn = 1.00). This was a particularly
interesting finding because DAMGO did not modulate AP threshold (Figure 19 and Table
6).
Additionally, αDTX significantly reduced ISI (t(20) = 2.70, p = 0.007) in Hresponders (M = 0.86, SD = 0.13)) versus the saline controls (𝑥̅ = 0.97, s = 0.04)).
Similarly, αDTX significantly increased (U = 22, p = 0.005) the number of APs in the Hresponders (Mdn = 1.22) versus the saline controls (Mdn = 1.00). Therefore, αDTX has
an opposite effect to DAMGO, which raises ISI and decreases evoked APs in these Hresponders. This suggests that αDTX-sensitive currents do indeed mediate some of the
DAMGO effect on suppressing the initiation of APs at suprathreshold depolarizations. In
a later analysis, we analyzed whether αDTX fully or partially reverted these properties on
a cell-by-cell basis (Figure 22).
We next investigated whether αDTX reversed the DAMGO effects on AP kinetics
through halfwidth and maximum rates of repolarization of an AP. αDendrotoxin failed to
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reverse (U = 48, p = 0.219) DAMGO effects in AP halfwidth in the H-responders (Mdn =
1.01) versus the saline controls (Mdn = 1.06). Similarly, we found that αDTX did not
significantly (U = 57, p = 0.423) alter the maximum rate of AP repolarization (Mdn =
0.91) when the H-responders were compared to the saline controls (Mdn = 0.96). Thus, it
appeared that the changes in AP waveform induced by DAMGO are mediated by
channels other than the αDTX-sensitive channels.
Finally, we investigated whether αDTX altered AHPs. We found that αDTX
produced a significant reduction (U = 29, p = 0.020) in AHP amplitude when Hresponders (Mdn = 0.84) were compared to the saline controls (Mdn = 0.98). Therefore,
DAMGO increased AHP amplitude, while αDTX reduced it.
PARAMETER

Mean Difference
Δ(αDTX+DAMGO)Δ(Saline)
-0.01
0.03
0.00

P value

95% Confidence Interval for
Difference
Lower
Upper
-0.04
0.03
-0.13
0.19
-0.17
0.17

RMP
0.374
AP Halfwidth
0.219
AP Max Repolarization
0.423
Rate
Interspike Interval
-0.11
0.007
-0.20
-0.03
Number of Evoked
1.51
0.011
-0.91
3.92
APs
AP Threshold
0.07
0.033
0.00
0.15
AHP Magnitude
-0.14
0.020
-0.27
0.00
Table 8. αDTX-sensitive channels reverse some DAMGO effects. Mean values in this summary were
derived by subtracting the mean fold change in the saline group from the mean fold change in the DAMGO
group. The fold changes for each of the groups were compared with unpaired t tests (one-tailed) for
significance or Mann-Whitney U-tests.

3.3.5 αDTX and magnitude of reversal
In H-responders, αDTX affected ISI, number of evoked APs, AHP amplitude, and AP
threshold (However DAMGO had not changed AP threshold). We next wanted to
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determine whether αDTX was fully reversing the effects of DAMGO in these parameters,
or only partially reversing them.
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Figure 22. αDTX partially reverses some effects of DAMGO in H-responders. To illustrate the fold
changes in all 7 parameters across the 3 timepoints, we baselined value for these measures in the (N = 11)
H-responders by their initial value; therefore, all neurons emanate from “1.00” which marks their original
values. The dotted line at 1.00 represents baselined starting value for all neurons. These graphs show the
fold changes over the course of their treatment with DAMGO, and then αDTX+DAMGO. (a) Change in
RMP, which was the basis of selection for (N = 11) H-responders, and not significantly reversed by αDTX.
(b) Change in AP threshold, which was not significantly altered by DAMGO, shifted towards
hyperpolarized Vm after αDTX. (c) Evoked APs in H-responders and (b) ISI changes in H-responders (n =
10; one neuron was not included because it became single-spiking after DAMGO). Changes in (c,d) had
before been found to be affected by both DAMGO and αDTX in H-responders. (e) Maximum
repolarization rate and (f) AP halfwidth, which were both significantly changed by DAMGO, but not
αDTX. (g) Afterhyperpolarizations were significantly enhanced by DAMGO and reduced by subsequent
addition of αDTX. Lines on all graphs connect the same neuron’s values across all 3 timepoints. Statistical
comparisons were made by comparing fold change in H-responders to fold changes in saline controls.
Changes were compared for significance with unpaired t-tests or Mann-Whitney U tests.

To visualize this variability effects of αDTX in a background of DAMGO, we
baselined each of the H-responders to their initial starting point and graphed all 7 changes
over the course of slots 1-3 (Figure 22). These analyses provided insight into the
direction of the αDTX effect, while also charting each neuron’s course individually.
From these graphs it is evident that not only did the effect of DAMGO and αDTX varies
between the interneurons, which can be expected of a heterogenous population of
neocortical interneurons.
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Figure 23. Example of αDTX reversal of DAMGO. A trace representing αDTX reversing effects of
DAMGO in AP number and interspike interval. Respectively, each row represents the initial, postDAMGO, post-αDTX+DAMGO timeslots. Each column represents one of the 20 sequential episodes as the
current applications progressively become more depolarizing. For example, E4 is the 4 th episode of
stimulation, which generally was around AP threshold, while E20 is the final and most-depolarizing of the
20 episodes of the stimulation. The blue horizontal bars below the APs represent the period of 1 second
where the depolarizing current was being applied. (Top Row) This neuron began firing APs in the early,
less-depolarizing current applications. Application of DAMGO (Middle Row) resulted in the neuron firing
APs only at later episodes. (Bottom Row) After addition of αDTX, the neuron once again began firing at
earlier episodes and more frequently than it had after exposure to only DAMGO. A slight RMP
hyperpolarization after DAMGO is evident here, which was not reversed by αDTX.

3.3.6 DAMGO alters RMP and AP waveform in S-responders
We began testing for DAMGO effects in S-responders by testing the 7 combined
variables in a mixed-model repeated measures MANOVA for a significant Slot*Group
interaction. We found a significant effect of DAMGO in S-responders (F(7,20) = 2.57, p
= 0.046, Wilk’s λ = 0.473) and we therefore investigated them further.

151

a

RMP
in S-Responders

b

RMP in S-Responders

-40

mV

-45

DAMGO

*

-50

Saline

-55

1.
10

1.
05

1.
00

Post

0.
95

Pre

0.
90

-60

Fold Change From Initial
Hyperpolarized

Figure 24. S-responders also hyperpolarize. We compared the fold change in RMP in the (N = 10) Sresponders versus random saline to determine if hyperpolarization is found in this group as well. (a) Real
values of resting membrane potential in S-responders before and after (3 µM) DAMGO. (b) Fold changes
in resting membrane potential in S-responders versus random saline controls (n = 10). We found that the Sresponders too underwent a significant hyperpolarization after exposure to DAMGO (p < 0.05) compared
to the polarization change in saline controls during the same period. Edges of the boxes are drawn at the 1 st
and 3rd quartiles while the “whiskers” connect the largest and smallest values for that group. We performed
statistical testing by confirming distribution was non-significantly different from a normal distribution with
the D’Agostino-Pearson omnibus K2 test, and then an unpaired t-test against the fold change of the saline
controls.

We first compared their change in RMP (M = 1.02, SD = 0.04) against saline
controls (𝑥̅ = 0.99, s = 0.02). Apparently, although this group fell short of the threshold
for the H-responder group compared to the saline group (Figure 16) the S-responders too
had undergone a significant hyperpolarization (t(18) = 2.53, p = 0.011) compared to the
saline controls. Although these S-responders underwent statistically significant
hyperpolarization after DAMGO, we classify them as S-responders because they were
not selected by that particular criterion, as the H-responders had been.
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Figure 25. S-responders have changes in AP waveform. We compared the change in each parameter in a
sample (n = 10) saline group versus the (N = 10) S-responders. Boxes are drawn around each set of real
values for each measure (bottom of each box), and the fold change (top of each box). We found that these
S-responders had significant reductions after DAMGO in (d) halfwidths and significant increases in (e)
maximum rates of repolarization compared to saline controls (p < 0.05). However, we did not find
significant differences in the changes in (a) AP threshold, (b) number of evoked APs, (c) mean interspike
interval, or (f) afterhyperpolarization magnitude (p > 0.05). Edges are drawn at the 1 st and 3rd quartiles
while the “whiskers” connect the largest and smallest values for that group. Prior to statistical testing we
tested for normality with D’Agostino-Pearson omnibus K2 test (p > 0.05). In most instances, we performed
statistical testing with unpaired t-tests (one-tailed). However, number of evoked APs and maximum
repolarization rates were nonnormally distributed (p < 0.05) and we therefore tested those with MannWhitney U tests (one-tailed).
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We tested their fold change in AP threshold to find a nonsignificant effect of
DAMGO (t(18) = 1.11, p = 0.141) when S-responders (M = 0.96, SD = 0.08) versus the
saline controls (𝑥̅ = 0.96, s = 0.07); there was no effect of DAMGO on Vm threshold for
an AP in the S or H-responders.
We did not find a significant difference in their changes in interspike interval
(t(18) = 1.42, p = 0.086) of these S-responders (M = 1.09, SD = 0.12) relative to the
saline controls (𝑥̅ = 1.00, s = 0.14). Nor did we find a significant (U = 30, p = 0.072)
decrease in number of evoked action potentials (Mdn = 0.90) relative to the saline-only
controls (Mdn = 1.01). Interestingly, we found effects in these 2 properties in the Hresponder group but apparently these effects are absent in the S-responder category;
although these neurons were selected for on the basis of their decreased spontaneous APs,
it appears that somatically-evoked APs were not similarly decreased or reduced in
frequency.
We next analyzed the AP kinetics of the S-responders to determine whether they
too had altered AP shapes after DAMGO as the H-responders did. We found that the Sresponders had significantly (t(18) = 2.42, p = 0.013) reduced their AP halfwidths (M =
0.95, SD = 0.13) after DAMGO compared to saline controls (𝑥̅ =1.07, s = 0.10). These Sresponders (Mdn = 1.07) also had a significant increase (U = 19, p = 0.009) in their
maximum rate of repolarization when compared with saline controls (Mdn = 0.87).
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Finally, we analyzed the fold change in afterhyperpolarizations in S-responders
(M = 1.07, SD = 0.24) versus changes in the saline control (𝑥̅ = 1.00, s = 0.09). However,
there were no significant differences in the changes of their AHP amplitude (t(18) = 1.72,
p = 0.051).
PARAMETER

Mean Difference
(DAMGO-Saline)

P value

95% Confidence Interval for
Difference
Lower
Upper
0.00
0.06
-0.23
-0.02
0.02
0.49

RMP
0.03
0.003
AP Halfwidth
-0.12
0.013
AP Max Repolarization
0.25
0.009
Rate
Interspike Interval
0.08
0.086
-0.04
0.21
Number of Evoked APs
-0.03
0.072
-0.03
0.07
AP Threshold
0.04
0.141
-0.03
0.10
Afterhyperpolarization
0.23
0.051
-0.05
0.52
Amplitude
Table 9. DAMGO Effect in S-responders. A statistical summary and estimates of effect sizes for the
spontaneous-AP responders (S-responders). The change in each property was derived by dividing the postDAMGO/pre-DAMGO values (i.e., slot 2/slot 1) to calculate the proportion of the change. For instance, a
change of 0.28 in AP maximum repolarization rate is an average increase of 28% in the DAMGO Sresponders. Comparisons of the change in saline and DAMGO group were performed by unpaired t-tests
(one tailed). Values for saline were subtracted from DAMGO values to calculate the true effect of the drug
(and subtract the effect of time). Prior to statistical testing, we tested for normality with D’AgostinoPearson omnibus K2 test. In most instances, we performed statistical testing with unpaired t-tests (onetailed) (p > 0.05). However, number of evoked APs and maximum repolarization rates were nonnormally
distributed (p < 0.05) and we therefore tested those with Mann-Whitney U tests (one-tailed) instead.

To summarize, spontaneous AP responders had relatively small
hyperpolarizations, and changes in AP kinetics compared to H-responders (Table 10). Sresponders lacked the DAMGO-induced ISI increase and reduced evoked AP number,
which were observed in H-responders (Table 6). Thus, it appears that DAMGO
influenced their RMP, spontaneous APs frequency, and AP repolarization kinetics, but it
did not change the somatically-evoked AP frequency, as DAMGO had done in the Hresponders. The effects of DAMGO in S-responders appeared to be smaller in magnitude
and in the range of affected parameters (Table 10).
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PARAMETER

Mean Difference H-responder
(DAMGO-Saline)

Mean Difference Sresponder (DAMGOSaline)
RMP
0.12
0.03
AP Halfwidth
-0.21
-0.12
AP Max Repolarization Rate
0.40
0.25
Interspike Interval
0.37
Number of Evoked APs
-0.35
AP Threshold
Afterhyperpolarization Amplitude
0.16
Table 10. Summary of effects for H-responders vs S-responders. To provide a side-by-side comparison of
H and S-responders and compare their response to DAMGO, we complied data from H-responders (Table
5) and data from S-responders (Table 6) and re-display them in this table. Numerical values reflect the
mean fold change in that particular responder group (see top row) for each parameter (left column). Mean
differences were derived by subtracting fold change in the saline group from the DAMGO responder group
to isolate the effect of DAMGO from the effect of time. For example, a value of 0.40 for H-responder AP
max repolarization rate reflects a 40% increase for maximum rate of AP repolarization in H-responders
compared to the control, which trended larger than the mean 28% change in the S-responders. Only
significant (p < 0.05) values are shown in the table; cells are intentionally left blank when effects were
nonsignificant (Unpaired t-test or Mann-Whitney U test, as described in Tables 3 and 6). We found that the
H-responders had a wider range of detected effects to DAMGO, as well as having larger effect sizes.

3.3.7 αDTX effects absent in S-responders
We also investigated whether there were αDTX effects in the S-responders, although we
did not expect a αDTX effect here since data from the H-responder suggested that the
effects of αDTX were restricted to AP threshold, ISI and number of evoked APs, none of
which were affected by DAMGO in the S-responders. We found a non-significant
Slot*Group interaction (F(7,19) = 0.81, p = 0.592, Wilks’ λ = 0.229) in this group for the
combined variables, indicating that there was not an effect of αDTX in the S-responders.
We also wanted to determine whether αDTX was reversing the measurement that
was used to initially identify the S-responders, their spontaneous APs. However, the
number of spontaneous APs was not significantly changed when αDTX was applied in a
background of DAMGO (U = 32, p = 0.069). Indeed, after DAMGO exposure, only 3 out
of 10 S-responders were firing spontaneously, and only 1 out of 7 had resumed firing
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spontaneous APs after αDTX. Thus, it appears that DAMGO-induced downregulation of
spontaneous APs was not detectably related to αDTX-sensitive channels.
3.3.8 Investigating the influence of RMP polarization
The identification of H-responders to DAMGO involved the selection of neurons with the
largest hyperpolarization in during those 80s of DAMGO incubation. Under that
procedure, it was possible that any subsequent differences we observed was simply a
consequence of that difference in polarity change between the sampling periods. To
investigate the confound of polarization, we selected the neurons that had hyperpolarized
the most in the saline control, and we also selected a comparison group of neurons that
had depolarized the most in the DAMGO group. Although we expected that this
depolarizing change was merely due to chance (and not a DAMGO effect) it enabled us
to “flip the sign” so that the saline-control neurons were relatively more hyperpolarized
than the DAMGO-exposed neurons. If all of these changes were actually a result of
hyperpolarization, the most-hyperpolarizing saline neurons should actually undergo
analogous changes as the H-responders. If they fail to do this, significant effects in AP
parameters are more likely to be caused by differential ion channel regulation by µORs,
rather than a polarizing shift in the Vm without ion channel regulation by µORs.
We found a significant Slot*Group interaction (F(7,12) = 2.57, p = 0.048, Wilks’
λ = 0.633) in these groups for the combined dependent variables, which included the
RMP change that they had been selected on. We therefore investigated them further for
changes in other parameters.
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Figure 26. Polarity shift does not account for other changes. In these analyses, we compared neurons that
depolarized in the (n = 11) DAMGO condition and neurons that hyperpolarized in the (n = 11) saline
control. These changes were expected to be due to stochastic fluctuations in their RMP during this period,
and we therefore expected null results. We selected these neurons based on their changes in (a) RMP
which, predictably, had significantly depolarized in the DAMGO condition relative to the change in saline
controls (p < 0.05). However, none of the other changes we tested were significantly different from controls
(p > 0.05); we did not find significant differences in their changes of (b) AP threshold, (c) number of
evoked APs, (d) interspike interval, (e) maximum repolarization rates, (f) AP halfwidth, nor (g) magnitude
of their hyperpolarization when the groups were compared to controls in the same manner as the H and Sresponders were. Comparisons of the DAMGO-depolarizers versus saline-hyperpolarizers were made with
unpaired t-tests (one-tailed) and summarized on Table 11. Edges of the boxes are drawn at the 1st and 3rd
quartiles while the “whiskers” connect the largest and smallest values for that group. We performed
statistical testing with unpaired t-tests (one-tailed) after testing for skewness and kurtosis with D’AgostinoPearson omnibus K2 test (p > 0.05). Only halfwidth and maximum repolarization rates were significantly
different (p < 0.05) from a normal distribution, and therefore tested with Mann-Whitney U tests.
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PARAMETER

Mean Difference
(DAMGO-Saline)

P value

95% Confidence
Interval for Difference
Lower
Upper
-0.07
0.03
-0.08
0.09
-0.15
0.08

RMP
-0.05
<0.001
AP Halfwidth
-0.02
0.405
AP Max Repolarization
-0.04
0.245
Rate
Interspike Interval
-0.04
0.135
-0.04
0.05
Number of Evoked APs
0.11
0.154
-0.11
0.32
AP Threshold
-0.03
0.104
-0.08
0.02
AHP Amplitude
-0.01
0.219
-0.12
0.09
Table 11. Comparisons for the effect of polarity shift. Neurons that depolarized in the DAMGO condition
were compared against the most hyperpolarizing neurons in the saline condition. This table compares the
mean changes in each measure for these groups. Statistical testing revealed no significant changes in any
parameter we compared, other than the RMP which was the basis for their selection to these groups.
Change in RMP was significantly different from the controls (t(20) = 4.61, p < 0.001), however changes in
AP halfwidth (t(20) = 0.24, p = 0.405), max repolarization rate (t(20) =0.25, p = 0.245), interspike interval
(U = 43, p = 0.135), number of evoked APs (t(20) = 1.05, p = 0.154), AP threshold (t(20) = 0.70, p =
0.245), and AHP (U = 48, p = 0.219) were nonsignificantly (p < 0.05) different from each other. Prior to
statistical comparisons, distributions were tested with D’Agostino-Pearson omnibus K2 test. Normallydistributed data (p > 0.05) were tested with unpaired t-tests (one-tailed) while nonnormally-distributed data
were tested with Mann-Whitney U tests (one-tailed).

Other than the change in RMP that they had been selected on, we did not find
significant changes in any of the 6 other parameters. These analyses suggest that
parameters following RMP were not being influenced by the change in the magnitude of
their polarity that served as the maker for H-responders, but instead were a result of
differential ion channel regulation that occurs during a DAMGO-response.
3.3.9 Investigating false negatives
We next wanted to determine whether there were DAMGO-induced changes in the
nonresponder group, which would have suggested that these groupings were too
exclusionary. This could contribute false negatives, i.e., true responders that were
excluded from the responder groups and passed unanalyzed into the pool of
“nonresponders.” Out of the 55 neurons that we recorded and exposed to DAMGO, there
remained 34 recordings that were excluded from the S&H-responder categories. We
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wanted to investigate this nonresponder pool for the same changes in AP parameters that
we sought in the S&H-responder categories. We decided to begin to address this issue by
seeking changes in the nonresponders for the 7 measures we have been testing for.
We individually graphed the change in polarity (x axis) versus all 7 measures
tested (y axis). If neurons had undergone changes in those measures without
hyperpolarization, they can be visually identified by appearing vertically displaced, but
horizontally close to the graph’s origin (Figure 26).
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Figure 27. Responder categories captured most large changes. To determine whether the changes we were
attempting to detect had successfully been predicted by the S and H responder groups, we compared
polarization (x ais) with the changes in AP parameters we were measuring (y axis).Vertical displacement
on the y axis therefore indicates that the neuron had large changes in the measure being compared and can
be compared with its polarization (horizontal displacement). Left column only includes the H-responders
(blue squares), while the right column expands the responder category to both S&H-responders (blue
squares). Saline-controls (black) are included in these images to illustrate the pattern of stochastic or
entropic changes that should be considered in interpretations of these graphs. (a,b) AP Threshold versus
polarization. We previously found no DAMGO effect in this measure, and the distribution shows scattering
around the origin. (c,d) Number of evoked APs show a downward and right skew, as we expected the
DAMGO responders were firing fewer evoked APs. (e,f) Interspike interval showed and upwards and right
skew in the responders, as we expected, since a DAMGO response should reduce spike frequency (and
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increase temporal spacing). (g,h) AP halfwidth showed a downwards and right skew, particularly in
DAMGO responders. (i,j) AP maximum repolarization rates show and upwards and right skew in the
DAMGO responders. (k,l) Afterhyperpolarization amplitude versus polarization shows an upward spread of
S and H-responders.

This comparison revealed that these 2 categories of responders had captured most
of the large changes in those parameters, and yet there seemed to be a small cluster of
“nonresponders” that seemingly had hyperpolarized and underwent very small reductions
in halfwidth and small increases in AP repolarization rates. For instance, the salinecontrols never fall in the hyperpolarized and quickly-repolarizing top-right quadrant
(Figure 26j) and yet 7 nonresponders do. Therefore, examining for hyperpolarization
seemed to predict the larger changes in these measures, but it left open the possibility that
weaker responders were being misclassified as DAMGO-nonresponders.
To investigate false negatives that were overlooked, we tested for a significant
Slot*Group interaction in the nonresponders with a mixed model repeated measures
MANOVA (N = 34) versus the saline controls (N = 21). However, the result for the
combined variables was nonsignificant (F(7,44)= 1.17, p = 0.342, Wilks’ λ = 0.156)
despite the higher sample size when compared to S and H-responders. While it’s possible
that some responders with weak effects (Figure 26) may have been misclassified as
nonresponders, the neurons with the largest changes in measures that we were testing for
seem to have been identified as H or S-responders and thus were previously analyzed
here.
3.3.10 Post-hoc analyses on DAMGO, αDTX and AP kinetics
Finally, we conducted a post-hoc analysis of 47 other parameters and ratios that have not
been previously addressed here. This included individually analyzing sequential APs to
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determine if the drugs had effects only one specific APs in their spike train, as well as
examining ratios for changes between sequential APs. For these post-hoc analyses, we
only considered H-responders for the DAMGO and αDTX effects, because only the Hresponders had systematic responses to αDTX and had stronger responses to DAMGO
(Table 10).
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Membrane and
Vm Threshold
Parameters

First AP
Parameters

Second AP
Parameters

PARAMETER

DAMGO
p value

DAMGO
Full MANOVA
Results

αDTX
p
value

Input Resistance

0.064

F(1,28) = 3.71,
ηp2 = 0.117

0.512

AP Number at Threshold

0.321

F(1,28) = 1.02,
ηp2 = 0.035

0.581

AP Halfwidth at
Threshold

<0.001

0.536

Maximum Depolarization
Rate

<0.001

Average Depolarization
Rate

0.001

Time to Max
Depolarization Rate

0.001

Time to peak

0.003

Peak Amplitude

0.084

F(1,28) =
23.13, ηp2 =
0.452
F(1,30) =
22.47, ηp2 =
0.428
F(1,30) =
13.33, ηp2 =
0.308
F(1,30) =
12.32, ηp2 =
0.291
F(1,30) =
10.60, ηp2 =
0.251
F(1,30) = 3.19,
ηp2 = 0.096

Maximum Repolarization
Rate

0.001

0.917

Average Repolarization
Rate

0.001

Time to max
Repolarization Rate

0.014

F(1,30) =
14.32, ηp2 =
0.323
F(1,30) =
13.65, ηp2 =
0.313
F(1,30) = 6.75,
ηp2 = 0.184

AP1 Halfwidth

<0.001

0.341

AP1 90% Width

<0.001

Afterhyperpolarization
Amplitude

0.042

F(1,30) =
21.79, ηp2 =
0.421
F(1,30) =
21.79, ηp2 =
0.421
F(1,30) = 4.53,
ηp2 = 0.131

Maximum Depolarization
Rate

0.001

0.462

Average Depolarization
Rate

0.001

Time to Max
Depolarization Rate

0.001

F(1,29) =
14.02, ηp2 =
0.326
F(1,29) =
15.56, ηp2 =
0.334
F(1,29) =
13.80, ηp2 =
0.322
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0.917

0.472

0.612

0.785

0.172

0.716

0.949

0.949

0.043

0.501

0.749

αDTX
Full
MANOVA
Results
F(1,27) =
0.44, ηp2 =
0.016
F(1,27) =
0.31, ηp2 =
0.011
F(1,27) =
0.39, ηp2 =
0.014
F(1,29) =
0.78, ηp2 =
0.011
F(1,27) =
0.53, ηp2 =
0.018
F(1,27) =
0.26, ηp2 =
0.009
F(1,27) =
0.08, ηp2 =
0.003
F(1,27) =
1.96, ηp2 =
0.063
F(1,27) =
0.01, ηp2 <
0.001
F(1,27) =
0.14, ηp2 =
0.005
F(1,27) <
0.01, ηp2 <
0.001
F(1,27) =
0.94, ηp2 =
0.031
F(1,27) <
0.01, ηp2 <
0.001
F(1,27) =
4.48, ηp2 =
0.134
F(1,28) =
0.56, ηp2 =
0.019
F(1,28) =
0.47, ηp2 =
0.016
F(1,28) =
0.11, ηp2 =
0.004

Average of
AP3+

Interspike
Properties

Time to peak

0.961

F(1,29) < 0.01,
ηp2= 0.000

0.265

Peak Amplitude

0.028

F(1,29) = 5.34,
ηp2= 0.156

0.110

Maximum Repolarization
Rate

<0.001

0.970

Average Repolarization
Rate

<0.001

Time to max
Repolarization Rate

<0.001

AP2 Halfwidth

<0.001

AP2 90% Width

0.229

F(1,29) =
16.45, ηp2 =
0.362
F(1,29) =
15.42, ηp2 =
0.347
F(1,29) =
17.35, ηp2 =
0.374
F(1,29) =
18.04, ηp2 =
0.384
F(1,29) = 1.51,
ηp2 = 0.049

Afterhyperpolarization

0.001

0.059

Maximum Depolarization
Rate

0.001

Average Depolarization
Rate

0.001

Time to Max
Depolarization Rate

<0.001

Time to peak

0.332

Peak Amplitude

0.023

F(1,29) =
13.42, ηp2 =
0.316
F(1,29) =
14.11, ηp2 =
0.327
F(1,29) =
15.08, ηp2 =
0.342
F(1,29) =
27.15, ηp2 =
0.484
F(1,29) =
16.21, ηp2 =
0.033
F(1,29) = 5.76,
ηp2 = 0.166

Average Repolarization
Rate

0.001

0.607

Time to max
Repolarization Rate

0.002

AP Multi 90% Width

0.001

ISI Slope

0.016

F(1,29) =
14.89, ηp2 =
0.339
F(1,29) =
12.02, ηp2 =
0.293
F(1,29) =
12.34, ηp2 =
0.298
F(1,26) = 6.71,
ηp2 = 0.205

ISI Standard Deviation

0.029

F(1,26) = 5.33,
ηp2 = 0.170

0.934
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0.748

0.438

0.915

0.868

0.371

0.445

0.716

0.440

0.098

0.453

0.759

0.184

F(1,28) =
1.30, ηp2 =
0.044
F(1,28) =
2.73, ηp2 =
0.089
F(1,28) <
0.01, ηp2 <
0.001
F(1,28) =
0.11, ηp2 =
0.004
F(1,28) =
0.62, ηp2 =
0.022
F(1,28) =
0.01, ηp2 <
0.001
F(1,28) =
0.03, ηp2 =
0.001
F(1,28) =
1.91, ηp2 =
0.122
F(1,28) =
0.83, ηp2 =
0.029
F(1,28) =
0.60, ηp2 =
0.021
F(1,28) =
0.14, ηp2 =
0.005
F(1,28) =
0.61, ηp2 =
0.021
F(1,28) =
2.93, ηp2 =
0.095
F(1,28) =
0.27, ηp2 =
0.010
F(1,28) =
0.58, ηp2 =
0.020
F(1,28) =
0.10, ηp2 =
0.003
F(,25) =
1.86, ηp2 =
0.069
F(1,25) =
0.01, ηp2 <
0.001

ISI min

0.001

F(1,26) =
15.36, ηp2 =
0.371
F(1,26) = 6.93,
ηp2 = 0.210

0.001

F(1,25) =
10.97, ηp2
= 0.305
ISI max
0.014
0.625
F(1,25) =
0.25, ηp2 =
0.010
ISI covariance
0.114
F(1,26_ = 2.67, 0.417
F(1,25) =
ηp2 = 0.093
0.68, ηp2 =
0.027
Instantaneous Frequency
<0.001
F(1,26) =
0.002
F(1,25) =
Median
18.77, ηp2 =
11.41, ηp2
0.419
= 0.313
Instantaneous Frequency
0.002
F(1,26) =
0.003
F(1,25) =
Mean
12.30, ηp2 =
9.07, ηp2 =
0.321
0.266
Instantaneous Frequency
<0.001
F(1,26) =
<0.001 F(1,25) =
Max
18.95, ηp2 =
21.82, ηp2
0.422
= 0.466
Instantaneous Frequency
0.002
F(1,26) –
0.335
F(1,25) =
Min
11.28, ηp2 =
0.97, ηp2 =
0.304
0.037
Ratios
AP2/AP1 Halfwidth
0.237
F(1,26) = 1.47, 0.492
F(1,25) =
ηp2 = 0.053
0.49, ηp2 =
0.019
AP3+/AP1 Halfwidth
0.342
F(1,26) = 0.94, 0.668
F(1,25) =
ηp2 = 0.035
0.19, ηp2 =
0.007
AP2/AP1 AHP Amplitude 0.463
F(1,26) = 0.58, 0.916
F(1,25) =
ηp2 = 0.022
0.01, ηp2 <
0.001
APmulti/AP1 AHP
0.669
F(1,26) = 0.19, 0.387
F(1,25) =
Amplitude
ηp2 = 0.007
0.19, ηp2 =
0.030
ISI max/min
0.453
F(1,26) = 0.58, 0.113
F(1,25) =
ηp2 = 0.022
2.70, ηp2 =
0.097
Table 12. Posthoc summary of electrophysiological changes. Our Python script analyzed 44 measures and
5 ratios, and only 7 have been discussed previously here. We therefore analyzed the 44 remaining measures
and 5 ratios not presented yet to determine whether DAMGO or αDTX were have significant effects on
parameters that have not yet been discussed here. Several mixed-model repeated measures MANOVAs
were repeated for every subcategory (left column) for both DAMGO and αDTX to identify Slot*Drug
interaction effects which may indicate that those drugs were modulating the properties listed on the leftside column H-responders (N = 11) were compared with saline controls (N = 21) on various parameters for
a Slot*Group interaction that would suggest a drug (DAMGO or αDTX) that was independent of
degradation reflected in the saline control group. Timeslots analyzed were Initial → DAMGO for DAMGO
effects, and DAMGO → αDTX+DAMGO for αDTX effects in a background of DAMGO. In order to
determine whether these drugs acted only specifically on certain APs (e.gs., only the first AP, second AP,
or only APs after that), we analyzed these APs separately for Slot*Group interactions. Boldtype are
significant effects.

We found that DAMGO was affecting a very wide range of AP kinetic parameters
across many sequential APs, with the notable exception of spike amplitude. However,
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αDTX’s effects were not seen in these parameters (Table 11). Broadly speaking, it
appears that DAMGO consistently alters many different features, from individual AP
kinetics, to the probability of firing an AP. Meanwhile αDTX-sensitive channels do not
seem to contribute the shape of APs in neocortical interneurons, and its effects appear to
be restricted to the probability of firing an AP and their firing frequency.
3.4 Discussion
Previous research indicates that the µOR exerts an excitatory effect on cortical networks
by suppressing inhibitory neurons (Homayoun & Moghaddam, 2007; C. Jiang et al.,
2019; H. K. Lee et al., 1980; Madison & Nicoll, 1988; Pang & Rose, 1989;
Zieglgansberger et al., 1979). The experiments here likewise demonstrate that the µOR
exerts a strong inhibition on many cortical interneurons. We found that over a third
(21/55; 38.1%) of the sample of interneurons either hyperpolarized (H-responder) or had
reduced spontaneous action potentials (S-responder). The influence of DAMGO in these
two populations of interneurons had overlapping characteristics but were distinct. For
instance, in H-responders DAMGO elicited clear hyperpolarization and affected AP
kinetics and firing frequency. In contrast, the S-responders exhibited relatively smaller
hyperpolarizations and small changes in AP kinetics, and no alterations in the probability
of somatically evoked APs.
The high degree of variability of neocortical interneurons between and within
their classes makes identification of interneurons in our system difficult. We did not
attempt cell-marker identification of the neocortical interneurons since identification
would have required a thorough multimodal analysis of their characteristics (The Petilla
168

Interneuron Nomenclature Group, 2008). Particularly because our system enabled more
expeditious data collection at the expense of laminar arrangement - itself an identifying
characteristic for interneurons.
We found that most H-responders displayed an Adapting firing pattern,
characterized by steadily-increasing interspike intervals. This is noteworthy because this
spiking pattern was found at much lower rates in the non-responders and S-responders
(Table 5). Other researchers have found interneurons with this firing pattern amongst
neuropeptide Y-expressing interneurons (Bruno Cauli et al., 1997; B. Cauli et al., 2004;
Férézou et al., 2007; Toledo-Rodriguez, Goodman, Illic, Wu, & Markram, 2005; Yun
Wang, Gupta, Toledo-Rodriguez, Wu, & Markram, 2002; Y. Wang et al., 2004). This
firing pattern in NPY+ interneurons is particularly common amongst Layer I interneurons
of the neocortex (Karagiannis et al., 2009), which others have found to express high rates
of µORs and hyperpolarize strongly to DAMGO exposure (Férézou et al., 2007), which
was the distinguishing feature of H-responders in our study but found in both groups of
responders.
Our data also suggest that some of the S or H-responders may have features
consistent with VIPergic interneurons of the neocortex based on reductions in inhibitory
postsynaptic potentials that we observed during recording. These experiments did not
include the use of GABAA and GABAB inhibitors, and IPSPs could therefore persist
through the spontaneous activity of the interneurons. Although we did not analyze these
events, we noticed reductions in IPSPs occurring after addition of DAMGO in some
interneurons, including some H-responders (data not shown, though partially visible off169

pulse in Figure 23). The VIPergic interneurons tend to inhibit other interneurons, which
may have been manifesting our data (Fu et al., 2014; Jackson et al., 2016; Pi et al., 2013).
It is interesting to note that previous research in neocortical slices has found a high
degree of overlap between VIP and µOR immunoreactivities (Taki et al., 2000).
Electrophysiological studies have also found high rates of VIP expression amongst
interneurons that hyperpolarize in response to DAMGO, including neurons that would
have been classified here as having Adapting spiking patterns (Férézou et al., 2007).
While speculative, this may hint at a relationship between the H and S responders and
VIPergic neurons of the neocortex.
It is also important to point out that H and S-responders may not represent
discrete populations of interneurons despite the different methodologies to distinguish
them from nonresponders; numerous effects we found in H-responders fell just short of
significance in the S-responders (Table 9). For example, many S-responders had
particularly robust changes in AHP amplitude, which was not captured in the group
mean. Although the S-responders generally had weaker responses to DAMGO (Table
10), significant differences in this group may have been more difficult to resolve due to
lower samples sizes (N = 10), versus the H-responders (N = 11).
We also found that neurons within the H-responder group possess a variety of
spiking patterns (Table 5) and also a range of responses to both DAMGO and αDTX
(Figure 22). Within the hyperpolarizing DAMGO responders, we found a spectrum of
changes in their AP kinetic parameters; some neurons had pronounced changes in their
parameters, and some changed barely at all despite their greater hyperpolarization. The
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assortment of ion channels in each particular neuron may have led to varied responses to
DAMGO, but variability may also have resulted from the complex intracellular signaling
cascades of GPCRs; µORs are shown in non-cortical regions to modulate αDTXsensitive currents through the Gαi subunit, phospholipase A2 and the lipoxygenase
pathway (Faber & Sah, 2004; Vaughan et al., 1997), meanwhile upregulation of GIRK
channels appears to be mediated through direct interaction by activated Gβγ subunits (C.L. Huang, Slesinger, Casey, Jan, & Jan, 1995; Inanobe et al., 1995; Logothetis, Kurachi,
Galper, Neer, & Clapham, 1987; Wickman et al., 1994). It is therefore conceivable that
neurons have a variety of responses to DAMGO ranging from activating GIRK channels,
to activating voltage-sensitive currents, based on diverging signaling cascades.
The neurons in the H and S-responder categories were identified using two
different measures (RMP and spontaneous APs, respectively), which themselves can be
manifestations of different target ion channels of µORs, or different localization of the
µORs among the neuron types. Studies in the cortex suggest that hyperpolarization is not
always found in a DAMGO response, and that there is incomplete overlap between GIRK
channels and µORs (S. B. Bausch et al., 1995; Wimpey & Chavkin, 1991). Therefore,
larger hyperpolarization may not always be seen in µOR+ neurons if GIRK channels are
not involved. However, the drop in spontaneous APs seen in the S-responders is another
interesting feature. Studies of this receptor in neocortical interneurons using DAMGO
have found reductions in non-elicited APs, which appear to originate in distal processes
of some interneurons (Krook-Magnuson et al., 2011; Norimitsu Suzuki et al., 2014).
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These mechanisms illustrate that the µOR has several known mechanisms to
downregulate interneurons which can vary among the interneuronal types.
We found a range of AP kinetics as well as firing frequency properties (Table 10)
are altered by the µOR. We found that the AP kinetics were not likely to be mediated by
the αDTX-sensitive channels, though measures of AP probability (ISI, AP number, and
AP threshold) were related to the αDTX-sensitive current (Figure 21 and Table 8). We
found that αDTX frequently reversed (Figure 22) DAMGO-induced changes in spiking
frequency in the H-responders with a wide spectrum of responses, with neurons that
underwent DAMGO-induced changes in ISI and evoked APs usually being partially or
fully reversed to baseline. Interestingly αDTX did seem to have an effect in 2 or 3
neurons in RMP and AP halfwidth which was not captured by the mean; however, it is
difficult to say whether this was a genuine reaction to the drug by certain subclasses of
interneurons, or if they were simply outliers in the data (Figure 22).
It is interesting that αDTX reversed DAMGO effects in ISI and number of evoked
APs without reversing any of the AP kinetic features that we measured. The mechanism
behind the αDTX-sensitive current suppression of follow-up APs is not immediately clear
considering that changes in AHP magnitude was not significantly changed by DAMGO
nor αDTX. In other parts of the brain, this current is responsible for modulating spike
frequency adaptation – a feature that limits follow-up APs during prolonged
depolarizations (Faber & Sah, 2004). It appears therefore possible that, based on
DAMGO’s effect and αDTX’s (usually) partial reversal of it (Figure 22) that other
voltage-sensitive potassium currents are being modulated by µORs. For example, the
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Kv3 and Kv4 family potassium channels are found in cortical neurons and are implicated
in modulating these properties (Burkhalter et al., 2006; Carrasquillo et al., 2012; Martina
et al., 1998; B Rudy et al., 2009). The relationship of AP threshold with the µOR and
αDTX-sensitive current was a particularly nuanced feature in hyperpolarizing DAMGO
responders and appears to track with prior findings from the BLA where µORs modulate
αDTX-sensitive current without changing the Vm threshold for an AP (Faber & Sah,
2004). Here, αDTX produced a hyperpolarizing shift in AP threshold despite the µOR’s
apparent noninfluence over AP threshold. Yet the µOR still appears to regulate αDTX
current; µOR stimulation with DAMGO suppressed follow-up APs, which was partially
reversed by αDTX. At face value, it appears that µOR+ interneurons have αDTXsensitive currents at rest that influence AP threshold, yet these currents can be
upregulated to suppress APs after µOR-stimulation. One explanation is that αDTXsensitive channels are expressed in areas that the µOR is not localized to. For instance,
αDTX-sensitive channels in axon initial segments of cortical neurons can modulate AP
threshold (Inda, DeFelipe, & Muñoz, 2006; Kole, Letzkus, & Stuart, 2007), but if the
µORs localize to soma and dendrites, they may very well modulate somatic channels, but
not AIS-localized ion channels, where they may be already functioning without DAMGO
stimulation.
One drawback of this study is that we did not test the inverse drug exposure of
αDTX before DAMGO and therefore it is difficult to assess the baseline function of the
αDTX-sensitive channels in DAMGO-responders to directly relate µOR-stimulation with
the upregulation of αDTX-sensitive channels. When designing these experiments, we
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believed it might have been possible that αDTX would block DAMGO-induced
hyperpolarization (the primary indicator of a positive DAMGO response) and therefore
prevent us from ultimately identifying H-responders. However, we found that αDTX
usually failed to reverse DAMGO effects, including hyperpolarization. The inverse drug
sequence may be the most ideal way to measure baseline αDTX activity in DAMGO
responders. On the other hand, there were some neurons that did undergo noticeable
depolarization and had pronounced increases in spontaneous APs, and we may have
overlooked several H-responders and S-responders had we used inverse drug exposures
(Figure 22a).
It may be argued that the hyperpolarizing effect of DAMGO found in the
hyperpolarizing responders and, to a lesser degree, in spontaneous DAMGO responders
may have influenced action potential parameters. This is unlikely for several reasons.
First, most of the action potential analyses were done at several current steps above
threshold and we used the average values for APs 3-5 in those trains, thereby mitigating
the influence of hyperpolarized RMP on action potential parameters. In addition, most of
the APs we observed were initiated from approximately the same Vm regardless of their
change in RMP. Second, αDTX reversed DAMGO-induced changes in ISI and number of
evoked APs in hyperpolarizing DAMGO responders despite αDTX’s failure to reverse
DAMGO-induced hyperpolarization (Table 6 and Figure 21a) and broad range of other
features in the post-hoc analyses (Table 12). Third, we compared DAMGO depolarizers
(predicted to have had no µOR response) against neurons that had hyperpolarized slightly
in the saline group; this comparison “flipped the sign” to the saline group being
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significantly more hyperpolarized then the DAMGO group. However, in all measures
resulting from this comparison, we found no significant differences in action potential
parameters, ISI, and number of evoked action potentials (Figure 25). This analysis
suggests that the parameters we were investigating during the current steps were not
being influenced by the neuron’s RMP regardless of if the neuron had depolarized under
the DAMGO challenge.
Our data demonstrates that the μOR modulates AP parameters, including the
halfwidth and maximum rates of repolarization to suppress the excitability of
interneurons. We observed halfwidth changes of 12% (S-responder mean) 21% (Hresponder mean) and mean maximum repolarization rates of 25% or 40% (Table 10) with also a high degree of variation between neurons (Figure 22). The consequences of
AP kinetics have been explored in models with large synapses by using real and pseudo
APs to shown that kinetics have consequences for voltage-gated calcium channel
(VGCC) activity, calcium entry, and neurotransmitter release (Augustine, 1990; Klein &
Kandel, 1980; Llinas, Steinberg, & Walton, 1981). Computer simulations and
developmental data from synapses suggest that most VGCCs are activated by an action
potential, but further broadening prolongs the kinetics of the VGCCs, and therefore
contributes to longer duration of Ca2+ entry (Borst & Sakmann, 1998; Geiger & Jonas,
2000; Sabatini & Regehr, 1997), Additional data from the calyx of Held have added that
depolarization phases affect the number of VGCCs recruited, while repolarization affects
their kinetics to influence the amount or duration of Ca2+ entry. Paired recordings have
shown that both features can modulate the release of neurotransmitter and the amplitude
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of postsynaptic potentials, depending on stages of development and adaptations at the
synapse (Chao & Yang, 2019; Y.-M. Yang & Wang, 2006)
The αDTX-sensitive channels Kv1.1, Kv1.2, and Kv1.6 have previously been
linked to regulation of cortical interneurons. In the neocortex, they have been found to
strongly influence firing through their localization at axon initial segments of
interneurons and excitatory neurons (Bekkers & Delaney, 2001; Guan et al., 2006). The
have previously been linked to the excitability of cortical interneurons by modulating AP
threshold and near-threshold spike frequency (Goldberg et al., 2008). In VIPergic
interneurons, these currents affect the frequency of output (Porter et al., 1998). Genetic
knockout of Kcna1 (encodes Kv1.1) and Kcna2 (encodes Kv1.2) are linked to seizures
and ataxia in both humans and rat models (Adelman, Bond, Pessia, & Mayliet, 1995;
Brew et al., 2007; Heeroma et al., 2009; Robbins & Tempel, 2012). Restoring regulated
activity of these channels has been proposed as a mechanism underlying a treatment for
Fragile X syndrome (Y.-M. Yang et al., 2020). Here, our data suggest that the μOR may
upregulate these currents, as evidenced by αDTX’s attenuation of the DAMGO effect on
firing frequency (Figure 22). The endogenous opioids of the neocortex are deeply
involved in reward-seeking and motivated behaviors. Studies in animal models have
shown enhanced µOR activity correlates with, and causes, binge-eating and drug intake
(Blasio et al., 2014; Morganstern, Liang, Ye, Karatayev, & Leibowitz, 2012; Unterwald,
Rubenfeld, & Kreek, 1994). The µOR is believed to reshape neocortical activity by
releasing Pyramidal Neurons from inhibition by cortical interneurons (Férézou et al.,
2007; Homayoun & Moghaddam, 2007; C. Jiang et al., 2019; H. K. Lee et al., 1980;
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Madison & Nicoll, 1988; Pang & Rose, 1989; Taki et al., 2000; Zieglgansberger et al.,
1979). Yet despite the supporting evidence for µOR’s disinhibitory role in the neocortex,
this receptor’s inhibitory influence has rarely been explored beyond its hyperpolarizing
effects (Baldo, 2016; Férézou et al., 2007). Here, we found that the neocortical µOR has
far-reaching inhibitory effects in neocortical interneurons that had not yet been described,
which includes the potential upregulation of αDTX-sensitive channels to modulate
interneuronal output through firing frequency.

CHAPTER 4: COMPREHENSIVE DISCUSSION

4.1 Overview
These chapters provide a comprehensive summary of the neurophysiological effects of
µOR agonism by documenting the electrophysiological effects within cortical
interneurons, as well as the downstream hyperactivity effects by using spontaneous
calcium oscillations s as an indicator for bursts of neuronal activity. These findings
advance our knowledge of the µOR significantly by providing a robust statistical profile
of DAMGO effects (Table 12) while also showing that most of the µOR’s net excitatory
effect appears to be secondary to inhibition of cortical interneurons. This dissertation
sheds light on the mechanisms and effects of the µOR, how opioid drugs dysregulate
cortical activity, and how endogenous opioid signaling modulates networks and
individual neurons.

177

The studies in this dissertation are laid on a foundation of confirmatory evidence
for research that previous investigators have discovered, while furthering our knowledge
of the µOR as well. For example, we detected µOR responses in the expected range of
1/3rd of cortical interneurons, and that hyperpolarization and reduction of spontaneous
APs is a typical indicator, which has been observed (Férézou et al., 2007). On top of that
foundation, we show that the µOR has many other effects on cortical interneurons that
have not been previously described. Additionally, the conclusions and data presented
here provide numerous other possible research avenues that can be utilized to thoroughly
understand the target channels of the µOR, as well as to understand the net effects of the
receptor on neuronal circuits.
Our calcium imaging studies also corroborate previous reports that investigated
the receptor – that it reduces GABA release onto both GABAA and GABAB receptors
(Olah et al., 2007; Tamás, Buhl, Lörincz, & Somogyi, 2000). But our experiments show
that calcium-imaging and SCOs can be used to detect this relationship as well, and they
lend a convenient model to studying the network dynamics by visualizing the network
activity of neurons. Furthermore, this model provided an effective means to assess the
respective roles of GABAA and GABAB receptors on the SCOs.
Data from electrophysiology corroborate other studies from neocortical
interneurons. For instance, we found that DAMGO hyperpolarizes interneurons and
reduces spontaneous firing. We found that the µOR employs several fascinating
mechanisms for suppressing interneurons, including hyperpolarization, but it also affects
AP kinetics – which has not previously been described. Therefore, the µOR utilizes
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several mechanisms to suppress interneurons, and many of these means have not been
previously described before the detailed analyses presented here.
4.2 αDTX-sensitive/insensitive effects
Our electrophysiology experiments sought to determine whether the µOR positively
regulated αDTX-sensitive currents, and our results suggest that they do; we observed a
αDTX-reversible change in AP frequency in H-responders. However, we did not narrow
this down to specific subunits (e.gs: Kv1.1, Kv1.2, and Kv1.6). It is presently unclear
which subunits are mediating this effect, though Kv1.1 or Kv1.2 are the mostly likely
suspects, given their previously-established relationship with the µOR (Faber & Sah,
2004; Finnegan et al., 2006; Vaughan et al., 1997) and their known localization in
cortical interneurons (J. Connor & Stevens, 1971; X. Li et al., 2012).
One of our main findings was that the µOR has far-reaching neurophysiological
effects and the αDTX-sensitive current mostly modulates firing frequency, and not the
AP kinetics. Naturally, this does lead to the question of which ion channels are mediating
these effects since it appears kinetics may be mediated by other channels. The most likely
suspects are K channel subunits that are more classically known to mediate faster (Atype) current (B Rudy et al., 2009), even though αDTX-sensitive currents are themselves
capable of faster kinetics (Casale et al., 2015; Geiger & Jonas, 2000; Pathak et al., 2016).
Considering the tendency for αDTX-sensitive channels to heterotetramerize when the two
are coexpressed, it would also be interesting to determine whether this takes place in
responder neurons (B Rudy et al., 2009). Further identification of subunits mediating this
effect of DAMGO could therefore be warranted.
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4.3 Predicting a DAMGO response
Future studies in this area may require higher response rates than achieved here. Data
collected from the electrophysiological experiments mostly use random selection of
mRuby2-positive interneurons to record from and we achieved an average response rate
of 1/3rd between the H-responder and S-responder criteria. While this response rate may
be adequate for future studies, there may also be other diagnostic criteria that can be used
to predict DAMGO responses. Data collected and presented in this dissertation can also
provide a basis for more targeted experiments directed at understanding the
electrophysiology of the µOR.
One of our first attempts to predict DAMGO responses was the use of
morphology. Unfortunately, we found that neurons in vitro had indiscernible shapes that
could not be identified; nearly every neuron appears to have a spherical soma with
indistinct neurites. Shapes such as pyramidal, bipolar/bitufted, or multipolar cannot easily
be determined in these cultures. However, the use of the mRuby2 AAV improves this
situation substantially, not only by selectively fluorescing the interneurons, but also
allowing the viewer to resolve the precise and shape and neurites of each neuron (Figure
8 and Figure 14). While I did not attempt to use this technique to predict a DAMGO
response, interneuronal shapes are much more resolvable with mRuby2. Anecdotally, it
may not be an entirely useful property to predict a DAMGO response, however mRuby2
makes it exceptionally easy to visualize the shapes of interneurons and, importantly, it
can be used effectively before committing to the slow step of the recording process:
sealing and breaking in.
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Resting membrane potential and membrane resistance tend to be characteristic
features of neurons as well. However, use of these features to predict a DAMGO
response would probably be unsuccessful. We found RMP tended to fall in a fairly tight
range, and membrane resistance is sometimes difficult to consistently determine in realtime. In addition, these properties can vary over the course of seconds, and spontaneous
spiking of the neurons also disrupts accurate reading. We typically calculated the RMP
based on an average value that represented its RMP over a period of seconds, rather than
being an instantaneous determination. Therefore, these basic properties of neurons were
not very useful for predicting DAMGO responses when they are put into practice during
the recording process. This made these properties more problematic to utilize to predict a
DAMGO response.
Our electrophysiological data suggest that most H-responders have Adapting
firing patterns, and that the Adapting firing pattern is less prevalent in the nonresponder
pool. Future investigations into the µOR should consider using this firing pattern to
predict a response. However, half of H-responders did not display an Adapting firing
pattern, and thus using this diagnostic feature may rule out potential H-responders. For
example, these Adapting neurons likely have unique ion channel profiles that lend them
their unique firing pattern. Including or excluding them can skew analyses. On the other
hand, perhaps future investigations may choose to focus on neurons with that firing
property. In summary, the most useful predictors for DAMGO responses are most likely
the spiking pattern, which can only be determined after the slow steps of the recording
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process (positioning and intrusion of the electrode), and also morphology – but only with
the assistance of the mRuby2 AAV credited in the methods section of those experiments.
4.4 Identifying responders by subtype
Cortical interneurons are remarkably diverse and often identified through the use of
protein-expressional markers (The Petilla Interneuron Nomenclature Group, 2008). To
expedite the data collection process, we did not identify neurons using protein markers.
Unfortunately, equipment malfunctions prevented us from collecting images for most of
the experiment as well. We instead utilized spike patterns to classify interneurons, which
is also a well-recognized characterizing feature (The Petilla Interneuron Nomenclature
Group, 2008). However subtyping interneurons by cell marker could assist in making
inferences about the roles of these interneurons in intact neocortex – in addition to
perhaps explaining some of the variability that we observed (Figure 22).
Our experiments grouped neurons into H-responders and S-responders categories
based on their response to DAMGO. These typings appeared to be necessary, because
they had been identified based on their drug responses, which were different criteria from
each other. However, it is possible that interneurons in the 2 groups are actually more
similar than they are presented, and their neuronal categories and typing by interneuronal
marker may reveal overlap between the populations. On the other hand, H-responders
were considerably more likely to be Adapting firing patterns than S-responders or
nonresponders, and therefore it is quite possible that the H-responder and S-responders
are composed of different interneuronal populations.
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4.5 Origin of spontaneous APs
We used a decreased rate of spontaneous APs as a diagnostic feature of S-responders in
this study. One interesting area of interest raised by this observation and technique is the
exact cause of spontaneous APs in this model, and the mechanism by which spontaneous
APs were produced and reduced. The simplest explanation is that these neurons RMP
was very close to its AP threshold, and the frequency of APs was simply a matter of
probability of APs at that Vm. While hyperpolarization was not the diagnostic criterion
for this group, the S-responders did hyperpolarize on average (Figure 23). Therefore, this
is a simple and plausible scenario for this observation.
Another more interesting and complex explanation may be lent by pioneering
studies in PV+ and neurogliaform neurons, which suggest that APs in these neurons can
be generated in distal processes, such as their axons and conduct back towards their
soma. This phenomenon is called retroaxonal barrage firing. These APs may only be
accompanied by small hyperpolarizations, which possibly indicates a larger
hyperpolarization in its distant axon. DAMGO has already been shown to reduce these
tonic APs, and thus this mechanism may apply here as well (Krook-Magnuson et al.,
2011; M. E. Sheffield et al., 2013; M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al.,
2014). In addition, these tonic APs can occur after depolarizing trains of current, due to
axonal terminals becoming tonically active and conduction of APs through gap junctions
which can be conducted into other interneurons; therefore, these are delayed evoked
action potentials, rather than truly being unevoked and spontaneous APs. The
involvement of gap junctions suggests that perhaps S-responders may not necessarily
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indicate a µOR+ neuron, but instead a neuron junctionally-linked to an µOR+ neuron.
However, this phenomenon has never been demonstrated in neuronal culture models, and
the frequency of this type of spiking seems to decrease from in vivo to brain slices
(Krook-Magnuson et al., 2011; M. E. Sheffield et al., 2013; M. E. J. Sheffield et al.,
2011; Norimitsu Suzuki et al., 2014). It’s therefore quite possible this phenomenon may
not occur in neuronal cultures.
This phenomenon, however, can be experimentally tested for, as has already been
done in vivo and brain slices (Krook-Magnuson et al., 2011; M. E. Sheffield et al., 2013;
M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al., 2014). In this case a long
depolarizing current could be applied and the “spontaneous” APs in the minutes that
follow this train could be counted. By comparing these tonic action potentials before and
after the current application, it may be possible to test for retroaxonal barrage firing in
vitro.
4.6 Drawbacks of whole-cell recording
Our approach during electrophysiology was establishing whole-cell configuration by
breaking into neurons for recording. Unfortunately, this may lead to artifactual changes,
as opposed to cell-attached which would have allowed us to record from neurons without
breaking into them and thereby altering their intracellular environment. Cell-attached
recordings were initially attempted during these experiments, but then aborted due to
spontaneous break-ins during the recording process. It became clear that the sample size
would have been prohibitively small to allow us to record from enough neurons to have a
reasonable number of responders, and we switched to whole-cell recording. Therefore the
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“real” values to AP kinetics may be subjected to artifactual challenges. However, we did
record from many saline controls as well, and our main data analyses were performed by
comparing fold changes in DAMGO-exposed neurons with those saline controls.
Therefore, artifacts were most likely evenly reflected in both groups and fold changes
that are calculated should still be accurate, even if true values may be subject to some
deviation. Utilizing this whole-cell recording approach therefore allowed us to collected
substantial amounts of recordings in a relatively short period, and further enabled the data
analysis step to identify changes in AP kinetic parameters occurring in responders. In
many ways, this expedited approach facilitated the robust data analysis and statistical
profiling shown here.
4.7 DAMGO and GABARs
Our experiments with SCOs are a unique approach in determining how DAMGO affects
GABAergic signaling and identifying the GABARs that are mediating that effect. This
approach enabled us to record from many (20+) neurons in a single recording, in order to
understand the dynamics of network activity and how DAMGO affects it. Using this
model, we reproduced several important findings in µOR research while answering key
questions about the receptor’s mechanisms. Firstly, this model successfully showed that
DAMGO does indeed lead to net excitation in neuronal networks, which was wellindicated by the SCO duration (halfwidth) enhancement by DAMGO. Secondly, our data
corroborate the well-supported view that DAMGO increases net excitation in neuronal
circuits by inhibiting GABAergic interneurons, and that net excitation is secondary to
interneuronal suppression.
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Our data also advance our knowledge of the field in several important ways; we
show that not only does DAMGO suppress GABA release onto GABAA receptors, but it
also suppresses GABA release onto GABAB receptors as well. On one hand, this result is
well-aligned with the established view that µORs localize to neurogliaform neurons
which activate postsynaptic GABAB receptors, but our data further suggest that the effect
of GABAB may be influential for terminating bursts of activity that are indicated by each
SCO. While extrapolating from these data into in vivo brain structures is inherently
speculative, these data may suggest that DAMGO enhances net excitation by promoting
bursts of activity and increasing the lag time before GABAergic interneurons are capable
of terminating that burst of activity – which clearly seems to be a role of GABAB
receptors in this model. Whereas our electrophysiological recordings helped us determine
the effects of DAMGO in single neurons, the SCO model illustrated how networks of
neurons interact and suggest that there may be a delay in responsiveness to excitation
within cortical interneurons. This aspect of time lag to inhibit discrete bursts of activity in
cortical networks could be an interesting topic to explore.
4.8 DAMGO inhibition and GABA release
As explained, we observed far-reaching electrophysiological consequences for the 1/3rd
of interneurons susceptible to DAMGO. But what about the consequences of this for
synaptic GABA release? This question is largely unanswered by the current data –
though the data in this dissertation certainly provide a necessary basis for such follow-up
experiments; we identified AP kinetic changes, but it’s not clear how this relates to
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GABA release. This topic could be explored by dual electrophysiological recordings to
record inhibitory postsynaptic potential magnitudes.
There are likewise similar experiments that could be done to address the neuronal
networks without the use of CNQX + AP5 at the neuronal network model. For example,
the cultured neurons could be exposed to DAMGO and concentrations of GABA could
be quantitatively measured before and after certain timepoints to determine how this
manipulation affects GABA release. Though, the results from this experiment may be
difficult to predict or draw conclusions from. For instance, DAMGO may counterintuitively increase GABA concentrations due to the greater glutamatergic input on
GABAergic interneurons; GABA concentrations during the experiment would provide
little information about whether bursts of GABA release into synapses was happening too
slowly. Perhaps another important factor to consider, for reasons described later in this
chapter, is proportionality to their glutamatergic input, i.e., standardizing the GABA
concentration by glutamate concentration. This may help evaluate not only whether
GABAergic interneurons are increasing GABA release, but whether their response is
proportional to glutamatergic input before and after DAMGO.
4.9 True role of µOR+ interneurons in cortical networks
Our SCO model for DAMGO responses showed a powerful way to visualize disinhibition
and cortical hyperactivity. Yet, this was one of the biggest surprises for these experiments
– why was hyperactivity with DAMGO so common at the circuit level, and yet the
receptor acted mainly through disinhibition (interneurons), and interneurons expressed
the receptor uncommonly?
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There were several striking features about the SCOs that we observed, which
were surprising given the likely low expression of the receptor. In our early experiments
with SCOs, we noticed how DAMGO’s enhancement of SCO duration (and sometimes
amplitude) were particularly prevalent. There may be several explanations for this.
Firstly, we observed 3 - 11 red interneurons in each imaging field, and our
electrophysiological experiments suggested that about 1/3rd were inhibited by DAMGO.
It is therefore possible that an average of 1-3 neurons in every frame were µOR+. We
also observed that neurites at this stage spanned far distances. Taken together, this
suggests that the interneurons were highly interlinked with many other neurons in an
imaging field (Figure 8 and Figure 14). Therefore, despite their low frequency, even one
µOR+ interneuron in a field could potentially influence many other neurons in a field.
However, there is a counterargument to this point, which may further reduce the
number of DAMGO responders that enable DAMGO-enhancement of SCOs; about a
third of responders (8/21) did not have spontaneous firing, which reduces the 1/3rd
responder proportion even lower, because many responders were not actively firing at
rest, and therefore inhibition of those neurons would presumably produce very little
effect on the network of neurons. To summarize the problem, about 17% of neurons were
interneurons, 38.1% of them were responders, and 61.9% of them spiked spontaneously.
This leaves about 4% of neurons which have the µOR+ and spike spontaneously (and
thus exert effects on the network at rest). Given that an imaging frame only contained 3060 neurons, it seems hard to imagine why the calcium imaging effects were so common
and noticeable.
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On the other hand, though, about 2/3rds of responders were firing at rest – which is
a slight majority. Additionally, and importantly, if excitatory activity in the network were
to increase, then the 1/3rd of responders (8/11 H-responders) may fail to be recruited into
inhibiting that excitation – because they may have undergone a severe hyperpolarization
that makes them less responsive (by requiring that they undergo more depolarization to
close the gap between AP threshold and RMP), in addition to the reduced firing
frequency and shortened APs that we observed (Figure 19). This model would suggest
that not only does DAMGO inhibit the spontaneous activity of interneurons, but also
prevents them from suppressing overexcitation in neuronal networks. In other words, not
only do µORs provide constant and tonic inhibition, but perhaps the µOR+ interneurons
also stop neuronal excitation from “snowballing.” Therefore, DAMGO might cause an
uptick in neuronal excitation due to reduced inhibition, but it may also prevent Hresponders from ameliorating this increased glutamatergic activity. Thus, it is a problem
of cortical interneurons not being able to mobilize effectively, despite the greater
glutamatergic stimulation being applied to them.
Another possible consideration is the interlinkage of interneurons, and the
influence of neurogliaform interneurons, which are already known to express this
receptor (Férézou et al., 2007; Krook-Magnuson et al., 2011). These interneurons are
believed to be powerfully inhibitory in neuronal circuits; they create gap junctions to
numerous neuronal types and synapse widely (Chittajallu, Pelkey, & McBain, 2013;
Niquille et al., 2018; Olah et al., 2007; Overstreet-Wadiche & McBain, 2015; A. Simon,
Olah, Molnar, Szabadics, & Tamas, 2005). Therefore, inhibiting neurogliaform neurons
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may cause a very disproportionate uptick in excitatory activity relative to their frequency,
which is very low. While we are not certain about their frequency in this neuronal culture
model, their postsynaptic target receptors (GABAB receptors) are apparently found in this
preparation, based on the substantial changes induced CGP55845 (Figure 12). Though
given the in vitro nature of this model, we cannot be completely certain that this is an
expressional aberration and perhaps an imperfect indicator of neurogliaform neurons in
culture, in spite of its congruence to findings in brain slices. We never attempted to
localize these neurons in this model due to their unfortunate lack of unique and distinct
cell markers (Conde, Lund, Jacobowitz, Baimbridge, & Lewis, 1994; Niquille et al.,
2018; Overstreet-Wadiche & McBain, 2015). Neurogliaform neurons are often known to
have late-spiking characteristics (Markwardt, Dieni, Wadiche, & Overstreet-Wadiche,
2011; Olah et al., 2007; Overstreet-Wadiche & McBain, 2015), and we did not observe
this firing pattern in any recording.
While some of the assumptions here are speculative, they do lay some
groundwork for future studies that explore the roles of µOR+ interneurons in cortical
network. The experiments in this dissertation not only provide experimental evidence for
the effects of the µOR in the neocortex, but they provide a substantial basis for this topic
to be further explored in greater detail.
4.10 GABAA receptors counteract hypersynchrony
We observed another interesting drug effect, which may not be obvious in the
quantitative data we collected. Picrotoxin (100 µM) always caused all neurons to produce
synchronous SCOs, whereas pre-picrotoxin conditions had some out-of-sync neurons or
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populations of neurons. It was always very clear in the images whether picrotoxin was
applied due to the nearly perfect synchrony of neurons in the field. Also, very noticeably,
picrotoxin dramatically increased amplitude and duration of SCOs (Figure 7). Together,
this created a profound and bright “blinking” effect as all neurons flickered on and off
collectively. But what does this tell us about interneurons, and their role in neuronal
networks? And what does this tell us about the particular roles of GABAA and GABAB in
neuronal networks? These basic questions have not been raised earlier due to the lack of
quantitation, but the experiments conducted here do shed some light on the answers to
these questions.
I posit that in pre-drug conditions, the interneurons maintained separate and
discrete populations of neurons, and kept the neurons from achieving perfect synchrony
with all their neighbors, though neurons started off fairly synchronous (Figure 2). This
may allow groups of neurons to act as semi-independent units for cortical processing.
Upon application of picrotoxin, the interneurons lost their ability to segregate the
neuronal networks, which produced universal SCOs and synchronous excitation in the
whole network of neurons. This would predict that the fast inhibition of the GABAA
receptor was primarily responsible for preventing excitation from simply reverberating
through the culture. Upon applying GABAB receptor antagonist (CGP55845) in a
background of picrotoxin, this universal synchrony did not seem to change, but instead
enhanced the durations of the synchronous SCOs (Figure 12). While this model is
speculative, the synchrony produced by picrotoxin should be noted because it was not
reflected in the quantitation we did. In addition, it is difficult to extrapolate what this
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means for in vivo brain circuits. Perhaps the beginning point for testing this would be to
measure SCOs in brain slices and determining whether picrotoxin likewise causes
complete synchrony in that model as well.
4.11 Unknown physiology of SCOs
One of the more obvious questions that the SCO study raises is the physiological events
that contribute to SCO duration and amplitude. SCO amplitude may be modulated by
NMDA receptor ion traffic, which could function to both depolarize the neuron as well as
conduct inward Ca2+ currents that induce an SCO (Canepari et al., 1997; Penn et al.,
2016; Przewlocki et al., 1999; T. Tanaka et al., 1996). Of the SCO phenomena, amplitude
remains the most well-studied measurement. However, halfwidth (a measure of duration)
is a much more complicated matter because few researchers have provided quantitation.
Of the studies that I cite in Chapter 2, (T. H. Murphy et al., 1992) is the only study I am
aware that examined it. In that study, function of the NMDAR (modulated through
manipulations of [Mg2+]out) is shown to strongly modulate SCO duration. However, my
own results repeatedly demonstrate that function of the GABAB receptor strongly
modulates SCO halfwidth, and therefore I believe it may also be indicative of
GABAergic termination of bursts of APs. However, these explanations are non-mutually
exclusive because both receptors may mediate this effect, and GABAB receptor activity
inhibits PNs, which may then release glutamate onto NMDARs.
My speculation is that the proximal cause of SCO halfwidth is the duration of the
EPSPs, which may allow NMDARs to conduct inward Ca2+ currents for longer periods.
Evidence for this interpretation is supported by our well-replicated finding that GABAB
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receptors appear to strongly modulate SCO halfwidth, and their expression on PNs which
release glutamate (J. R. Chalifoux & Carter, 2010; Jason R. Chalifoux & Carter, 2011;
Corrêa, Munton, Nishimune, Fitzjohn, & Henley, 2004; Olah et al., 2007).
On the matter of SCO coupling to calcium-induced calcium release (CICR), we
did often observe both smaller high-frequency SCOs, as well as much larger ones that
often showed a refractory period associated with them (Figure 4). My interpretation of
these data is that the peaks caused by VSCCs, NMDARs and calcium-conducting
AMPARs might trigger CICR when the peaks are of a certain threshold amplitude or
duration. This may make tall peaks with a refractory period that tower over smaller
calcium peaks that have failed to induce CICR. Coupling between extracellular sources
of calcium and intracellular calcium release could potentially be an interesting study that
can show how various drug interventions modulate the coupling efficiency between the
two. However, there are several practical problems that can limit such a follow up.
Firstly, it may be difficult to identify peaks that are linked to CICR from those that are
only from extracellular sources and did not induce CICR. Secondly, my experiments
were unable to determine how the µOR itself couples to intracellular calcium release
because the µOR is only expected to be expressed in about a third of the interneurons that
I recorded from. Thirdly, the SCO is a complicated model to study because it involves a
web of interacting factors. For instance, applying DAMGO often intensifies SCO
duration and amplitude, yet it happens in too many neurons to be a primary effect of the
µOR. Instead, the µOR likely enhances glutamatergic outflow which primes NMDARs
and enables inward calcium current. NMDARs, in turn, may be in an ideal location for
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coupling smaller SCOs with the larger CICR-induced SCOs. In this scenario the ultimate
cause may have been µOR agonism, but the proximal cause of enhanced coupling
between small SCOs and CICR SCOs are the NMDARs, and not any intracellular
mechanism of the µOR. Although this exact scenario may not be shown to be true,
follow-up studies should consider alternate possibilities.
4.12 SCOs: glutamatergic input or neuronal output?
Our experiments in this dissertation contributed to the field by resolving ambiguity about
how the µOR exerted its effects by showing disinhibition and not direct excitation.
However, it also presents another compelling opportunity for future research;
investigating whether SCOs correspond to (glutamatergic) input or neuronal output
(through prolonged opening of voltage-sensitive Ca2+ channels). Thus, whether SCOs in
a given neuron corresponds to its incoming input or its own action potential output.
In the discussion of Chapter, I previously described how red and nonred neurons
did not generally react to the various drug combinations differently from each other. I
speculated that their lack of a difference, even as the various drugs had clear effects on all
the neurons, may have been due to the origin of the calcium transients; most literature
suggest that these calcium oscillations are actually a measure of the glutamatergic input
being applied to the neurons by their neighbors, and therefore that calcium transients are
not a direct measure of the output of the neurons, i.e., VS Ca2+ channels only constitute a
small component of the calcium oscillations (Canepari et al., 1997; Dravid & Murray,
2004; Flint et al., 1999; Penn et al., 2016; Przewlocki et al., 1999; T. Tanaka et al., 1996).
However, this is not a settled issue, and some authors have proposed that VSCCs are
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modest or substantial components of SCOs (Bacci et al., 1999; Dravid & Murray, 2004;
Inglefield & Shafer, 2000). It’s quite possible this is due to variance in neuronal types,
and experimental conditions.
While glutamatergic input and output of the neuron are almost certainly positively
correlated, they are not exactly the same thing. Specifically testing the relationship
between input and output in the red vs nonred neurons would be an interesting follow-up
to my experiments, because this would predict that a proportion (maybe a 1/3rd, a
suggested by my electrophysiology data) may be µOR+. The consequences of a DAMGO
response may cause them to become relatively suppressed in proportion to their input.
For instance, these µOR+ interneurons may fire fewer APs, and their APs may be
hastened in response to DAMGO. In other words, their output given their input may
become less intense. This output/input ratio may be difficult to measure, because it would
require calculating an area-under-the curve estimate in the electrophysiological trace (for
instance, calculating the area of an excitatory postsynaptic potential) and then also
quantify their (indicator fluorescence) output in the imaging trace, perhaps also through
an area-under-the curve estimate. Perhaps another way to quantify output is counting
discrete APs, though bursts of APs appear to have various and irregular amplitudes and
this method would also ignore the duration of APs. This output/input calculation may
demonstrate that although excitatory drive increases in µOR+ neurons, their action
potential output may not be proportional to their excitatory drive, as indicated by the area
of the SCO. To synthesize the idea into a hypothesis: DAMGO reduces the output/input
ratio in µOR+ interneurons, which then facilitates disinhibition. Affirming this
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hypothesis would assist in explaining why interneurons are unable to prevent net
excitation in spite of their uptick in glutamatergic input.
While most articles on the topic of SCOs support the view that they are
visualizations of glutamatergic input, other explanations exist. Some data by other labs
suggest that voltage-sensitive calcium channels contribute to this affect as well (Dravid &
Murray, 2004; Robinson et al., 1993). Indeed, while our data show that CNQX+AP5
combination prevented SCOs from occurring (Figure 3), I also observed that under this
condition some rare flickering in a few neurons still seemed to occur. This may
correspond to bursts of tonic activity and voltage-sensitive calcium channels, but it is
unclear. In addition, application of depolarizing current into neurons could cause a
calcium oscillation, though these calcium oscillations were frequently not as large as
SCOs, though, but sometimes they were. It’s possible that VSCCs may contribute to this
effect as well. In these scenarios, the SCOs may indicate output of the neurons, and not
necessarily their glutamatergic input.
4.13 SCOs: AMPARs, NMDRs or mGluRs?
In our experiments with SCOs, we blocked VS sodium channels with TTX, and we also
blocked glutamate receptors with the combination of CNQX and dAP5. However, we did
not separately block AMPARs and NMDARs. Although practically-speaking, these
experiments would be trivial to conduct using our testing model, the main issue was data
interpretation and understanding the conclusions that could be drawn from the data since
these SCOs are spontaneous – not evoked by a constant stimulus. We anticipated that
decreasing excitatory drive by separately blocking NMDARs or AMPARs may simply
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reduce excitatory drive in this model, and therefore reducing the proximal factor
mediating the SCO. For example, blocking AMPA receptors selectively may also lead to
a substantial reduction in NMDAR activity by reducing the depolarizations produced by
EPSPs. Similarly blocking NMDARs or AMPARs would likely reduce excitatory drive
being input into glutamatergic neurons that ultimately release glutamate onto Gq
receptors.
4.14 Relationship between SCO halfwidth and interneuronal function
Using the SCO model to correlate neuronal activity enabled us to identify a particularly
persistent feature of a DAMGO response: the prominent increase in halfwidth of SCOs.
This feature was penetrant in the presence or preincubation with picrotoxin and absent in
the presence or preincubation with CGP55845 (Figure 7). We also found that CGP55845
could substantially and significantly increase SCO duration (Figure 12). Utilizing this
model allowed us to effectively measure the effect of DAMGO in this environment and
determine that it disinhibited cultures and acted through GABAA and GABAB receptors.
However, going beyond this; what does this feature tell us about interneuronal activity?
What does halfwidth indicate about GABAergic interneurons in this environment?
This question is largely unanswered by these data, yet the electrophysiological
recordings could provide a reasonable starting point, because those data report the effects
in single neurons. This starting point could be extrapolated from, in order to provide
theoretical framework for understanding what halfwidth tells us about interneuronal
function in this mode.
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Recalling our electrophysiology protocol; we applied depolarizing current over a
fixed 1s period to measure DAMGO’s effects on interneuronal action potentials. One
clear metric involved is the latency to spike, which records how quickly a neuron can be
induced into firing an action potential. However, this is unlikely the whole explanation
here because it seems unlikely that interneurons firing their first AP can bring an end to
glutamate release in the network. Instead, a critical amount and duration of GABA might
be required for glutamate release from PNs to grind to a gradual halt and terminate the
SCO for that cycle. SCOs did not stop abruptly; they had slow decline phases. This
suggests that sustained actions of GABAergic interneurons were required to stop SCOs.
Therefore, The AP halfwidth and spike frequency may modulate this critical amount of
GABA, and latency to spike is only one feature of this model.
SCO halfwidth is clearly a complex and multifactorial phenomenon, and given its
consistent modulation by DAMGO, it warrants more attention. It suggests a complex
interaction between glutamatergic and GABAergic signaling and it may assay the ability
of interneurons to respond quickly to bursts of excitation from PNs.
4.15 Factors other than GABARs can modulate SCO halfwidth
In the picrotoxin condition, which induced long and synchronous SCOs, the long
halfwidths likely reflected that only the GABAB receptor was functioning due to the
block on GABAA by picrotoxin. The GABAB receptors appear to require longer durations
of GABAergic stimulation to suppress the PNs. There were clear effects of CGP55845 in
a background of picrotoxin, which supports this idea (Figure 12). Yet, in the combined
picrotoxin + CGP 55845 condition, the neurons still flickered (albeit slowly, perhaps only
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2-3 times per 80 seconds); but why did the neurons flicker at all – why did they not
simply stay “on” since the GABAA and GABAB receptors were blocked? If GABA
receptors were required to end an SCO for a cycle, the neurons would simply stay
“flickered on” for the entire duration of the recording, as the PNs release glutamate moreor-less indefinitely. On one hand, it may be possible that 100 uM picrotoxin and 10 uM
CGP55845 did not completely block all the GABA receptors. Or perhaps factors other
than GABA receptors were in play in this condition. One possible explanation is that the
PNs have internal mechanisms that can terminate SCOs when GABAergic inhibition is
absent. For example, delayed rectifier K channels, slow inactivation of synaptic terminal
VSCCs, or calcium-activated K channels. Or perhaps supply of synaptic glutamate
becomes depleted, due to the seconds-long bursts of APs that PNs appear to undergo.
Another possibility is that this just a result of calcium stores becoming depleted from
internal stores and undergoes a refractory period, and thus not necessarily an
electrophysiological phenomenon.
It would be interesting to record from PNs in the presence of picrotoxin and
CGP55845 and observing the neurophysiological events that correspond to the end of an
SCO in this condition. As mentioned in this paragraph, it may simply be slow actions of
K channels that terminate bursts of activity from PNs, or depletion of synaptic glutamate.
If the termination of SCOs in picrotoxin + CGP55845 did not correspond to an abatement
of electrophysiological phenomena (i.e., the Pyramidal Neuron kept firing even after the
SCO ends), then depletion of glutamate or calcium stores seems more likely. Though,
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depletion of glutamate may cause a chain reaction through the culture that terminates the
SCO by diminishing excitatory drive.
To provide a more comprehensive summary of factors modulating SCO
halfwidth; perhaps there are layers of factors that can modulate this feature. Perhaps
GABAA receptors provide quick modulation and blockading them makes the GABAB
receptor the next-in-line mitigator. After blockade of both GABAA and GABAB, perhaps
only the slow action of intracellularly-stored calcium can stop SCOs. It’s fairly clear from
the data that a multitude of factors can modulate this and that they may come with their
own temporal range of responses.
4.16 Sub-threshold calcium oscillations
We used an all-purpose general peakfinder setting that culled a wide variety of peak sizes
with a lower cutoff, but virtually no upper cutoff. These settings were chosen after an
extensive trial-and-error period of peakfinder adjustments, an ensuring that many peaks
were culled and not overlooked. It also screened out minor fluctuations in baseline that
could have been culled alongside larger peaks. This separation prevented us from
conflating miniscule peaks from much larger ones.
However, some refinements or adjustments may also be made. For example,
perhaps certain drugs only affect small peaks, and not larger ones. In this case, perhaps
multiple peak profiles could have been used. Anecdotally, I rarely observed specific drug
effects in certain peak profiles during the trial-and-error period; drug effects were usually
consistent. Nevertheless, this topic could be explored further.
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In addition, analyzing the RMS may be a useful measure, which could
presumably measure some of the frequent, small-scale calcium fluctuations which were
not explored here. This perhaps may be a way of analyzing calcium events that are too
small to induce CICR and may represent scattered synaptic events that are too out-ofsync to be interpreted as an SCO.
4.17 Additional peakfinder measures
In a similar vein, other features of SCOs could have been analyzed as well, analogous to
the action potential peakfinder. This calcium peak finder could include rate of rise, rate of
decay, time to maximum rates, 90% width, and maximum rates. These may all be
important and distinctive features that can inform us on the physiology of SCOs. This
may lie outside the scope of this dissertation, since we were primarily focused on
amplitude and duration to find DAMGO effects, but such analyses could provide grounds
for future studies.
We sometimes noticed that neighboring neurons had different characteristics,
including shape and size. One explanation for this is that neighboring neurons have
different physiological characteristics, which create SCOs of different sizes. Drastic
differences in peak amplitudes between (and within) neurons may indicate different
physiological mechanism; for instance; large peaks may indicate CICR, whereas smaller
peaks may be NMDARs/AMPARs. Perhaps shapes as well indicate different
physiological mechanisms. For instance, CICR might correspond with sudden upward
inflections, and slow decays. This may or may not be associated with Gq receptors
(because membrane calcium channels may also induce CICR). NMDARs, on the other
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hand, may be associated with faster kinetics than CICR, but perhaps could also induce
CICR on top of their own peaks. AMPARs may be similar. Meanwhile, even smaller
peaks may be simply voltage-sensitive calcium channels. RMS values may capture
VSCC activity, due to their fast kinetics and constant fluctuations. Perhaps neuronal
variability and testing systems all contribute to some of the conflicts in the literature (as
discussed earlier, whether SCO amplitude is due to VSCCs or glutamate receptors).
While speculative, these can beget testable hypotheses directed at understanding all the
underpinnings of SCOs.
4.18 SCOs for drug discovery and assays of glutamatergic activity
Other labs have proposed the idea of developing a medium-throughput platform for
measuring and analyzing SCOs as a means of drug discovery and mechanistic studies on
epilepsy and its treatment (Cao et al., 2015; Pacico & Mingorance-Le Meur, 2014). Our
lab performed a variety of experiments with other drugs by using SCOs, after we had
developed the software to analyze them. The data presented here were deemed central to
the hypotheses presented here, but we applied this testing system more broadly to test
other drugs. These pilot experiments could have led to other projects and some data is
therefore shown here.
As an example, I hypothesized that nicotinic agonism would have opposing
effects of DAMGO, considering their antagonistic effects in µOR+ interneurons (Férézou
et al., 2007). I therefore tested the effects of the nicotinic receptor agonist 1,1-Dimethyl4-phenylpiperazinium (100 µM; DMPP) on primary neuronal cultures using the same
time course presented in Chapter 2 (Figure 5).
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Figure 28. Nicotinic modulation of SCOs. We tested the effects of the nicotinic acetylcholine receptor
agonist 1,1-Dimethyl-4-phenylpiperazinium (DMPP; 100 µM) using the same slot model (Figure 5). DMPP
alone significantly enhances SCO halfwidth. But the combination of DMPP + the µOR antagonist D-PheCys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; 1 µM) blocked the effect of DMPP, which was
significantly (p < 0.05) lower than DMPP alone, but not significantly different from the saline controls (p >
0.05).

Surprisingly, we found that DMPP actually enhanced SCO halfwidth compared the nodrug condition, in a manner similar to DAMGO. However, nicotinic agonism could also
stimulate enkephalin release in cortical neurons (Dhatt et al., 1995), and therefore we
tested DMPP in the presence of D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) to
block the µORs. This drug blocked the effect we observed with DMPP. These results do
indeed support the notion that DMPP enhancement of SCO halfwidth was due to
increased enkephalin release, which was blocked in the presence of CTAP. This line of
evidence was not followed up on further, but these results do show that this testing
system has broader implications for drug discovery and mechanistic studies. We
attempted similar experiments with Cannabidiol, but we obtained nonsignificant results;
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however, we did not troubleshoot potential problems with solubility because it was not a
necessary part of this dissertation. In conclusion, while this experiment did not contribute
to the central experiments of this dissertation, testing SCOs using our experimental
design may provide a platform for future studies that are directed at determining how
various drugs affect glutamate release.
4.19 Between SCOs and interneuronal suppression
The experiments in this dissertation found inhibition of about one third of interneurons,
and the calcium imaging approach found detectable enhancement of duration of SCOs,
and often amplitude as well. However, the question remains; how does suppression of
interneurons produce an enhancement of SCOs? In other words, having found that
DAMGO inhibits a proportion of interneurons – how do we explain increased durations
of bursts of activity (SCO halfwidth)?
Both Chapter 2 and Chapter 3 are congruent insomuch as they both suggest that
the µOR suppresses cortical interneurons. Yet, these experiments set two points, and it is
presently difficult to develop a model that relates these points. For example: how does
reduced AP halfwidth and firing frequency in interneurons produce SCOs of longer
durations in both interneurons and excitatory neurons? As mentioned earlier, these
changes may result in interneurons that are simply slower to be recruited to stop bursts of
excitatory activity. Perhaps the 1/3rd of cortical interneurons that are inhibited by
DAMGO are too slow to secrete critical amounts of GABA that halts glutamate release.
However, there may be practical experiments that can be done as well. This idea might be
tested by tracking SCOs through inhibitory interneurons (using mRuby2) and PNs with a
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much higher-speed camera. This may allow investigators to resolve the precise timing
between the two populations of neurons – with glutamatergic neurons causing SCOs to
move back and forth between PNs and interneurons, and then perhaps allowing
researchers to determine whether DAMGO alters the temporal delay. However, SCOs
likely only monitor glutamatergic input, and not neuronal output. Thus, SCOs in a given
cell will indicate their glutamatergic excitation – not their delay to start spiking. Perhaps
paired electrophysiological recordings may assist in this determination.
4.20 Summary
The calcium imaging studies highlight that DAMGO enhancement of cortical activity is
likely secondary to inhibition of interneurons, and therefore provides some clarity in a
field of ambiguities. Additionally, we substantiate findings that the µOR inhibits GABA
release onto both GABAA and GABAB receptors, and therefore provides evidence that
the µOR may be found on neurogliaform neurons. Going further than that however, these
results provide fertile ground for follow-up studies directed at investigating the
physiological correspondent phenomena that contribute to SCOs and may serve as an
initial screening test for drug discovery assays.
Throughout the experiments presented here, I show that the µOR inhibits
interneurons in numerous ways, and that a spectrum of responses may represent
interneuronal type. I provide a detailed statistical analysis of these data, and a framework
of categorizing DAMGO responses for future studies. Our data show that DAMGO not
only inhibits interneurons through hyperpolarization, but also causes detectable changes
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in their firing kinetics and AP frequency, which could have consequences for their
control of network activity.
As described in this chapter, these studies are built upon a foundation of studies
that have investigated the µOR. We successfully recapitulated many expected findings
about the µOR and its excitatory effects on neuronal circuits, hyperpolarizing effects, and
suppression of spontaneous APs. In doing this, we provide a framework for further
investigations of the receptor. On top of that foundation, these studies profile many more
complex effects of the µOR on APs and affirms that the receptor positively regulates
αDTX-sensitive currents to modulate some of these effects, as well as non-αDTXsensitive currents to mediate other effects.
The experiments presented here significantly promotes our understanding of the
µOR in the brain. We show how the receptor produces dysregulation of cortical circuits
by increasing excitatory outflow. These studies shed light on the mechanisms of the µOR,
and its effects in cortical neurons.
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